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SUMMARY
Subjects who have had gestational diabetes mellitus (GDM) are, by definition, not
hyperglycemic after pregnancy and do not usually receive the benefit o f detailed follow
up o f their metabolic status. We examined the metabolic status o f 65 women who had
had a diagnosis o f GDM and 65 women who had had a normal non-diabetic pregnancy
(control women) approximately one year after delivery.

We hypothesised that the

women who had had GDM would on the whole have more abdominal obesity than
control women, that they would be relatively hyperinsulinemic and hyperglycemic, and
that they would have a characteristic dyslipidemia on fasting (high VLDL, IDL and LDL
and low HDL concentrations, high plasma non-esterified fatty acid (NEFA) concentration
and cholesteryl ester transfer protein (CETP) activity in plasma, more small LDL and
HDL particles). It was expected that these women would have been more likely to have a
family history o f NIDDM. We hypothesised also that the women who had had G D M
would have a high plasma testosterone and low plasma sex hormone binding globulin
(SHBG) concentration, would have higher blood pressure, and be more likely to have
microalbuminuria than control women. Many of these predictions were borne out.
The study shows that the population o f women who have had GDM are overall far from
normal one year after the end of pregnancy. They are likely to have a set o f abnormalities
which our current knowledge suggests are precursors of the insulin resistance syndrome
such as obesity, a positive family o f diabetes mellitus, dyslipidemia, hyperinsulinemia,
hyperandrogenicity, raised blood pressure, and microalbuminuria.

M any o f these abnormalities are found in a subgroup of GDM subjects who appear to
have developed the insulin resistance syndrome.

CHAPTER ONE
INTRODUCTION

1.1 Background
Gestational diabetes mellitus (GDM) is a problem of global significance (Boyd et al,
1991). GDM is a heterogenous clinical problem with phenotypic and genotypic variety
(Freinkel et al, 1985). GDM is common in obese women and in those over 30 years old
(Freinkel et al, 1985).

There are geographical, ethnic, and racial differences in the

prevalence of GDM.

The pathogenesis of GDM is not fully understood, but the syndrome is similar to non
insulin-dependent diabetes mellitus (NIDDM). In the GDM patients, the insulin response
to glucose intake is delayed, while the basal plasma insulin level is normal or elevated
(K uhlet al, 1985).

In the development of GDM, like NIDDM, at least three factors may play important
roles. They are as follows: a genetic tendency to the disease, an impaired pancreatic (3
cell function, and a decreased insulin action in insulin-sensitive tissues including adipose
tissue, skeletal m uscle, and the liver (Horton, 1991).
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Maternal obstetric complications of GDM include hydramnios, pregnancy-induced
hypertension, chronic hypertension, pyelonephritis, and delivery by caesarean section
(Goldman et al, 1991).

The Third International Workshop-Conference on GDM noted that the neonates of
GDM mothers are at increased risk of macrosomia, neonatal hypoglycaemia,
hypokalaemia, polycythemia, and hyperbilirubinemia (Metzger and The Organizing
Committee, 1991). Macrosomia can cause birth trauma to both mother and neonate and
it is thought that it may increase the risk of obesity and diabetes mellitus in later life in
the offspring of mothers with GDM (Hod et al, 1991).

Mestman et al (1972) have reported that 30-50% of women with prior GDM develop
diabetes mellitus during 3-5 years after delivery and the proportion is 60-100% after 12
18 years (Mestman, 1987).

1.2 Etiology of Gestational Diabetes Mellitus
O'Sullivan (1978) reported that up to 60% of women who had had GDM eventually
developed diabetes. Oats et al (1988) have reported that 9.1% of women who had had
GDM were found to be diabetic and 16.9% had impaired glucose tolerance using the
WHO criteria at intervals from 1-15 years following diagnosis in Australia.

The etiology of GDM is poorly understood. The predisposing causes are probably the
same as for NIDDM, clearly precipitated by the metabolic and hormonal changes of
pregnancy (Brinkman HI, 1987).

Glucose tolerance normally deteriorates in human pregnancy. It is known that plasma
levels of the anti-insulin hormones rise in pregnancy (Peterson et al, 1991). The major
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insulin antagonists of pregnancy are estrogen, prolactin, progesterone, cortisol, and
human placental lactogen. These are at their highest concentration in the blood at 24-28
weeks of gestation, at which time GDM most commonly occurs (Peterson et al, 1991).

Several studies have suggested that the diabetic effect of pregnancy is not due to reduced
secretion of insulin or disproportional secretion of pro-insulin or glucagon, nor is it due
to an increased insulin degradation (Kuhl, 1991). The diabetogenicity of pregnancy is
associated with induction of pronounced peripheral resistance to insulin (Kuhl, 1991,
Buchanan, 1991).

The resistance is of a similar magnitude in normal pregnant women and those with GDM,
and it does not seem to be caused by significant alterations in insulin receptor binding to
target tissue (Kuhl, 1991). The insulin resistance of the whole body is increased to about
three times that seen in the non-pregnant state. It is thought to be due to post-insulin
receptor events and is probably caused by the cellular effects of increased plasma levels
of one or more of the pregnancy-associated hormones and free cortisol (Kuhl, 1991).
Evidence indicates that the insulin resistance occurs predominantly in skeletal muscle
tissue.

Most normal pregnant women are able to counteract the peripheral insulin resistance by a
significant increase in their basal and nutrient-stimulated insulin secretion. However, a
few (2-3%) of the women are not able to produce a sufficiendy large increase in insulin
secretion and hence cannot overcome the peripheral insulin resistance.

Thus, they

become glucose intolerant and fulfd the diagnostic criteria for GDM (Kuhl, 1991).
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Recent studies suggest that a high percentage of pregnant women who screen positive
for glucose intolerance have serological evidence of an autoimmune response against the
pancreatic islets, in spite of the state of relative immune tolerance during pregnancy.
These data suggest that autoimmune phenomena may play a role in GDM and that the
presence of islet cell antibodies can predict insulin-requiring gestational diabetes
(McEvoy et al, 1991). It might be an explanation for those GDM subjects who will
develop IDDM but the finding requires confirmation.

1.3 Pathogenesis ofNIDDM
By definition, diabetes mellitus is characterized by a rise in glycemia above normal
concentrations which is a consequence of an inability of body tissue to dispose of
glucose, an excess production of glucose by the liver or both (Felber et al, 1993). Non
insulin-dependent diabetes mellitus (NIDDM) is thought to be caused by an imbalance
between insulin sensitivity and insulin secretion (DeFronzo et al, 1992).

1.3.1 Impaired glucose tolerance
Glucose tolerance, as estimated by the oral glucose tolerance test (OGTT), depends on
complex iteration among several physiological processes, including first-phase and
second phase insulin secretion, insulin removal, insulin sensitivity, and the tendency of
high glucose concentration (independent of insulin) to increase glucose utilisation
(Martin et al, 1992).

Subjects with insulin resistance may be euglycemic maintained by hypersecretion of
insulin, with hyperinsulinemia both in the fasting and postprandial states (Beck-Nielsen et
al, 1990).

Introduction
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The risk for subsequent glucose intolerance or diabetes in women with previous GDM is
related to pre-pregnancy body mass index (BMI) and fasting plasma glucose during
pregnancy.

Subjects who are fatter before pregnancy and whose plasma glucose

concentrations are higher during pregnancy are more likely to develop glucose
intolerance or diabetes after delivery (Coustan et al, 1993).

Effendic et al have reported that 60% of normal weight women with previous GDM had
borderline or decreased oral glucose tolerance 6-36 months postpartum which could be
explained either by low insulin response or by the combination of a low insulin sensitivity
and low insulin response (Effendic et al, 1987).

1.3.2 Insulin Resistance
Insulin resistance may be defined as a state (of a cell, tissue, system or body) in which
more than normal amounts of insulin are required to draw out a quantitatively normal
response (Berson and Yalow, 1970). It should be emphasised that the level of glycemia
may be within the normal range in a person with insulin resistance as a result of
compensatory hyperinsulinemia (Flier, 1993).

Insulin regulates blood glucose by inhibiting hepatic glucose synthesis and by stimulating
glucose utilization in skeletal muscle.
NIDDM patients (Mitakou et al, 1992).

Both insulin actions are impaired in IGT and
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1.4 The Cause of NIDDM Development
Several investigations including prospective studies have suggested that increased insulin
resistance precedes the development of IGT and NIDDM (Bennett, 1990, Haffner et al,
1990a, Skarfors et al, 1991, Martin et al, 1992).

The progression from normal glucose tolerance to IGT to NIDDM with mild fasting
hyperglycemia (< 6.7-7.8 mmol/L) is characterized by progressive hyperinsulinemia
(DeFronzo et al, 1992).

Most evidence indicates that insulin resistance is the major factor which initiates the
sequence of events resulting in NIDDM. While the pancreas carries a sufficiently high
insulin secretory response to degree of insulin resistance, glucose tolerance remains
normal to

mildly impaired. However, then the ß-cell starts to fail, glucose tolerance

impairs rapidly and overt diabetes mellitus follows (DeFronzo et al, 1992). Most studies
have found a reduction in ß-cell mass in NIDDM patients (Klöppel et al, 1985, Clark et
al, 1988).

Genetic or familial factors contribute to the pathogenesis of NIDDM (Bennett, 1990,
Martin et al, 1992, Haffner et al, 1988).

'The thrifty phenotype’ hypothesis is another proposed explanation for ß-cell failure in
the pathogenesis of NIDDM. This hypothesis proposed that ß-cell failure is due to intra
uterine and early postnatal malnutrition in fetus and newborn respectively (Hales and
Barker, 1992). Malnutrition during intra-uterine period of life may lead to poor fetal
development of the pancreas, particularly ß-cells, which consequently are not capable to
compensate sufficiently for insulin resistance later in life (Hales and Barker, 1992).
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1.4.1 The Development of Insulin Resistance
Sedentary life-style is associated with obesity and physical inactivity, and these are
causes of insulin resistance (Yki-Jarvinen, 1994). The distribution of fat within the body
is an important factor in developing insulin resistance in individuals.

Upper body

(android) obesity is more common in NIDDM patients than in equally obese non-diabetic
men and women (Bjomtorp, 1988). Helmrich et al (1991) have reported that physical
activity even without weight loss plays an important role in the prevention of NIDDM,
even in genetically susceptible people.

Furthermore, epidemiological studies have suggested that a high intake of dietary fat
(Tsunehara et al, 1990, Marshall et al, 1991), an excessive consumption of refined
carbohydrates particularly sucrose (Baird, 1972, Freskens and Kromhout, 1989), and a
low dietary fibre intake (Truswell, 1975) play roles in the etiology of NIDDM.

1.4.2 The Development of Impaired Insulin Secretion
Several hypothesis have been proposed to account for the defect in insulin secretion in
NIDDM.

Several studies have suggested that chronic hyperglycemia is deleterious to insulin
secretion and also persuades insulin resistance. It may eventually result in progressive
loss of P-cell function and in the NIDDM state (Yki-Jarvinen, 1992).

Amyloid deposition has been found frequently in NIDDM patents and amylin was shown
to be its precursor (Clark, 1989, Nishi et al, 1990). Recently, amylin was suggested as a
contributor to the defect in insulin secretion in isolated rat pancreatic islets (Ohsawa et
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Galanin is the newest hormone that has been proposed to be involved in

impaired insulin secretion in NIDDM (Dunning and Taborsky, 1988).

1.5 Significance o f the Thesis
The identification of subjects at risk for diabetes mellitus has been a goal for physicians
and scientists (Stem and Haffner, 1986, Nelson et al, 1988).

The hope is that

identification may lead to action which may help to prevent new cases or at least delay
the onset of disease. Furthermore, early detection of diabetes in subjects who have the
disease will enable the physician to initiate early treatment well before the onset of long
term complications such as atherosclerosis.

GDM is a strong predictor of glucose intolerance or NIDDM later in the life of the
mother (O’Sullivan, 1989, Persson et al, 1991).

Several studies have suggested that

normoglycemic obese and non-obese women with previous GDM exhibit abnormalities
of insulin response to glucose administration and evidence of increased insulin resistance
(Ward et al, 1985, Catalano et al, 1986, Effendic et al, 1987).

The factors responsible for development of impaired glucose tolerance and NIDDM in
subjects with previous GDM are unclear (Persson et al, 1991). Effendic et al (1987)
have reported a significantly decreased early insulin response and insulin sensitivity in
women of normal weight who previously had GDM and who have had normal and
abnormal oral glucose tolerance test (OGTT) postpartum. Abnormal glucose tolerance
arising in women who have had GDM within the first postpartum year has been reported
by several researchers (Metzger et al, 1985, Catalano et al, 1986).
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Although several studies have shown that women have a severe risk of developing
diabetes mellitus if they have had GDM, these have been

few studies of metabolic

abnormalities in a population of women who have had GDM.

A strategy to prevent or delay the development of NIDDM in women with previous
GDM has the potential to save millions of health care dollars and to prevent substantial
suffering caused by the disease (Gregory et al, 1993).

This study is of a group of such women one year after delivery, compared with a control
group.

It is a population-based study, which should form the basis for a later longitudinal study.

1.6 Aims o f the Study
The aim of this study is to test the following hypotheses:

1. We hypothesise that women who have had GDM are more likely to have known or
postulated risk factors for NIDDM, namely age, a maternal history of diabetes mellitus
and central obesity than controls.

2. Women who have had GDM are more likely (than controls) to have developed a high
blood concentration of non-esterified fatty acids (NEFA) in the context of a disordered
lipid metabolism. These are thought to be factors which predict the early development of
NIDDM.

Dyslipidemia includes moderate hypercholesterolemia, hypertriglyceridemia,

and a low HDL-cholesterol concentration.

Furthermore, correlates of dyslipidemia

include higher plasma concentrations of apolipoprotein B, VLDL, and IDL, and lower
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apolipoprotein A-I concentrations. Other correlates include denser and smaller LDL and
HDL particles and increased cholesteryl ester transfer protein (CETP) activity in plasma.

3. We hypothesise that women with previous GDM are more likely (than controls) to
have accelerated insulin resistance (evidenced by fasting hyperinsulinemia).

4. We hypothesise that women with previous GDM are more likely (than controls) to
have developed elements of the insulin resistance syndrome (obesity, associated with
hyperandrogenesity, dyslipidemia, hyperinsulinemia,

high diurnal plasma glucose

excursion, high blood pressure).

5. We hypothesise that women with previous GDM are more likely (than controls) to
have high dietary intake of saturated fat and lack of exercise.

6. We hypothesise that women with previous GDM are more likely (than controls) to
have microalbuminuria, suggesting organ damage associated with diabetes.

CHAPTER TWO
LITERATURE REVIEW
2.1 Introduction
Diabetes mellitus is the most common metabolic disorder in humans, affecting about 2
5% of the general population worldwide. The National Diabetes Data Group (1970) and
the WHO Expert Committee on Diabetes Mellitus (1980) classified the heterogenous
syndrome diabetes mellitus according to its etiopathology (Table 2-1), but other
classifications persist (Weiss, 1988).

Table 2-1 Classification of diabetes mellitus
* Type I: insulin dependent diabetes mellitus (IDDM)
* Type II: non-insulin-dependent diabetes mellitus (NIDDM)
Obese
Lean

* Secondary diabetes mellitus
* Impaired glucose tolerance
Obese
Lean

* Gestational diabetes mellitus

Non-insulin-dependent diabetes mellitus (NIDDM) has an insidious onset and may exist
for years without diagnosis. A number of risk factors have been recognized, including
hyperglycemia, hyperinsulinemia, and other metabolic abnormalities obesity, physical
inactivity, dietary factors (a high dietary fat intake, a lack of dietary fibre, and an
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excessive consumption of sucrose and other refined carbohydrates), and low socio
economic status, (Knowler et al, 1988).
Some risk factors such as hyperinsulinemia may be recognized many years before the
onset of NIDDM (Sicree et al, 1987, Saad et al, 1988, Lundgren et al, 1990, Haffner et
al, 1990 b, Warram et al, 1990,Charles et al, 1991)

2.2 Gestational Diabetes Mellitus
Gestational diabetes mellitus (GDM) is the most common metabolic disorder in
pregnancy. About 90% of all pregnant diabetic patients have GDM, and, IDDM and
NIDDM together account for the remaining 10% (Hagay et al, 1992).
It is defined as carbohydrate intolerance of variable severity with onset or first
recognition during pregnancy (Hunter et al, 1990). The onset is usually recognized in
the latter part of the second and early part of the third trimester (24-36 weeks)
(Brinkman HI, 1987).
The incidence of GDM has been reported to be 2-13% of all pregnancies (Hadden, 1980,
Sepe et al, 1985).
The majority of women who develop GDM will return to normal glucose tolerance
during the puerperium.

However, a significant number of these women, variously

estimated to be between 30%-60% will progress to type II (NIDDM), within 5-10 years
(Brinkman III, 1987).
Beischer et al have studied women living in Australia and reported that there are
significant increases in the incidence of the more severe grades of GDM in women born
in the Mediterranean region, Asia, the Indian subcontinent, Egypt, and Arabic countries.
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The incidence of GDM increased significantly with time in all racial groups, rising from
3.3% during 1979-1983 to 7.5% during 1984-1988 (Beischer et al, 1991).

GDM is considered to be associated with increased perinatal morbidity and mortality
which may be reduced by adequate diagnosis and management (Backx et al, 1989). In
addition, women who develop GDM have an increased risk of permanent diabetes which
increases with time of follow-up (Martin, 1991).

2.2.1 Screening
Currently, most obstetricians screen all of their pregnant women for gestational diabetes.
The simplest screening test for GDM is the taking of a history. Historic risk factors such
as the presence of a family history of diabetes, a previous perinatal loss, or the previous
birth of a macrosomic baby clearly identify individuals at increased risk for GDM in their
current pregnancies.

Unfortunately, the taking of a history is a relatively insensitive

screening test, identifying only half of women who proceed to develop GDM (Coustan,
1993).
The likelihood of GDM is increased with advancing maternal age (Coustan et al, 1989).
Additionally, as hormonally produced insulin resistance in pregnancy is apparent by the
end of the second trimester, testing is best performed between 26-30 weeks’ gestation.
Renal glycosuria is common in pregnancy and is hard to evaluate. However, women with
unrecognized pre-existing diabetes may become pregnant and the presence of glycosuria
on routine testing in the first 12 weeks of pregnancy may then be significant.

Such

women would be regarded as having pre-existing diabetes, not GDM (Martin, 1991).
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A modified oral glucose tolerance test (OGTT) is used to screening for GDM. A 75 g
oral glucose load is given to all pregnant women at between 26-30 weeks’ gestation in
the non-fasting state.

The plasma glucose level is then measured one hour later and women who ‘screen
positive’ should have a 75g OGTT before 30 weeks’ gestation (Martin, 1991). For a
75g glucose load the cut-off plasma glucose value at 1 hour is 8.0 mmol/L and for 50g it
is 7.8 mmol/L (Martin, 1991).
These recommendations must not prevent the recognition and testing for diabetes at any
stage of pregnancy if suggestive clinical features are present (Martin, 1991).
Serum fructosamine and glycosylated haemoglobin (H bA lc) give similar clinical
information, and may be used interchangeably for the metabolic control of diabetes
mellitus patients. Neither have diagnostic value as screening test for GDM. It may be
because fructosamine originates mainly from the nonenzymatic glycation of albumin, so,
its concentration depends therefore not only on the concentration of glucose but also on
albumin (Vermes et al, 1989).

2.2.2 Diagnostic Criteria
Oral glucose tolerance tests have been used for diagnosing GDM for many years (Hunter
et al, 1990). The Procedure for the diagnosis of GDM is shown in Table 2-2.

2.2.3 Medical Management
The goal of medical management of GDM is the prevention of perinatal mortality and
morbidity (Coustan, 1993).

Several treatment strategies have been proposed: diet,
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exercise, pharmacologic intervention using oral hypoglycemic agents, and insulin therapy
(Langer, 1993).

Table 2-2 Procedure for diagnosis o f GDM (Martin, 1991 ).
Indication

Optimal

Test performed

gestation

Diagnostic criteria-plasma
glucose level (mmoi/L)

(weeks)
Clinical suspicion of

any time

75 g OGTT (fasting)

0 hours > 5.5

GDM
2 hours > 8.0
Screening

26-28

50 g glucose load

1 hour > 7.8

(non-fasting)
Confirmation of

26-30

75 g OGTT (fasting)

0 hours > 5.5

diagnosis after positive
screening test

2 hours > 8.0

The majority of GDM patients can be managed by diet alone (Hoolysworth et al, 1992)
or exercise and diet (Horton, 1991), and a small percentage may require insulin to
achieve euglycemia (Brinkman III, 1987).

These patients are not prone to develop

ketosis (Hoolysworth et al, 1992).

2.2.4 Diet Therapy
The diet therapy mainly improves the body’s sensitivity to insulin. Diet therapy may
include caloric restriction. It is currently recommended that diet should include 50-55%
carbohydrate, mainly complex carbohydrate with an emphasis on reduced intake of
simple sugars because of their high absorption rate. Fat consumption should be limited
to 20-30%, with decreased saturated fats and cholesterol and increased polyunsaturated
fats. The diet should include a modest 20-30% protein. This diet approach will usually
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result in a 0.83-1.1 mmol / L decline in maternal glucose level (Langer, 1993). Diet
program must provide a caloric intake sufficient to avoid ketonuria (30 kcal / kg in
women 80-12% ideal body weight) (Peterson et al, 1991). In addition, even a small
weight loss will improve maternal glucose levels (Langer, 1993).

2.2.5 Exercise
GDM patients should be encouraged to walk 2-3 miles an hour for 20-30 minutes, 4 days
a week or engage in any other equivalent activity that they enjoy (Langer, 1993).
Cardiovascular conditioning exercise for 20 minutes three times per week has also been
shown to be useful in lowering both fasting and post-prandial glucose levels (Mulford et
al, 1993). Exercise has a major effect on glucose metabolism and reduction in lipid levels
(Peterson et al, 1991).

2.2.6 Oral Hypoglycemic Agents
Oral hypoglycemic agents play a limited role in diabetes in pregnancy.

The main

objection to their use in pregnancy is the fear of congenital anomalies or fetal
compromise through direct stimulation of the fetal pancreas (Langer, 1993). Langer et al
recently have reported that second-generation oral hypoglycemic agents (glyburide) do
not cross the placenta. It suggests that second-generation hypoglycemic agents may play
a role in the management of type II and GDM in the future (Langer, 1993).

2.2.7 Insulin Therapy
If diet and exercise do not achieve the requisite glucose levels (glucose levels < 4 . 4
mmol/L or < 7.8 mmol/L 1 hour after meals), insulin therapy based on body weight and
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gestational age is required (Peterson et al, 1991). Insulin is generally discontinued at
delivery (Peterson et al, 1991).

2.3 Complications of GDM
The rationale for treatment of GDM is to prevent diabetic complications. Poor glycemic
control in early pregnancy is associated with an increased risk of major congenital
abnormalities in the fetus (Gregory et al, 1992).

In managing the pregnant diabetic

patients, two patients are being treated, the mother and fetus (Lieb, 1987). Studies both
in

vivo

and in v itro using animal models have provided data suggesting that

hyperglycemia, hyperketonemia, and reduced glucolysis are, under certain conditions and
circumstances, all potentially teratogenic, particularly when they occur in the earliest
stages of pregnancy (Baird, 1986).
Most neonatal complications such as macrosomia, hypoglycemia, hyperbilirubinemia,
hypokalaemia, polycythemia, major congenital anomalies (Hod et al, 1991), intra-uterine
death, prematurity, and respiratory distress syndrome are readily avoided if GDM
diagnosed and treated early and promptly (Lieb, 1987).
The adult female offspring of GDM mothers may exhibit impaired glucose tolerance and
develop GDM when they become pregnant (Van Assche et al, 1991).
Obstetric management centers around surveillance to detect potential fetal compromise
and the establishment of the proper time for delivery. Other goals are the diagnosis of
fetal macrosomia and the avoidance of shoulder dystocia.

Sudden fetal death, most

likely is related to suboptimal metabolic control, is well documented in diabetic
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pregnancies, but is less likely in GDM (Coustan, 1993). Antepartum fetal surveillance
should begin at 28 weeks gestation (Landon et al, 1985).

Goldman et al reported that polyhydramnios, pre-term labor, and pyelonephritis were not
more frequent in GDM, but hypertension without proteinuria and pre-eclampsia were
more frequent in GDM patients. Despite this, cesarean delivery was more common in
GDM (Goldman et al, 1991).

2.4 Long-term Follow-up
Women with history of GDM are at increased risk for future development of NIDDM.
Follow-up studies have estimated that 30-50% of these women develop diabetes during
the first 3-5 years after a pregnancy complicated by GDM, which after 12-18 years the
proportion is 60-100% (Gregory et al, 1993). For this reason, the American Diabetes
Association (ADA) has recommended that at the first postpartum visit, subjects who
have had GDM should have a standard 75g 2-hours OGTT.
The high prevalence of subsequent diabetes may serve to make women with previous
GDM an ideal group on which to attempt interventions designed to prevent the
development of diabetes in the future (Coustan, 1993).
Persson et al speculate that an elevated proinsulin / insulin ratio in women with previous
GDM could be a marker for later development of NIDDM (Persson et al, 1991). The
usefulness of this measurement in follow-up is unclear.
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2.5 Metabolic Changes in Normal Pregnancy and GDM
In normal pregnancy insulin secretion increases throughout gestation whereas peripheral
insulin sensitivity is decreased.

Fasting plasma glucose levels are decreased by

approximately 10% during the first trimester.

Maternal amino acid levels are also

reduced.

On the other hand, plasma lipids are increased.

As gestation advances, progressively

increasing concentrations of insulin antagonistic hormones are secreted by the placenta
(Reece et al, 1994). In addition, the fasting insulin/ glucagon ratio is increased in both
normal and gestational diabetic pregnancy (Reece et al, 1994). Plasma total cholesterol,
LDL-cholesterol, and triglyceride concentrations are higher in pregnancy compared with
non pregnancy (Loke et al, 1991).
GDM patients exhibit an increased insulin response to oral glucose and amino acids
during pregnancy when compared with the postpartum period (Kuhl et al, 1985).
Fasting insulin concentration, plasma glucose, and free fatty acids are higher in obese
GDM women compared with normal non-obese pregnant women, whereas 3hydroxybutyrate levels are similar (Carpenter, 1993). Non-obese GDM patients have
fasting insulin levels similar to non-diabetic pregnants.

Fasting plasma glucagon is

probably not increased in GDM.
Lipids and amino acids levels are significantly elevated in GDM subjects compared with
normal control subjects (Carpenter, 1993).

The postpartum fall in insulin sensitivity

measured by the euglycemic clam technique is also more marked in GDM than in normal
pregnancy (Carpenter, 1993).
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2.6 Metabolic Abnormalities in Women With Previous GDM
Considerable research has been done on GDM subjects during pregnancy in the last two
decades.

Subjects with histories of GDM, particularly those with fasting hyperglycemia, are at
high risk for developing subsequent overt diabetes mellitus (Metzger et al, 1985, Kjos et
al, 1990).
Several follow-up studies have been conducted on the populations with previous GDM.
Those indicated a high prevalence of overt diabetes mellitus years after the onset of
GDM (Table 2-3) (Mestman, 1988).

Table 2-3 Follow-up studies on the GDM population (Mestman, 1988)
Author

Total subjects

Follow-up period

Overt DM

(years)
O’Sullivan (1984)

615

22-28

25%

Stowers et al (1985)

112

22

7

Metzger et al (1985)

113

1

38%

Mestman et al (1972)

232

5

23%

On the other hand, Kjos et al (1991) have reported that lipid abnormalities are
uncommon at 36 months postpartum in women with previous GDM and manifest
predominantly as a mild elevation in the plasma TG level.
Our current understanding of the development of metabolic disorders in women with
previous GDM until they develop diabetes mellitus is incomplete.
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2.7 Lipid and Lipoprotein Metabolism
GDM is a potentially serious disease.

Evidence from autopsy, clinical, and

epidemiological studies indicates that atherosclerosis more readily becomes advanced in
diabetic than in non-diabetic subjects (Stout, 1992). A group of 89 women were studied
12-18 years after the diagnosis of GDM. The results showed that the incidence of overt
diabetes was 65.2%. 8.6% of the subjects who developed overt diabetes mellitus had
had a cerebral vascular accident, 6.8% had suffered a myocardial infarct, and 3.4% were
on dialysis therapy (Mestman, 1988).
Lipid and lipoprotein abnormalities have been implicated in the pathogenesis of
atherosclerosis in both diabetic and non-diabetic individuals (Assmann et al, 1988, Stern
et al, 1989). Kjos et al (1991) have studied women with recent GDM for a period of 36
months after delivery. They have reported that plasma TG level was elevated and HDL
C was decreased in women with previous GDM at 3-11 months after delivery but not
thereafter (Kjos et al, 1991).
These findings prompted us to examine the lipid and lipoprotein levels of women with
recent GDM, to determine whether they have lipid and lipoprotein profiles indicative of
increased

risk

for

atherosclerosis

in

particular

hypercholesterolemia

and

dyslipoproteinemia (characterized by hypertriglyceridemia and low plasma HDL-C
concentrations).

2.7.1 Endogenous and Exogenous Pathways of Lipoprotein Metabolism
Dietary lipids are transported from the intestine to the liver via the exogenous pathway
(Figure 2-1), and lipids synthesised by the liver are transported from the liver to
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peripheral tissues via the endogenous pathway (Figure 2-2) (Trimble and McDowell,
1992).
Dietary cholesterol, mostly as cholesteryl ester, is absorbed in the intestine. Esters are
hydrolyzed by cholesterol esterase to release free cholesterol and fatty acids. TG are
hydrolyzed by pancreatic and intestinal lipase and absorbed mainly as free fatty acids and
monoglycerides. TG, cholesterol, and apolipoproteins are assembled into chylomicrons,
lipoprotein particles which are secreted into the lymph and enter plasma thorough the
thoracic duct. Chylomicrons are normally found post-prandially in plasma (Dominiczak,
1994).

Intestine
Dietary
Fat

Figure 2-1 Exogenous pathway of lipoprotein metabolism
(Trimble and McDowell, 1992).

VLDL

Remnant

Liver

other pathways

Figure 2-2 Endogenous pathway o f lipoprotein metabolism
(Trimble and McDowell, 1992)
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The exogenous pathway of lipoprotein metabolism (Figure 4-1) begins with secretion of
chylomicrons by the intestine following absorption of dietary fat.

Lipoprotein lipase

(LPL) acts on chylomicron particles to produce chylomicron remnants.

Chylomicron

remnants are removed from plasma by the liver (Trimble and McDowell, 1992). The
nature of the receptor is unclear (Trimble and McDowell, 1992).
The endogenous pathway of lipoprotein metabolism (Figure 4-2) begins with hepatic
secretion of the triglyceride-rich lipoprotein (VLDL) into the plasma. This apoB-100
containing lipoprotein is converted to IDL and subsequently to LDL in the plasma
compartment.
In the process, the particles’ core is hydrolysed by lipolytic enzymes (Trimble and
McDowell, 1992). Both of the major plasma lipolytic enzymes, lipoprotein lipase and
hepatic lipase (HLP) have been implicated in the metabolism of apoBlOO containing
particles. It seems that the affinity of LPL is higher for large triglyceride-rich lipoprotein
particles than for smaller remnants, whereas HLP, which expresses both triglyceride
lipase and phospholipase activities, seems to have higher affinity for smaller VLDL and
IDL particles (Nicoll and Lewis, 1980).
CETP also is involved in these processes. LPL hydrolyses TG and CETP exchanges TG
for cholesteryl ester from HDL.
Subsequently, LDL is cleared from plasma by the LDL receptor. Chemically modified
LDL may be cleared by other pathways such as the scavenger receptor on macrophages
Brown and Goldstein (1990) have suggested that the macrophage scavenger pathway
may be involved in the formation of foam cells and initiation of the atherosclerosis
process.
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2.7.2 Cholesterol
Numerous epidemiological and genetic studies have shown that hyperlipoproteinemia, in
particular hypercholesterolemia, is one of the principal risk factors for coronary heart
disease (Douste-Blazy and Kloer, 1989).

2.7.3 Triglyceride
Primary and secondary hypertriglyceridemias (HTG) are the commonest lipid transport
disorders found in patients obesity and diabetes mellitus (Eisenberg, 1987).
In obese individuals with upper body obesity appear to have a higher lipolytic activity
adipocytes compared with obese subjects with peripheral obesity (fat distribution in the
hips, buttocks, and thighs), resulting in a greater flux of FFAs toward the liver (Kissebah
and Peiris, 1989). High FFA concentrations have been reported to decrease the hepatic
extraction of insulin, resulting in systemic hyperinsulinemia (Kissebah and Peiris, 1989).
HTG in obesity is associated with increase in the hepatic production of VLDL (Howard
et al, 1987).
Hepatic lipase is an enzyme that contains triglyceride lipase, monoglyceride lipase, and
phospholipase activity. Hepatic lipase catalyzes the degradation HDL particles, more
specifically HDL2 (Tikkanen, 1989). Despres et al (1990 b) have suggested that LPL
activity is decreased and hepatic triglyceride lipase activity is increased in abdominal
obesity.

Low LPL activity results in the reduction in the catabolic rate of TG-rich

lipoproteins and high hepatic triglyceride lipase activity causes a reduction in plasma
HDL2 concentration.
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Thus, hypertriglyceridemia and a low concentration of HDL-C, particularly HDL2, are
common in abdominal obesity (Despres et al, 1990 a, Kissebah and Peiris, 1989,
Despres, 1991).

The apo CIII gene is a part of a cluster with apo A-I and apo A-IV on chromosome 11,
and variation in this cluster has been implicated in hypertriglyceridemia. Apo CIII has
been suggested as candidate for a rate limiting mediator in the control of plasma TG
levels since apo CIII inhibits LPL (Talmud, 1993). Whether other factors such as diet,
alcohol consumption, obesity, smoking, exercise and oral contraceptive use significantly
aggravate hypertriglyceridemia (NIH Consensus Conference, 1993) via increasing apo
CIII activity is uncertain.
In western countries, plasma TG concentrations usually are inversely related to plasma
HDL-C (Marmot, 1993). The PROCAM study has shown that plasma TG and LDL-C
are independent predictors of coronary heart disease (CHD) incidence, but the predictive
effect of TG for the development of CHD is observed only where the LDL-C/ HDL-C
ratio is high (greater than 5) (Marmot, 1993).
The association of hypertriglyceridemia with premature atherosclerosis may not be due
to the direct effects of the TG itself, but may be associated with changes in the
concentration and composition of lipoproteins such as IDL, LDL and HDL.
HTG may result in an alteration in CETP activity which has an important role in lipid
transport (Deckelbaum et al, 1984). The presence of an increased mass of circulating
VLDL and chylomicrons promotes plasma lipid transfer activity with loss of cholesteryl
ester from HDL and production of TG-enriched HDL particles. This TG-enriched HDL
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particle is susceptible to lipolysis by hepatic lipase resulting in further HDL degradation
and the generation of smaller HDL3 particles (Tikkanen, 1989).
Postprandial hypertriglyceridemia may be more important than the high fasting TG
levels, but little is known about this at present (NIH Consensus Conference, 1993).

2.7.4 Non-esterified Fatty Acids (NEFA)
In human, ~ 200 g of NEFAs (often termed free fatty acids) are mobilized from adipose
tissue each day and transported in the circulation at concentrations ~ 100-1000 fold
higher than their monomer solubility limit (Cistola and Small, 1991). They principally
consist of oleic (about 38%), palmitic (28%), stearic (15%) and linoleic (9%) acids
(Fruchart et al, 1989).
Solubilization and transport is mediated primarily by serum albumin. Albumin prevents
the combination of fatty acids into liquid-crystalline or crystalline aggregates at neutral
pH (Cistola et al, 1988) and supplies a source of fatty acid for lipid synthesis and energy
production (Cistola and Small, 1991).
Under normal circumstances, approximately 99% of the circulating NEFAs are bond to
serum albumin. However, cellular membrane and plasma lipoproteins have a high affinity
for NEFAs and under some circumstances (eg high NEFA concentration in plasma) they
may compete with albumin for NEFA binding (Cistola and Small, 1991).
In NIDDM patients, the action of insulin in both suppressing hepatic glucose output
(HGO) and stimulating peripheral glucose uptake into skeletal muscle is impaired, and
the combination of these defects is the principal cause of postprandial hyperglycaemia
(Walker et al, 1993). In addition, the action of insulin in suppressing adipose tissue

Chapter Two

27

Literature Review

lipolysis and increasing re-esterification is impaired, leading to increased plasma NEFA
levels and rates of lipid oxidation in the insulin-stimulated state in both obese and non
obese patients with NIDDM (Walker et al, 1993).
Elevated plasma NEFA concentration in NIDDM may contribute to insulin insensitivity
(Walker et al, 1993).

Studies on rat liver have shown that NEFA stimulates

gluconeogenesis (Williamson et al, 1966). An increased NEFA concentration in plasma
diminishes the suppressive action of insulin on hepatic glucose output (HGO) and also
decreases peripheral insulin-mediated glucose disposal in healthy man (Lee et al, 1988).
Glucocorticoid induced insulin resistance in normal rats has been shown to be due to
excessive NEFA oxidation; possibly via an increase in the glucose-fatty acid cycle
ultimately inhibiting glucose transport, or via decreased glycogen synthesis, or by a direct
effect on glucose transporter translocation or activity (Guillaume-Genil et al, 1993).

2.7.5 VLDL
VLDL is the primary lipoprotein product of the liver and the carrier of endogenous
triglycerides. Most of the TG in the plasma is carried in VLDL, whereas LDL carries
most of the cholesterol (Chappell and Spector, 1991).
Because of the essential role played by VLDL in lipoprotein metabolism and substrate
flux and the possibility that VLDL may (indirectly) induce atherosclerosis (Howard et al,
1987), its concentration was measured in this study.

2.7.6 IDL
Epidemiological studies in humans suggest that plasma concentration of IDL or remnant
lipoproteins

are

predictors

of the

severity

or

progression

of

atherosclerosis.
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Nordestgaard and Tybjaery-Hassan (1992) have suggested that IDL or remnant
lipoprotein concentrations were better predictors of the extent of atherosclerosis than
were LDL or VLDL. Cholesterol-fed animals also demonstrate accumulation of IDL
and rapid development of atherosclerosis (Nordestgaard and Lewis, 1991).
Analysis of human plasma by gradient gel electrophoresis (GGE) has shown the IDL
fraction from normal subjects consist of two major subspecies with particle diameters in
the range of 27.5 to 30.0 nm. The larger, usually predominant, subspecies has been
designated IDL-1, and the smaller, IDL-2 (Musliner et al, 1986).
The IDL subfractions differ in their cholesterol enrichment, with IDL-2 being more
cholesterol enriched than IDL-1.

The plasma triglyceride level influences the

predominant IDL subfraction present in the circulation.

With higher plasma TG

concentrations, IDL-1 is predominant and may facilitate lipid transfer by CETP action to
a greater extent. Greater CETP activity is thought to result in the formation of smaller
and denser LDL particles (Krauss, 1987).

2.7.7 LDL
In vivo studies of the metabolism of human VLDL and IDL subfractions in a rat model

system have suggested pathways for production of two of the major LDL subclasses,
LDL-I and LDL-II. Small VLDL and the larger IDL species (IDL-1) are specifically
converted by lipolysis in the absence of CETP activity to particles of size and density
similar to LDL-II, while IDL-2 appears to be a precursor of larger, more buoyant LDL-I
particle. However, it is not known how the two major, discrete IDL size subspecies
originate (Musliner et al, 1991).
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Several studies in animals and in humans have shown that the preferential substrates of
hepatic triglyceride lipase are chylomicrons and VLDL remnants (Nicoll and Lewis,
1980). The decreased hepatic triglyceride lipase activity may results in the accumulation
of IDL and the TG-enrichment of LDL (Robert et al, 1989).
Austin et al (1988) identified two distinct human phenotypes (denoted A and B) by non
denaturing gradient gel electrophoretic analysis of plasma LDL.

Phenotype A was

characterized by predominance of large, buoyant LDL particles, and phenotype B by a
major peak of small, dense LDL particles. Phenotype B appeared to be inherited as a
single-gene trait with a dominant mode of inheritance (Austin et al, 1988), although later
studies revealed a more complex picture.
Pattern A is defined as an LDL subclass pattern with the major gradient gel peak at a
particle diameter of 25.5 nm or greater and the presence of a secondary peak of smaller
LDL particles. Pattern B has the major peak at a particle diameter of less than 25.5 nm,
with skewing of the curve toward larger particle diameters (Austin et al, 1988).
Later the same researchers reported that LDL subclass phenotypes are related to other
lipoproteins and also apolipoproteins (Austin et al, 1990).

Phenotype B is positively

related to plasma TG and apoB levels, and VLDL and IDL mass. In addition, there is a
negative correlation between phenotype B and HDL-C, HDL2 mass, and plasma apoA-I
concentration (Austin et al, 1990).
LDL subclass phenotype B is related to relatively increased plasma TG, apoB, VLDL,
and IDL concentrations, decreased HDL and plasma apoA-I levels, and increased risk of
coronary artery disease in comparison with subjects with LDL subclass phenotype A
(Feingold et al, 1992). It is possible, therefore, that the initial observation by Austin et al
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suggesting a single gene trait with dominant inheritace may need to be revised, in the
light of these more complex associations.

2.7.8 HDL
HDL appears to be associated with ‘reverse cholesterol transport’, the delivery of
peripheral tissue cholesterol back to the liver for recycling or for excretion from the body
(Barter, 1993).

HDL appears to protect against the development of premature coronary atherosclerosis
probably through the reverse cholesterol transport process (Miller and Miller, 1975).
The Framingham Study has provided evidence that HDL-C is inversely related to the
development of a myocardial infarction in both men and women (Miller and LaRosa,
1991). Elevated HDL levels have been shown to lead to regression of atherosclerosis in
animal models (Johnson, et al, 1991).
In addition, Schmitz and Williamson (1991) suggested that HDL metabolism plays a
major role in cell membrane protection.

Another interesting reason for the anti

atherogenic properties of HDL may be that HDL prevents the oxidation of LDL (Tribble
and Krauss, 1993).
HDL3 is the major substrate for the esterification of plasma cholesterol by the enzymes
CETP and LCAT, and therefore plays an important role in the transport of cholesterol
through the plasma (Barter et al, 1985). The reason for the increased substrate reactivity
of smaller HDL3 particles with LCAT is not clear.
Several hypotheses have been suggested, for instance that the phospholipid / FC and
apoA-I / apoA-II ratios in same way affect substrate reactivity (Fielding et al, 1972).
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The increasing amount of CE in particles causes enlargement and enlargement may
reduce their ability to act as substrate for LCAT (Fielding et al, 1972).

2.7.9 Lp(a)
Lp(a) was first reported in human plasma as a genetic variant of LDL by Berg in 1963
(Berg, 1963). Like LDL, CE is the major constituent of Lp(a), but the particle contains
more TG than LDL (Fless et al, 1986). Lp(a) particles contain two proteins, apo(a) and
apoB, linked together by a single di-sulfide bond (Gaubatz et al, 1983).

Apo(a) is

thought to be synthesized mainly in the liver (Tomlinson et al, 1989).
Elevated plasma Lp(a) concentration is a risk factor for coronary artery disease (CAD)
(Loscalzo, 1990) and peripheral vascular disease (PVD) (Widmann and Sumpio, 1993).
James et al (1995) have suggested that Lp(a) concentrations greater than 30 mg / dl are
independently correlated with vascular disease in IDDM and NIDDM patients.
Apo(a) seems to be little affected by age, sex, and diet (Nestel et al, 1993), although a
recent study has reported that the apo(a) level was increased 25% by the trans fatty acid,
elaidic acid in the diet (Nestel et al, 1993). Haffner et al (1992) reported that Lp(a)
levels were significantly higher in diabetic patients who had higher total and LDL
cholesterol levels.
Apo(a) levels are higher in both IDDM (Jenkins et al, 1991) and NIDDM (Jenkins et al,
1992) patients with microalbuminuria and may contribute to their tendency to
macrovascular disease and early mortality.

Apo(a) is elevated in active diabetic

retinopathy (Maioli et al, 1993) and renal failure (Black and Wilcken, 1992). Whether
elevated Lp(a) is a consequence or a cause of diabetic microvascular disease need further
study (Jenkins et al, 1992).
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The physiological functions of apo(a) or Lp(a) are not clear. The structural homology of
Lp(a) with LDL and plasminogen suggests that Lp(a) may be involved in both atheroma
formation and thrombosis which are most important mechanisms in the pathogenesis of
atherosclerosis (Campbell et al, 1992).

Lp(a) may promote thrombosis through

interference with plasminogen activation, but it does not interfere with thrombolytic
therapy during acute myocardial infarction (Simons, 1993).

2.7.10 CETP
Human plasma contains a lipid transfer protein commonly called cholesteryl ester transfer
protein (CETP).

CETP facilitates the transfer of cholesteryl ester, triglyceride, and

phospholipid among lipoproteins (Albers et al, 1990). The major function of CETP in
human plasma is believed to be the transfer of LCAT-derived cholesteryl ester to
lipoprotein acceptors, LDL, VLDL, or lipoprotein remnants. During this process, the
acceptor lipoproteins donate triglyceride and phospholipid to HDL. Thus, CETP play a
key role in the ’reverse cholesterol transport’ pathway (Albers et al, 1990).
HDL cholesteryl ester also can be delivered to the liver by other mechanisms such as
selective uptake of CE from HDL without particle endocytosis, and uptake of CE
mediated by apoE on the hepatocyte membrane (McPherson, 1993).
A diet high in cholesterol content increases the plasma CETP concentration in man
(Martin et al, 1991). Marcel et al (1990) reported that the levels of CETP are 25%
higher in women compared with men.
CETP is synthesized in a number of tissues, mainly in the liver and adipose tissue
(McPherson, 1993).
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2.7.11 Apolipoproteins A-I and B
In patients with coronary heart disease, total plasma apoB levels is often significantly
elevated in the presence or absence of a reduction of total plasma apoA-I (Douste-Blazy
and Kloer, 1989).
Many studies have reported that plasma apolipoprotein A-I, the major protein of HDL, is
a good negative predictor for coronary heart disease (Fruchart, 1990).
These are at least two main lipoprotein subclasses containing apo A-I: those which
contain, as the main protein components apoA-I and apoA-II, designated Lp A-I:A-II,
and those contain apoA-I but not apoA-II, designated Lp A-I (Fruchart, 1990). These
subclasses can be separated immunochemically.
Fruchart et al recently reported that cholesterol efflux from cells is mediated by Lp A-I
and not by Lp A-IiA-II, and that the lower HDL concentrations in coronary artery
disease were linked with lower Lp A-I levels, while Lp A-LA-II was unchanged
(Fruchart et al, 1990).

2.8 Carbohydrate Metabolism

2.8.1 Factors Influencing Rates of Glucose Uptake
There are three major sources of plasma glucose (Figure 2-3), diet and hepatic
gluconeogenesis and glycogenolysis (Owen et al, 1969).
Several factors influence the rate of glucose uptake. These are: plasma glucose level,
free fatty acids, muscular work, and hormonal effects. A high concentration of available
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NEFA will result in a decrease in the rate of glucose uptake by skeletal and cardiac
muscle at any given level of insulin (Randel et al, 1963).

2.8.2 Insulin
Insulin is secreted by the pancreas. Insulin acts in two major ways: (1) it has a key role
in the metabolism of carbohydrate, lipid, and proteins, and (2) it has growth-promoting
effects on DNA synthesis, cell division, and cell differentiation (Vander et al, 1994 c).
Insulin and glucagon play a major role in the regulation of glucose homeostasis. Insulin
stimulates anabolic processes and favours energy storage, whereas glucagon stimulates
catabolic processes,

which consume energy substrates. Thus, their effects on

glyconeogenesis, glycogenolysis and gluconeogenesis are opposed, and their activities in
relation to these multi-enzyme systems are complex (Freychet, 1990).
The major sites of action of these hormones are the liver, adipose tissue, and skeletal
muscles. Insulin and glucagon act via specific membrane receptors in their target cells
(Freychet, 1990).

2.8.3 Glucose Tolerance
Glucose tolerance, as estimated by the oral glucose tolerance test (OGTT), depends
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Sources

Figure 2-3 Sources and sinks fo r plasma glucose (Steinberg, 1990)

on complex iteration among several physiological processes, including first-phase and
second phase insulin secretion, insulin removal, insulin sensitivity, and the tendency of
high glucose concentration (independent of insulin) to increase glucose utilisation
(Martin et al, 1992). Subjects with insulin resistance may be euglycemic with normal
blood glucose concentrations, maintained by hypersecretion of insulin. In these case,
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hyperinsulinemia may be noted both in the fasting and postprandial states (Beck-Nielsen
et al, 1990).

The risk of subsequent glucose intolerance or diabetes in women with previous GDM is
related to pre-pregnancy body mass index (BMI) and fasting plasma glucose during
pregnancy (as well as current BMI).

Subjects who are fatter before pregnancy and

whose plasma glucose concentrations are higher during pregnancy are more likely to
develop glucose intolerance or diabetes during pregnancy and/or after delivery (Coustan
et al, 1993).
Effendic et al have reported that 60% of normal weight women with previous GDM had
borderline or decreased oral glucose tolerance 6-36 months postpartum which could be
explained either by low insulin response or by the combination of a low insulin sensitivity
and low insulin response (Effendic et al, 1987).

2.8.4 Insulin Resistance
Insulin resistance may be defined as a state (of a cell, tissue, system or body) in which
more than normal amounts of insulin are required to draw out a quantitatively normal
response (Berson and Yalow, 1970). It should be emphasised that the level of glycemia
may be within the normal range in a person with insulin resistance as a result of
compensatory hyperinsulinemia (Flier, 1993).
During last two decades, several possible mechanism have been suggested for the
pathogenesis of insulin resistance.
The classification of insulin resistance:
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(1) Circulating anti-insulin antibodies and excess insulin degrading enzymes have been
suggested, but those have not been shown to be important causes.
(2) A primary (ie. genetically determined) defects in the ability of insulin to signal its
target cells (ie. receptor mutations) is again not an important cause.
(3) The major category of mechanisms for insulin resistance involves post-receptor
mechanisms. These include the mediation of local or circulating factors on target cells to
increase resistance to one or more pathway of insulin action. This category may include
primary genetic defects and cellular consequence of metabolic changes (Flier, 1993).

2.8.5 Insulin Resistance Syndrome
Insulin resistance is a common and multifaceted syndrome which occurs with high
frequency in the general population. Much attention has recently been focused on the
insulin resistance syndrome, also referred to as ‘syndrome X ’. The syndrome of insulin
resistance

may

include

a

cluster

of

several

common

metabolic

disorders:

hyperinsulinemia, obesity, NIDDM, hypertension, dyslipidemia, and as a complication of
these, atherosclerotic vascular disease (DeFronzo and Ferrannini, 1991). Central obesity
also has been added to the cluster (Zammet, 1989).
The evidence suggests that hyperinsulinemia plays a major role in the development of the
features of syndrome X.

While hyperinsulinemia appears to be crucial for the

development of syndrome X, it must usually develop secondary to a decrease in insulin
sensitivity. In terms of etiology, therefore, a decrease in insulin sensitivity may be the
primary event in syndrome X (Walker and Alberti, 1993).
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Insulin sensitivity has been shown to vary considerably in the normal population and be
influenced by many different factors such as dietary composition and intake, physical
activity, and endocrine status (Walker and Alberti, 1993).
Studies have suggested that genetic factors also may play role in the development of
insulin insensitivity and hence syndrome X. Studies on the Pima Indian have shown that
insulin resistance in this population may be due to an important genetic effect related to
the fatty acid binding protein gene on chromosome 4 (Prochazka et al, 1992).

In

addition, studies on persons with a positive family history of diabetes in first degree
relatives have suggested that these persons have insulin resistance which probably has a
genetic basis (Eriksson et al, 1989).
Thus, it seems the likely sequence is that a combination of both environmental and
genetic factors influence the overall insulin resistance state, then hypednsulinemia occurs,
and then phenotypic features of syndrome X occur (Walker and Alberti, 1993).
NIDDM is the disease classically associated with insulin resistance (Seely and Olefsky,
1993). Impaired glucose tolerance is a common clinical feature in all types of insulin
resistance syndrome and hyperinsulinemia occurs in compensation for this defect in
affected subjects (Moller and O ’Rahilly, 1993).

2.8.6 HbAlc
Haemoglobin can combine non-enzymatically with glucose, and the haemoglobin
conjugate, haemoglobin A le, can be measured in blood. It increases in concentration
roughly in proportion to the degree of sustained hyperglycaemia and is used clinically as
a tool to indicate the degree of control of the hyperglycaemia in people with diabetes
(Steinberg, 1990).
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Other plasma proteins and a number of tissue proteins are also glycated in diabetes.
Whether such glycation of proteins contributes to clinical complications is still not clear
(Steinberg, 1990).
The Framingham Heart Study has reported that the plasma H bA lc levels are significantly
above normal in non-diabetic women with an early cardiovascular event (Singer et al,
1992).
Giugliano et al (1992) also reported a significant correlation between HbA lc and classic
risk factors of cardiovascular disease such as hypertension, and cholesterol in diabetic
patients.

2.9 Raised Blood Pressure
Hypertension is defined as a chronically elevated systemic arterial pressure. The dividing
line between normal blood pressure and hypertension is an arbitrary one, set at
approximately 1 4 0 /9 0 mm Hg.
Hypertension may be due to increased total peripheral resistance or increase in cardiac
output or both.

Increased total peripheral resistance may be the result of increased

arteriolar constriction (Vander et al, 1994 b). About 95% of people with hypertension
have essential hypertension (primary hypertension) in that the cause of hypertension is
unknown (Ross, 1990).

2.9.1 Essential Hypertension and Insulin Resistance
The association between NIDDM, obesity, and essential hypertension has been known
for many years (Kannell and McGhee, 1979, reporting data from the Framingham Heart
Study).
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Others have linked high blood pressure to insulin resistance. Modan et al reported that
postprandial insulin concentrations were higher in both treated and untreated
hypertensive patients than in normotensive controls. This finding was independent of the
presence of obesity and diabetes (Modan et al, 1985).

Parillo et al reported greater

serum insulin and glucose levels 60 to 180 minutes after a glucose tolerance test in
hypertensive patients than in controls (Parillo et al, 1988).
The CARDIA study reported that high fasting insulin concentration was associated with
elevation in both systolic and diastolic blood pressure in 5115 participants, aged 18-30
years, of different sex, race, and education levels. The strength of these associations
decreased (but the association were still significant) after adjustment for age, sex, race,
BMI, alcohol consumption, smoking, physical activity, and exercise (Manolio et al,
1990).
Studies on hypertensive subjects using the euglycemic hyperinsulinémie clamp and
minimal model techniques indicated that the increased insulin levels are a compensatory
response to impaired insulin-stimulated glucose uptake (Ferrannini et al, 1987, Pollare et
al, 1990).
Istfan et al (1992) have reported that obese hypertensive subjects had greater insulin
resistance compared with obese non-hypertensive subjects.

It is thought that the

relationship between primary hypertension and insulin resistance is independent of
obesity (Pollare et al, 1990).
The association between insulin resistance and high blood pressure has not been
determined in all populations. Insulin level was correlated with blood pressure in young
Caucasians but not in a black American population or in the Pima Indians (Saad et al,
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1991). Pima Indians have a higher prevalence of insulin resistance and hyperinsulinemia
than other American (non- Indian American) populations but not a higher prevalence of
hypertension (Saad et al, 1991).
It should be emphasized that the relationship between hyperinsulinemia and high blood
pressure is not found in renal disease. Hypertension secondary to renal disease is not an
insulin resistant state and is not associated with hyperinsulinemia (Marigliano et al,
1990).
An abnormal lipoprotein profile has been demonstrated in patients with essential
hypertension similar to the dyslipidemia of diabetes (hypertriglyceridemia and a low level
of HDL-c) (Shieh et al, 1987), suggesting that a number of patients with essential
hypertension, in fact, have hypertension associated with the insulin resistance syndrome.
It is not known whether hyperinsulinemia is a cause of high blood pressure or is
secondary to high blood pressure, or if both hyperinsulinemia and high blood pressure
result from other factors. Shen et al reported that the reduction of blood pressure in
hypertensive subjects is not related to normalisation of the plasma insulin levels (Shen et
al, 1988), suggesting that hyperinsulinemia may be a causal factor for high blood
pressure, or both may be caused by another factor or factors.

2.10 Microalbuminuria
Qualitative and quantitative analyses of urinary protein excretion are used to diagnose
renal disease.

A urinary albumin excretion rate (UAER) of 200 |ig / min termed

microalbuminuria (Jensen et al, 1993).
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UAER also

appears to be elevated after prolonged upright posture and vigorous muscular exercise
(Waller et al, 1989).

2.10.1 Pathophysiology of Microalbuminuria
Healthy adults normally excrete small amounts (less than 150 mg / day) of protein in the
urine including mainly albumin and Tamm-Horsfall protein. Excretion of greater than
150 mg / day is termed proteinuria (Wilson, 1992).
Increased protein excretion may happen whenever there is an increased filtered load
secondary to an increase in glomerular permeability (glomerular proteinuria), an increase
in the plasma concentration of a protein (overflow proteinuria), or an increase in
glomerular filtration rate (GFR).
Proteinuria will also result from a decrease in the tubular absorption of normally
absorbed proteins (tubular or low molecular weight proteinuria) or an increase in protein
secretion or non-specific addition of protein to the fluid in the urinary tract such as
increase in secretory IgA during inflammation (urogenic or secretory proteinuria)
(Beetham and Cattell, 1993).
Albuminuria associated with diabetes is usually a consequence of increased glumerular
permeability. Diabetic nephropathy evidenced by hypertension, macroalbuminuria, and
renal dysfunction, develops in about 40% of IDDM patients approximately 10-20 years
after the onset of disease (Harris et al, 1987, Selby et al, 1990) and also in 25% of
NIDDM patients 5-10 years after their diagnosis (Selby et al, 1990).
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The relative

contributions of hypertension, dietary protein, glucose control, dyslipidemia and other
factors in the initiation and continuation of renal injury are not fully known. Strict blood
pressure control and protein restriction are important treatment strategies in both early
and established diabetic kidney disease (Carella et al, 1994). More than 25% of all cases
of end-stage renal disease in the United Statesare due to diabetes mellitus (Krolewski et
al, 1985).
Microalbuminuria independently predicts decrease in renal function (Mogensen, 1986)
and atherosclerotic cardiovascular disease in diabetic patients (Messent et al, 1992). It
occurs before overt nephropathy in both IDDM (Harris et al, 1987, Selby et al, 1990,
Mogensen and Christensen, 1984) and NIDDM (Harris et al, 1987). Microalbuminuria is
thus considered to be a predictor for the development of nephropathy (Harris et al, 1987,
Selby et al, 1990, Mogensen and Christensen, 1984).
The Pittsburgh Epidemiology of Diabetes Complications Study (PEDCS) suggested that
glycémie control, age or duration of IDDM, dyslipidemia, and possibly hypertension all
may contribute to the development of microalbuminuria. In addition, PEDCS proposed
that the adverse cardiovascular risk profile exist in subjects with overt nephropathy may
begin to develop even before the discovery of microalbuminuria (Coonroo et al, 1993).

2.11 Obesity and Androgen Status
2.11.1 Obesity
Obesity is a major problem for developed nations, affecting approximately 10-50% or
more of the adult population (Bray, 1985). A useful measure of obesity is the body mass
index (BMI), which is the weight in kilograms divided by the height in meters squared
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2

(kg/m ) (Redmond, 1991). Obesity is associated with premature mortality, morbidity,
and social disadvantage (Pi-Sunyer, 1991).
The reference range for BMI is 20 to 25 kg/m2 for men and 19 to 24 kg/m2 for women.
Above 25 kg/m2 for men and 24 kg/m2 for women is considered ‘overweight’ and above
30 kg/m2 for both men and women regarded as ‘obese’ (Egger, 1992). According data
from the National Heart Foundation Risk Factor Prevalence Survey in Australia (No 3,
1989), approximately 48% of men and 34% of women aged 20-69 years have a BMI
more than 25 kg/m2 (Calvert, 1991).
The health risks of obesity increase with its severity and reach significance at a weight >
20% above optimal weight in individuals. Mortality risk begins to increase when the
BMI exceeds 30 in adults (Redmond, 1991).

2.11.1.1 Classification
Obesity can be classified into categories.

The most common classification divides

subjects into two categories: upper body (android) and lower body (gynoid) obesity
(Kissebah et al, 1989). Subjects with upper body obesity present a higher waist / hip
ratio

(WHR),

increased

deposition

of mesenteric

or

visceral

adipose

tissue,

hyperinsulinemia, with greater insulin resistance, and dyslipidemia in comparison with
subjects with lower body obesity (Kissebah et al, 1989).
Abdominal obesity may be calculated by subscapular / triceps skinfold ratio (Centrality
Index) or waist / hip ratio (WHR). WHR has been suggested as an independent risk
factor for several diseases (ie diabetes mellitus, hypertension, cardiac events stroke,
dyslipidemia, varicose veins, and arthritis), and also for mortality. WHR of more than
0.9 in males and 0.8 in females should be taken as representing increased risk (Egger,
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1992). Kalkhoff et al (1983) suggested that women with WHR = 0.83-0.99 should be
considered to have upper body segment obesity and women with WHR = 0.50-0..73
should be considered to have lower body segment obesity.
Recently, Fujioka et al (1987) have proposed that there are two different types of obesity
with respect to metabolic and clinical features: one is the ‘visceral type’, characterised by
marked fat accumulation in the abdominal cavity and an association with metabolic
alterations such as glucose intolerance, hyperlipidemia, and the other one is the
‘subcutaneous type’ in which fat accumulates predominantly in the subcutis and is rarely
associated with metabolic disorders.
Both men and women with abdominal subcutaneous or visceral obesity tend to have
large fat cells, increased LPL activity, increased lipolysis, and low antilipolytic effect of
insulin.
High plasma sex steroid, glucocorticoid, catecholamine, and growth hormone
concentrations are associated with the amount of visceral fat, and the association may be
somewhat different in men and women (Bouchard, 1994)

2.11.1.2 Pathophysiology of Obesity
The causes of obesity are multiple.

Energy expenditure is an important factor in

determining weight gain or loss. Daily energy expenditure can be divided into three
major components: basal metabolic rate, which represents 50-70% of daily energy
expenditure, the thermic effect of food which represents about 10%, and the energy cost
of physical activity which represents 20-40% of daily energy expenditure (Ravussin and
Swinbum, 1992).
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Dietary factors play an important role in the regulation of body weight. Diets high in fat,
sugar, or both are the most effective promoter of obesity in animal investigations
(Sclafani, 1986, Lucas and Scla fani, 1990).

In addition, the endocrine system plays an important role in the etiology and maintenance
of obesity.

Abnormalities in insulin secretion and function are probably the most

important factors in metabolic changes in the obese subjects (Heber, 1994).

2.11.1.3 The Role of Obesity in the Pathogenesis of Diabetes Mellitus
The relationship between obesity and insulin resistance and NIDDM is very complex.
Most patients with NIDDM are obese.

Fujioka et al (1987) have reported that the

fasting plasma glucose and area under the plasma glucose concentration curve after oral
glucose loading (plasma glucose area) were significantly greater in obese than non-obese
patients.
Subjects with excess intra-abdominal (visceral) fat have more insulin resistance related to
obesity (Bjomtorp, 1989).

Abdominal obesity is considered as a risk factor for the

development of insulin resistance and its metabolically related abnormalities (Bjorntorp,
1990).

2.11.2 Androgen Status
Sex-hormone-binding globulin (SHBG) is a steroid-binding globulin which binds to
oestradiol and testosterone. In normal women, about 65% of the circulating testosterone
is tightly bound to SHBG, while most of the remaining hormone is loosely bound to
albumin.

Only 1-2% of the total testosterone is free.

It is generally accepted that
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testosterone bound to SHBG is not readily available to intracellular androgen receptors
in target tissues and thus has little biologic activity (Goldfien and Monroe, 1994).

Women with overall or central obesity exhibit a lower plasma SHBG (Lindstedt et al,
1991, Haffner et al, 1991).

SHBG shows a much higher affinity to testosterone than

oestradiol and therefore any changes in SHBG concentrations cause a greater change in
the free testosterone fraction than the free oestradiol fraction (Reed et al, 1993).
Some studies have reported that low plasma levels of SHBG and central obesity are
correlated with higher plasma concentrations of free testosterone (Haffner et al, 1989).
Thus, a low plasma concentration of SHBG results in hyperandrogenicity in women
(Rosenfield, 1975).
Preziosi et al (1993) found a significant and negative relationship between SHBG and
insulin level in healthy pre-menopausal and post-menopausal women. This relationship
was independent of age, BMI, subscapular skinfold, and fasting and 2-h plasma glucose.
Studies have shown that excess sex steroid and glucocorticoid concentrations in the body
may be associated with regional fat distribution (upper body segment) and related
metabolism disorders and have suggested that this relationship may be causal (Kissebah
et al, 1989).

Hyperandrogenicity may decrease insulin sensitivity in pre-menopausal

women (Evans et al, 1983).
Tikkanen and Nikkila (1987) have reported that sex steroids demonstrate significant
effects on lipoprotein metabolism.

Steroids with androgenic activity increase hepatic

triglyceride lipase activity and decrease plasma HDL2-C levels. This phenomenon was
also reported in obese women with a high abdominal adiposity (Despers et al, 1989).
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2.12 Haemostatic Disorders
Diabetes mellitus is a common endocrine disease which exhibit an increased risk of
atherosclerosis. The classic risk factors predict only 30% of all cardiovascular events
(Heller et al, 1984).

Several prospective epidemiological investigations suggest that

plasma fibrinogen concentration is an independent cardiovascular risk factor (Meade et
al, 1986, Kannel et al, 1987, Yarnel et al, 1991, Resch et al, 1992).

2.12.1 Fibrinogen
The Framingham Study has reported that fibrinogen levels independently are associated
with cardiovascular disease and increase with age in both women and men (Kannel et al,
1987, Wilhelmsen et al, 1984).
Plasma fibrinogen concentration

seems

to

be related

to

hyperlipoproteinemia,

hypertension, smoking, and several life style factors such as dietary habits (Koenig and
Ernst, 1992). Several studies have reported that the fatty acid composition of the dietary
lipids is an important factor in the athero-thrombotic process (Berg-Schmidt et al, 1990,
Grundy and Denke, 1990). Cigolini et al (1994) examined the fatty acid composition of
adipose tissue as an objective index of dietary fat intake in healthy men and they found
no correlation between fibrinogen level and adipose tissue fatty acids.
Baxter et al (1988) suggested hyperfibrinogenemia may be an important risk factor for
peripheral

arterial

disease

in

men.

Cigolini

et

al

(1994)

suggested

that

hyperfibrinogenemia may be considered as an integral part of syndrome X and that it may
contribute along with impaired fibrinolytic activity to a ‘procoagulanf state.
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The exact mechanism underlying hyperfibrinogenemia and risk of CHD is not clear.
There are several hypotheses.

Hyperfibrinogenemia can adversely influence platelet

aggregability and plasma viscosity, and thus predispose (perhaps) to thrombosis.

In

addition, atherosclerosis can cause hyperfibrinogenemia as fibrinogen is an acute-phase
protein (Heinrich et al, 1994).

2.12.2 Factor VII
Factor VII is a vitamin K-dependent glycoprotein with a molecular weight of 50,000
dalton composed of a single polypeptide chain, synthesized in the liver.

The

physiologically important activator of factor VII is factor Xa which, in the presence of
calcium and phospholipids, rapidly converts factor VII to factor Vila. In the presence of
thromboplastin, factor V ila activates factor IX and factor X very rapidly. The coagulant
pathway proceeds, ending in the production of thrombin (Vander et al, 1994 d). Figure
9-1 shows the classical view of the intrinsic and extrinsic pathways of the clotting
cascade in humans (Vander et al, 1994 d).
Factor VII levels increase with age in both men and women, and may be higher in
women. Factor VII levels increase in late pregnancy, with use of oral contraceptives,
obesity, and in post-menopausal women (Bloom and Thomas, 1987, Poller et al, 1990).
Factor VII coagulant activity is also increased in hyperlipidemia (Miller et al, 1985),
diabetes (Fuller et al, 1979), and with high dietary fat intake (M iller et al, 1986).

High levels of factor VTIc have been shown to be associated with ischaemic heart disease
in men (Meade et al, 1986, Wilhelmsen et al, 1984). Increased factor VII levels have
been reported in NIDDM patients with microalbuminuria and cardiovascular disease
(Stehouwer et al, 1992).
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EXTRINSIC PATHWAY

Figure 2-4 Classical view o f two independent pathways (intrinsic and extrinsic), leading
to the generation o f thrombin (Vander et al, 1994 d)

Ceriello et al (1988) suggested that the plasma factor VII levels may be directly raised by
high blood glucose in diabetic and normal subjects. On the other hand, Schernthaner et
al (1989) showed that an altered haemostatic status (high plasma fibrinogen and factor
VII) may not be completely corrected by better glycaemic control.
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2.12.3 Von Willebrand Factor (vWF)
vWF is a complex glycoprotein synthesized by vascular endothelium (Bloom et al, 1973)
and megakaryocytes (Nachman et al, 1977).

The initial response to blood-vessel damage is vasoconstriction and this is facilitated by
formation of a platelet plug, then blood coagulation in the damaged blood vessels. vWF,
secreted by the endothelial cells, is necessary for platelet aggregation (Vander et al, 1994
d).

High plasma levels of vWF, indicating endothelial cell dysfunction, have been found in
diabetic patients with retinopathy (Stehouwer et al, 1992, Porta et al, 1987, Coller et al,
1978). In addition, Silveira et al (1992) have suggested that abnormal degradation of
vWF occurs in kidneys in IDDM patients with and without nephropathy.
The role of vWF in the pathogenesis of diabetic nephropathy is not clear. It is probably a
marker of endothelial dysfunction, without being directly involved in the pathogenesis of
diabetic nephropathy. Alternatively, vWF may stimulate adhesion of platelets to exposed
subendothelium in the kidney (Stehouwer et al, 1991).
Cross-sectional studies have suggested that raised plasma factor VIII and vWF level is
associated with clinical coronary artery disease (Sugrue et al, 1985). However, Myreng
et al (1986) and Hamsten et al (1986) have reported no correlation between plasma vWF
level and either clinical or angiographical findings of coronary artery disease.
Chetty et al (1988) found that race is a major determinant of vWF and factor VIII.
Black people in the USA have higher factor VIII and vWF levels than whites.
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Numerous studies have suggested that coagulation disorders in diabetic patients, which
seem to be caused by hyperglycaemia (Ceriello, 1993), give rise to a thrombotic
tendency.
High levels of plasma fibrinogen (Coller et al, 1978, Ganda and Arkin, 1992), factor VII
(Ceriello et al, 1988), factor VIII, vWF (Osterman and Va-deLoo, 1986), factor X
antigen and low activity of factor X in plasma (Ceriello et al, 1990) have been reported in
diabetic patients and thought to be due to hyperglycaemia.
Figure 2-5 shows the pathway linking hyperglycaemia and a tendency to thrombosis in
diabetic patients. Hyperglycaemia may influence thrombosis by two mechanisms; either
by a mechanism connected with non-enzymatic glycation or by an increased oxidative
reaction (Ceriello, 1993).

Figure 2-5 Pathway linking hyperglycaemia and thrombosis in diabetes mellitus.
(+ = increased and - = decreased, Adapted from Ceriello, 1993).
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2.13 Dietary Habits and Other Lifestyle Factors

2.13.1 Dietary Habits
Recently, there has been much interest in elucidating the underlying links between
NIDDM and genetics, obesity, nutrition, physical activity, and other factors. Diet plays a
significant role in determining plasma concentrations of TG, cholesterol, TG-rich
lipoproteins, and also HDL-C.
The relationship between lipids and lipoproteins and atherosclerosis also encourages
investigators to pay more attention to dietary factors related to disease.

2.13.1.1 Dietary Fat and Blood Lipids and Lipoproteins
The type and amount of fat in the diet influences blood lipid and lipoprotein
concentrations. Keys et al (1965) have shown that dietary polyunsaturated fatty acids
decrease and saturated fatty acids increase total plasma cholesterol concentrations.
However, the mono-unsaturated oleic acid and saturated stearic acid are neutral. Many
researchers have reported that monounsaturated fatty acids have no significant influence
on serum cholesterol concentrations (Thomson et al, 1967, McGandy and Hegsted,
1975).
Grundy and Denke (1990) recently reported that only saturated fatty acids with chain
lengths of 12, 14, and 16 carbon atoms in the diet increase total plasma cholesterol levels
mainly by elevating the LDL levels, and the other fatty acids (such as stearic acid) have
less effect on plasma LDL levels. Both polyunsaturated and monounsaturated fat reduce
LDL levels when replacing saturated fat (Grundy and Denke, 1990).
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The plasma TG concentrations change with diet.

Postprandially, the plasma TG

concentration increases due to the appearance of chylomicrons and their remnants in
plasma. The concentration of TG depends on both the amount and the type of fat in the
diet. Saturated fat in the diet produces a longer postprandial plasma triglyceride than
polyunsaturated fat. The type and amount of fat in the diet also influence the fasting
levels of TG, mainly by increasing the concentrations of VLDL (Norum, 1992).
The fasting TG concentration in plasma decreases when monounsaturated fat is
substituted for carbohydrates (Grundy, 1986).

Polyunsaturated fatty acids (n-6 type)

also decrease the fasting TG concentrations in plasma (Chait et al, 1974).
Diet affects LPL activity.

In the fasting state the LPL activity increases in muscle,

however, in the postprandial state, the activity increases in adipose tissue. The activity
of LPL seems to be mediated by insulin and the insulin sensitivity of the muscle and
adipose cells (Kiens et al, 1989).
Dietary unsaturated fatty acids tend to cause larger chylomicrons than saturated fatty
acids intake (Ockner et al, 1969 and Ockner and Jones, 1970). Larger chylomicrons are
cleared from plasma faster than smaller chylomicrons.
Saturated fatty acids in the diet increase the plasma VLDL concentrations. However,
dietary fish oil decreases the plasma VLDL concentration resulting a small effect on
plasma cholesterol (Harris, 1989, Sullivan et al, 1986). The main effect of marine fish oil
on plasma lipids is a reduction in plasma TG level (Sanders, 1987, Schmidt et al, 1993).
The proposed mechanisms for the VLDL-lowering effect of fish oil might be due to
reduced plasma FFA concentrations resulting from decreased peripheral lipolysis of TG
(Singer et al, 1990), increased oxidation of fatty acids in the liver, or because saturated
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and monosaturated fatty acids stimulate VLDL synthesis and n-3 polyunsaturated fatty
acids do not have this effect (Harris et al, 1990, Dixon et al, 1991). In addition dietary
marine fish oil tends to increase HDL-C (Schmidt et al, 1993).

LDL concentration is increased by using saturated fats in the diet, probably through
effects on hepatic LDL receptors (a decrease in LDL receptor activity and thus a
reduction in the LDL catabolism rate), but the mechanism is not clear (Norum, 1992).
Dietary fatty acids do not appear to alter the rate of plasma cholesterol synthesis.
Alteration in the plasma cholesterol concentrations may be due to an increase in the
output of faecal neutral sterols and of faecal bile acids (Durrington, 1995).
On the other hand, saturated fat in the diet tends to produced smaller VLDL particles
than polyunsaturated fat.

It seems that smaller VLDL particles are more prone to

convert to LDL particles than large VLDL particles are.

This may be a possible

mechanism underlying increased LDL levels by using saturated fat (Norum, 1992).
Bonanome et al (1992) have found that a diet rich in monounsaturated fatty acids
(MUFA) compared with polyunsaturated fatty acids increases the resistance of plasma
LDL to oxidative modification, independent of their content of antioxidant. This effect
might lower the atherogenicity of these lipoproteins.
Thus, a low fat, monounsaturated fatty acid-rich diet is as effective as a low fat,
polyunsaturated fatty acid rich diet in lowering total and LDL-C, but both also lower
HDL-C concentrations (Wahrburg et al, 1992). Wahrburg et al (1992) suggested that
the monounsaturated fatty acid-rich diet may be more advantageous than the
polyunsaturated fatty acid-rich diet because it does not lower plasma apoA-I
concentration as much as the polyunsaturated fatty acid rich diet.
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Because of the anti-atherogenic effect of HDL-C, the effect of dietary fat on HDL-C has
been investigated intensively. Diets low in fat cause both low plasma HDL and LDL
concentrations, however a diet high in saturated fat results in high HDL and LDL
concentrations. Dietary polyunsaturated fat, but not monounsaturated fat, leads to lower
HDL-C levels (Grundy and Denke, 1990).
Animal studies have suggested that a diet rich in cholesterol and saturated fat (an
atherogenic diet) enhances the plasma CETP activity (Stein et al, 1990, Quinet et al,
1990). Increased CETP activity may result in decreased levels of HDL-C and increased
levels of VLDL-C and LDL-C (Grundy and Denke, 1990).
Trans-isomers of fatty acids, formed by the partial hydrogenation of vegetable oils to
produce margarine and vegetable shortening, increase the LDL-C / HDL-C ratio. As a
result, consumption of partially hydrogenated vegetable oils may contribute to the
occurrence of coronary heart disease (Willett et al, 1993).

2.13.1.2 Dietary Cholesterol and Blood Lipids and Lipoproteins
Fungwe et al (1992) have reported that increasing dietary cholesterol intake increase the
concentrations of TG and cholesteryl ester in liver and plasma in rat.

This is

accompanied by reduced fatty acid oxidation and increased incorporation of exogenous
fatty acid into hepatic TG and increased secretion of VLDL (Fungwe et al, 1992).
Interestingly, Fungwe et al (1994) have recentiy suggested that dietary cholesterol
stimulates the biosynthesis of FFA, while the addition of TG to the diet stimulates
production of cholesterol.
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Dietary cholesterol intake causes elevation in the plasma total cholesterol and LDL-C
(Erickson et al, 1964, Hegsted et al, 1965).

Studies have shown that the serum

cholesterol response to dietary cholesterol tends to plateau at high cholesterol intakes
(Keys, 1984, Hegsted, 1986).

Riccardi et al (1987) suggested that the most effective dietary change to reduce plasma
cholesterol concentrations in human is to decrease the consumption of saturated fat and
cholesterol.

2.13.1.3 Dietary Carbohydrate and Blood Lipids and Lipoproteins
A high carbohydrate diet increases plasma TG concentration but not that of cholesterol.
The effects of dietary carbohydrates depend on the type of carbohydrate.

Intake of

sucrose or fructose within the range usually found in the population does not have any
elevating effect on plasma triglycerides in most normal and diabetic subjects (Truswell,
1994). While the plasma TG levels increase, HDL-C levels decrease (Gonen et al, 1981,
Brinton et al, 1990).

In human, increased fasting TG levels are observed with very high carbohydrate intake, >
35% of energy from sucrose or > 20% of energy from fructose, more commonly in men
and in conjunction with saturated fat intake (Truswell, 1994).
The Lipid Research Clinics Study Prevalence Programme reported that there is a positive
correlation between dietary cholesterol intake and the serum HDL-C in school-age white
boys (Glueck et al, 1982).

However, another study reported that serum HDL-C

concentration was relatively unaffected by increases in dietary cholesterol (Mahley et al,

1978).
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2.13.1.4 Dietary Fibre and Blood Lipids and Lipoproteins
Wheat bran and cellulose (insoluble polysaccharides) do not decrease plasma cholesterol
concentration. In contrast, pectin, guar gum, oat bran, psyllium husk, bean (legumes),
fruit and vegetables decrease plasma cholesterol and LDL-C concentrations (Schneeman
and Tietyen, 1994, Riccardi and Rivellese, 1991).

There is a negative correlation

between plasma total cholesterol concentrations and dietary fibre intake (Kirby et al,
1981).
In general, evidence that fibre in fruits and vegetables has some hypocholesterolemic
effect is better than for most of the cereals so far studied. One aim of a lipid-lowering
diet must be to decrease saturated fat consumption and increase fibre intake (Durrington,
1995). Therefore, in practice, the consumption of legumes, vegetables, and fruit should
be encouraged (Riccardi and Rivellese, 1991).
The mechanisms by which dietary fibre acts as a hypoglycemic and hypolipidemic agent
are not clear. Several mechanisms have been proposed including increasing the faecal
excretion of bile acids and decreasing the rate of lipid absorption in the large intestine
(Schneeman and Tietyen, 1994).
The ability of dietary fibre to delay food digestion and nutrient absorption clearly has an
important effect on lipid and carbohydrate metabolism (Riccardi and Rivellese, 1991).

2.13.1.5 Effect of Dietary Factors on Carbohydrate Metabolism and Insulin
Resistance
Diet is an environmental factor that has changed in those populations with changing
prevalence of non-insulin (type II) diabetes (Kawate et al, 1979), suggesting that diet is a
causative factor for diabetes.
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The San Luis Valley Diabetes Study has suggested that high fat / low-carbohydrate diets
are correlated with the onset of NIDDM in humans (Marshall et al, 1991). Thus, fat
consumption significantly predicts NIDDM risk in subjects with IGT after controlling for
obesity and markers of glucose metabolism (Marshall et al, 1994).

Several hypotheses have been proposed on the mechanisms relating high fat intake to the
etiology of NIDDM. A diet rich in fat causes obesity (Dreon et al, 1988, Romieu et al,
1988) and increased body fat and altered fat distribution (Storlien et al, 1986). These
abnormalities lead to altered glucose metabolism (Leibel et al, 1989).

Impaired fat

oxidation and / or glycogen storage accompanying a diet rich in fat may increase FFA
concentration in blood and lead to insulin resistance (Randle, 1989).
Another possible explanation for the correlation between fat consumption and NIDDM
can be impaired insulin action due to altered cell membrane composition and (possibly)
altered signal transduction across the cell membrane (Olefsky et al, 1988, Storlien et al,
1989) .
Animal studies have revealed that a high fat diet leads to the induction of insulin
resistance and hyperinsulinemia (Storlien et al, 1986). In addition, The Normative Aging
Study has suggested that a diet high in saturated fatty acids is an independent factor for
both fasting and postprandial insulin concentrations (Parker et al, 1993). Diets with high
saturated fat content decrease insulin response and insulin resistance in isolated rat
adipocytes (Van Amelsvoort et al, 1988, Chattaway et al, 1990).
Dietary treatment of diabetes remains a controversial area and the ideal diet remains to
be defined. The specific diet and approach chosen will depend on the patient, the degree
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of obesity and the extent of metabolic compensations and complications present (Griver
and Henry, 1994).
The American Diabetes Association (1987) has recommended a the suitable diet for
diabetic patients should provide 55-60% of energy as carbohydrates and < 30% as fat.
The high amount of complex carbohydrates may cause an increase in insulin sensitivity.
Smith (1994) suggested the diet for diabetic people should contain food with low
glycemic index and be high in dietary fibre, particularly soluble fibres.
food

Diet containing

with low glycemic index and high in dietary fibre appears to increase insulin

sensitivity and may well reduce the problem of increased TG and decreased HDL-C levels.

2.13.2 Alcohol Consumption
Ethanol is a source of energy and it also has potent pharmacologic and biochemical
properties that may influence other aspect of nutrition and metabolism (Mitchell, 1990).
Ethanol is metabolized in the liver to form acetaldehyde, which in turn is oxidized to
acetate. Acetaldehyde (in excess) may cause liver damage by decreasing mitochondrial
functions. In heavy alcohol consumers, alcohol becomes a preferred fuel for the liver and
displaces fat as a source of energy.
production of TG is increased.

Oxidation of fatty acids is decreased and the

If this processes continues a fatty liver may develop

(Lieber and Pignon, 1989).

2.13.2.1 The Effect of Alcohol Ingestion on Lipids and Lipoproteins
The interaction of ethanol with lipid metabolism is complex. Alcohol intake may affect
all lipid components of the plasma.
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A number of studies have reported that alcohol consumption increases plasma TG levels
(Ostrander et al, 1971, Castelli et al, 1977). The consumption of enough ethanol to give
a blood concentration over 1 g/L and mild intoxication results in a rise in TG
concentration in the plasma of normal subjects (Lieber and Pignon, 1989).

Ethanol

consumption leads to an increase in VLDL synthesis and limitation of alcohol may
markedly decrease plasma TG concentrations (Ginsberg et al, 1974, NIH Consensus
Conference, 1984).
There is a positive correlation between alcohol intake and HDL-C levels in population
studies (Moore and Pearson, 1986).

Several studies have found alcohol consumption

may lead to increase in both HDL2 (the putative atherogenic protective fraction) and
HDL3 (Lieber, 1987), however other researchers have reported that only the HDL3
fraction is increased (Haskell et al, 1984). ApoA-I and apoA-II are increased by alcohol
(Camargo et al, 1985). Studies have reported that alcohol-related HDL-C elevation may
be due to increased hepatic apoA-I synthesis (Taskinen et al, 1987, Okamoto et al,
1988).
Sillanaukee et al (1993) have reported that moderate to heavy intake of alcohol had no
effect on HDL2 but increased the HDL3 fraction. The mechanism of elevated VLDL,
HDL2, and HDL3 levels after ethanol intake was described by Lieber (1987).
Overproduction of VLDL particles by the liver occurs, resulting from increased activities
of synthetic enzymes and ready availability of precursors such as TG, cholesterol, and
apolipoproteins.

At the same time, HDL3 synthesis will increase in association with

moderate alcohol intake.

The degradation of VLDL and chylomicrons by LPL is

associated with conversion of HDL3 to HDL2. As a result, an increased synthesis of
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VLDL by the liver and increased LPL activity will cause increased HDL2 levels (Lieber,
1987).

A reduction in LDL-C level may be seen in alcohol drinkers (Taskinen et al, 1982). The
modification of LDL-apoB by acetaldehyde (the first metabolite of ethanol) increases
the catabolic rate of LDL particles in the rat, resulting in lower LDL-C levels
(Savolainen et al, 1987, Kesaniemi et al, 1987). It can be an explanation for decreased
LDL-C concentrations in alcohol users.

2.13.2.2 The Effect of Alcohol Ingestion on Insulin Sensitivity
Women drinking a moderate amount of alcohol had lower plasma insulin concentrations
and higher HDL-C levels than non-drinking women (Razay et al, 1992).
In addition, Facchini et al (1994) reported that light to moderate alcohol intake is
correlated with increased insulin-mediated glucose uptake, lower plasma glucose and
insulin levels in response to oral glucose, and a higher HDL-C level. The changes in
insulin and glucose metabolism may contribute to the lower risk of coronary heart
disease described in light to moderate drinkers.

2.14 Smoking
Smoking may be an important contributors to both glucose level and diabetes risk
(Bjorntorp, 1988, Pederson, 1989). Smoking is a risk factor for ischaemic heart disease
(IHD) (Meade et al, 1987).
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2.14.1 Effects of Smoking on Lipoprotein Metabolism
Epidemiological studies have shown that smoking is associated with a number of
abnormalities in plasma lipoproteins particularly decreased HDL-C (Criqui et al, 1980,
Wilson et al, 1983). The correlation between smoking and decreased HDL-C was also
confirmed by using multivariate analysis (Craig et al, 1989, Maede et al, 1991, Muscat et
al, 1991). However, some researchers rejected the independent effect of smoking on
HDL-C after correction for lifestyle factors (lack of exercise, obesity, alcohol intake, etc)
(Wallentin and Sundin, 1985, Manttari et al, 1991).
Plasma HDL-C rises within 2-8 weeks to the normal range after smoking cessation
(Fortman et al, 1986, Stamford et al, 1986, Moffatt, 1988). Some investigators consider
it uncertain whether increased HDL-C level is due to stopping smoking or dietary
changes (Quensel et al, 1989, Maida and Howlett, 1990). Quensel et al (1989) believe
that the changes in HDL result from increased dietary fat and carbohydrate intake after
stopping smoking.
Smokers have been reported to have lower plasma concentration of HDL2 (Shennan et
al, 1985), HDL3 (Haffner et al, 1985, Moriguchi et al, 1990), and HDL2 and HDL3
(Robinson et al, 1987).
Craig et al (1989) also have found that apo A-I concentration is low in smokers. In
addition, plasma levels of TG (Simons et al, 1984), VLDL (Freedman et al, 1986) and
LDL-C have been reported to be higher in smokers compared with non-smokers (Craig
et al, 1989, Freedman et al, 1986, Muscat et al, 1991).
Dullaart et al (1991) have reported that the CETP activity is elevated in ID DM patients
who smoke. The concentrations of tissue LPL are elevated in smokers and this seems to

Chapter Two

Literature Review

64

be associated with their lower body weight (Brunzell et al, 1980 and Chajek-Shaul et al,
1987). LCAT activity is decreased in smokers (Haffner et al, 1985, Moriguchi et al,
1990), however hepatic lipase activity is increased (Moriguchi et al, 1990).

2.14.2 Smoking and Diabetes Mellitus
Cigarette smoking favours the development and progression of diabetic nephropathy.
Several large prospective cohort studies have reported that the relative risk for all-cause
mortality is approximately twice as high for smoking compared to non-smoking diabetic
patients. Stopping smoking is probably the most cost-effective risk factor intervention
for diabetic patients (Muhlhauser, 1994).

2.14.3 Smoking and Fibrinogen Levels
Data from several studies have suggested that the plasma levels of fibrinogen are higher
in smokers than non-smokers (Balleisen et al, 1985, Kannel et al, 1987) and this may be
one reason why smokers are more prone to ischaemic heart disease (Meade et al, 1987).

2.15 Physical Activity
Sedentary lifestyle is related to increased coronary atherosclerosis and physical activity
decreases the risk of coronary atherosclerosis (Paffenbarger et al, 1986).
Physical activity tend to be associated with lower body fat, lower blood pressure, and
beneficial effects on glucose, insulin, lipids, and lipoproteins (Bush, 1991).

2.15.1 Effects of Physical Activity on Lipids and Lipoproteins
It is well accepted that physical activity improves lipoprotein metabolism (Huttunen et al,
1979, Berg and Keul, 1985).
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Researchers have reported decreased LDL levels in human (Wood et al, 1977, Goldberg
et al, 1984, Hurley et al, 1986).

Plasma TG concentration is reduced in both sexes

(Wood et al, 1977, Farrell and Barboriak, 1980). Endurance exercise decreases VLDLTG and LDL-C levels (Thompson et al, 1988, W ood et al, 1988). These changes are
due to increased LPL activity and plasma TG clearance (Thompson et al, 1988).
M oreover, exercise increase the plasma concentration of HDL-C fractions (Gordon and
Rifkind, 1989, M cHenry et al, 1990).

Exercise programs with moderate intensity seem to modify the effects of a hypocaloric,
fat-restricted diet on HDL-C (Taylor and W ard, 1993).

2.15.2 Effects of Physical Activity on Carbohydrate Metabolism
In low to moderate intensity exercise, rapid adjustment in the supply of energy is the
result of a fall in plasma insulin, and steady or increased glucagon production to maintain
euglycemia. Hepatic glucose synthesis in moderate exercise is regulated mainly by the
glucagon / insulin ratio (Purdon et al, 1993).
In contrast, intense exercise is related to a marked stimulation of glucose synthesis with
resulting hyperglycemia, marked increases in plasma catecholamines, and moderate
hyperglucagonemia.

The hyperglycemia increases in recovery and is accompanied by

hyperinsulinemia (Purdon et al, 1993).
King et al (1988) have reported that the reversal of increased insulin action that occurs
within a few days after stopping exercise is due to a decrease in insulin sensitivity, not to
a decrease in insulin secretion.
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2.15.3 Therapeutic Exercise for GDM Patients
Besides diet and insulin therapy, exercise is im portant in the treatment of people with
diabetes (W asserman and Vranic, 1987).

Exercise is known to increased glucose utilization by several mechanisms, and regular
exercise has been recommended since early time as an addition therapy (Bung et al,
1993).
Bung et al (1993) suggested that in the absence of ominous fetal heart rate changes or
significant alterations in uterine activity following the exercise sessions or diabetesrelated peri- and neonatal morbidity, regular physical activity appears to be a safe
therapeutic m ethod for the fetus of GDM mothers.

2.16 Obstetrics and Family Medical History
Subjects with GDM may present more frequent obstetric complications, affected both
baby and m other (Beydoun, 1987). They also are more likely to have a positive family
history of diabetes mellitus (Henry and Beischer, 1991).

2.16.1 Obstetrics History
Obstetric complications are more likely to occur in diabetic pregnancies and may increase
both mortality and morbidity (Beydoun, 1987).
W omen with GDM exhibit more frequent and severe obstetric complications. Cousins
(1987) reported that subjects with GDM had a higher frequency of maternal
complications such as polyhydramnios (5.3%), preeclampsia (10%), chronic hypertension

Chapter Two

Literature Review

67

(9.9%), pyelonephritis (4%), and delivery by cesarean section (20.4%) than women with
non-GDM pregnancies.

The fetus of the diabetic mother runs an increased risk of major congenital
malformations, complications related to macrosomia, intra-uterine growth retardation,
and biochemical abnormalities resulting from fetal hyperinsulinemia (Barret, 1987). The
Third International Workshop Conference on GDM (1991) reported that the infant of the
mother with GDM is also more likely to develop these morbidities.
Fetal macrosomia is a potentially dangerous complication of diabetic pregnancy, may be
caused by hyperinsulinemia, a response to fetal hyperglycaemia following maternal
hyperglycaemia.

This and other complications can be prevented by strict control of

maternal blood glucose levels, particularly in late pregnancy (Barret, 1987).

2.16.2 Oral Contraceptive
The most widely used contraceptive method is the combined-type oral contraceptive
containing an estrogen and a progesterone steroid.

Oral contraceptive intake causes

alterations in glucose, lipid and protein metabolism (Molsted-Pedresen et al, 1991).

2.16.2.1 Effects of Oral Contraceptive on Lipids and Lipoproteins
Estrogen increases LDL receptor activity, so increasing the rate of clearance of both
LDL and remnant particles (Knopp et al, 1993).
Estrogen also increases the amount of apoA-I in HDL particles by increasing synthesis
and / or decreasing the catabolism of apoA-I, resulting in an increased number of HDL
particles and increased plasma HDL-C levels including the HDL2 subfraction (Knopp et
al, 1993). It also increases TG and VLDL-C levels. The mechanisms by which these
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changes occur are not clear but probably related to the effect on estrogen in reducing
hepatic triglyceride lipase activity and inhibiting HDL catabolism (Miller and LaRosa,
1991).

The progestin component of oral contraceptives reduces glucose tolerance, increases
insulin resistance, and tends to increase cholesterol concentration (Kjos et al, 1990).
Dyslipidemia characterised by elevated LDL and VLDL and also reduction of HDL
particles has been reported during use of the combination-type oral contraceptive. This
would increase the risk of atherosclerosis complications (Molsted-Pedersen et al, 1991).

2.16.2.2 Effects of Oral Contraceptive on Carbohydrate Metabolism
Exogenous oestrogen has an antagonistic effect to insulin (Spelsberg and Manson,
1993).
A combination of estrogens and progesterones has been reported to decrease insulin
sensitivity at the cellular level in peripheral tissue (Skouby et al, 1987).
Eschwege et al (1990) reported that women who are using currently oral contraceptives
have higher plasma glucose and insulin levels after a standard glucose challenge.
Rimm et al (1992) have found only a slightly increased in risk of NIDDM among women
who have used oral contraceptives compared with those who have never used oral
contraceptive. However, another study showed no increased risk of NIDDM in post
menopausal oral contraceptive users (past or present) in comparison to those who had
never used oral contraceptives (Manson et al, 1992).
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2.16.3 Family Medical History
A family history of diabetes and cardiovascular disease is often found in subjects who
develop diabetes and cardiovascular disease.

Studies have suggested that genetic factors play a major role in the development of
NIDDM (Newman et al, 1987, Fajan, 1989).

In the rare cases single genes alone can lead to NIDDM, but in the most cases it seems
that NIDDM is results from combined defects of (3-cell function and insulin action, either
of which can in principle have a genetic or environmental basis (McCarthy and Hitman,
1993).

2.16.3.1 Family History o f Diabetes Mellitus
Several studies on populations at high risk for developing NIDDM have showed that
history of diabetes in a first degree relative is a powerful predictive factor for the
development of diabetes and impaired glucose tolerance preceding NIDDM is more
prevalent in non-diabetic offspring of diabetic patients than in control subjects without a
positive family history of diabetes (Leslie et al, 1986, Haffner et al, 1988, Eriksson et al,
1989).
Warram et al (1990) have reported that decreased glucose clearance may be
demonstrated one or two decades before NIDDM is diagnosed. This decreased glucose
clearance is accompanied by compensatory hyperinsulinemia, suggesting that the primary
defect in development of NIDDM is in the peripheral tissue response to insulin and
glucose.
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2.16.3.2 Family History of Cardiovascular Disease (CVD)
Bell et al (1990) have reported that black women with GDM have a higher incidence of
family history of CVD.

Diabetic patients have an increased chance to develop ischaemic heart disease (BarretConner et al, 1985) and black women have a 70% greater risk of CVD and mortality
than white women (Johnson et al, 1986).
development of GDM is unclear.

However, the relationship of CVD and

CHAPTER THREE
MATERIALS AND METHODS

3.1 Introduction
This chapter introduces the data collection techniques, levels of measurements, and
statistical techniques for analyzing data.

3.2 Subjects
This is a cross-sectional study. The study was performed on 65 wom en who had had
GDM in their last pregnancy (the GDM group), studied approximately one year after
delivery, and 65 w om en w ho gave birth at the same time as the women with GDM and
who did not have G D M (the control group).
All women who have had GDM diagnosed and treated in the Mawarra Health Service
(IAHS) in June 1992-January 1993 (80 subjects) were contacted and were offered a
check which was centred on those factors thought to increase the chance of developing
diabetes m ellitus. O f the G D M group, 65 agreed to join the study (81%).

A control group o f 90 individuals was chosen at random from the list of women
presenting for labour at the same time as the patients with GDM. O f wom en from the
control group, 65 also agreed to join to the study (72%).
Subjects received a full description of the study and gave informed consent. All subjects
received a detailed inform ation sheet and consent form were signed by all participants.
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Those enrolled in the study were examined at the Outpatient Clinics, Illawarra Regional
Hospital (Wollongong Campus), at the Medical Research Unit (MRU), and for 4
subjects at their homes by the investigator. This study was approved by the University of
Wollongong Human Research Ethics Committee (HR 92/213).

3.3 Experimental design
Subjects were examined after an overnight (~12 h) fast. All subjects received a clinical
examination and were interviewed before blood and urine sampling.

3.3.1 Demographic information
Demographic information was obtained including age, country of birth, details of
obstetric and medical history and family history of diabetes mellitus, coronary heart
disease, other inherited disease, peripheral vascular disease (PVD) and kidney disorders,
smoking status, alcohol consumption, medication and oral contraceptive use (Appendix
I).

3.3.2 Blood pressure measurement
Blood pressure measurement was done after 5 minutes rest in the sitting position, using a
standard desk mercurial sphygmomanometer. Two blood pressure measurements were
obtained and the mean was accepted as the blood pressure. Systolic blood pressure was
defined by the appearance of sound, and diastolic blood pressure by the disappearance of
sound.
Mean arterial pressure (MAP) was calculated by adding the sum of two thirds of the
diastolic pressure and one third of the systolic pressure (Konen et al, 1993).
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The pulse pressure was calculated as systolic blood pressure minus diastolic blood
pressure (Vander et al, 1994 a).

3.3.3 Blood sample taking
A blood sample (40 mL) was obtained from the left antecubital vein of seated subjects
after approximately 5 minutes rest in the sitting position after blood pressure
measurement.

A tourniquet was used but was released before collection of the blood sample to avoid
artifactual increases in the concentration of plasma proteins and lipids.

Blood samples were divided into several types of tubes: (1) tubes containing di
potassium EDTA (1 mg/mL), (2) 3 mL tubes containing 0.3 mL sodium citrate solution
(109 mM, 3.2%), and (3) plastic tubes containing gel (SARSTEDT M omovette, Serum
Gel S/7.5 mL)) for separation of serum.
All blood samples were mixed thoroughly and cooled immediately (by placing in fridge
or ice box).

The plasma was separated from the blood samples collected in the EDTA tubes by
centrifugation (2300 rpm for 20 minutes) and stored at 4°C for lipid studies.

Other

blood samples (citrated plasma and serum) had analyses performed in the Pathology
Laboratories, Illawarra Regional Hospital.

Remaining plasma or serum samples were frozen at -85°C, in 2 mL snap-top plastic
tubes within a few hours for further study.
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Some tests were carried out on fresh plasma and the others on frozen plasma (after
approximately 5-6 months at -85 °C) as listed in Table-3-1.

T able 3-1 L a b o r a to r y tests in this stu d y

Fresh plasma or urine

Frozen plasma

TC, TG, apoA-I, and apoB in plasma

NEFA in plasma

VLDL isolation (Cholesterol, FC, TG, apoB,
measurement)

Factor VII

IDL isolation (Cholesterol, FC, TG, apoB,
measurement)

von Willebrand factor (vWF)

HDL isolation (Cholesterol and apoA-I
measurement)

Lipoprotein (a)

H bA l-c

CETP activity %

Fasting blood glucose
Insulin
Testosterone
Fibrinogen
Albumin in urine
TC = total cholesterol, TG = triglycerides, apo = apolipoprotein, NEFA = non-esterified
fatty acids, CETP = cholesterol ester transfer protein.

3.4 Lipid Study
EDTA plasma was used for lipid studies. Blood was cooled rapidly, briefly stored at
4°C, and standard lipid laboratory procedures were initiated within 0.5-2 hours after
venipuncture.

3.4.1 Lipids and apolipoproteins in plasma
Total cholesterol, free (non-esterified) cholesterol (FC), and triglycerides were measured
on a Cobas-Fara automated centrifugal analyzer (Roche Centrifugal Analyzer, France).
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Total cholesterol concentrations in plasma and different lipoproteins were measured by
CHOD-PAP method (a standard enzymatic colorimetric method) based on Siedel et al,
1983 and Kattermann et al 1984) (Appendix II) with reagents supplied by Boehringer
Mannheim, Germany (Q C materials: Precinorm L, Cat No: L 781827 and Precipath Cat
No: L 128574). Cholesterol was determined by enzymatic hydrolysis with subsequent
determination of the liberated cholesterol (Test principle is presented in Appendix II) by
colorimetry. The reaction product was read optically at 546 nm and compared to a
known standard curve.

Six reference points (254, 508, 1016, 2032, 4065, and 8130

(imol/L) and 2 quality controls, one low (range 3635-5585 fimol/L) and one high (7350
11250 |imol/L) for total cholesterol (Roche Control Serum Lipid Cat No 2023624) were
used.
Boehringer-Mannheim Diagnostic kits for lipid standards, calibrators, and controls are
traceable to Centers for Disease Control (CDC) (Myers et al, 1994).
As reference ranges 750-1070 ^imol/L (calibrator or standard) for free cholesterol (FC),
the Boehringer Mannheim standard (Preciset Cat No: 125512) was used.
TG concentrations in plasma and lipoproteins were measured by Triglyceride GPO-PAP
(a standard enzymatic colorimetric method) based on Wahlefeld (1974) and Trinder
(1969) (Appendix II) with reagents supplied by Boehringer Mannheim, Germany (Q C
materials: Precinorm L, Cat No: L 781827 and Precipath Cat No: L 128574). Enzymatic
hydrolysis of triglycerides was determined with subsequent determination of the liberated
glycerol by colorimetry.

The reaction product was read optically at 500 nm and

compared to a known triglyceride standard curve.

Quality Control Values:

Precinorm L (1650 |imol/L)
Precipath L (4650 pmol/L)
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ApoB, and apoA-I concentrations were measured in fresh plasma on a Cobas-Fara by
Apolipoprotein B, T Antiserum (standard immunoturbidimetric method)
Diagnostics, France) (Appendix II).

(Roche

Turbidity of the antigen-antibody reaction was

measured at 340 nm. As quality control (QC) for apo B and apo A-I, the apolipoprotein
T Control (art. 0730696, Roche Diagnostics, France) was used.

Reference Values:

ApoA-I

ApoB

Male

1.15 -1.90 g/L

0.70-1.60 g/L

Female

1.15-2.20 g/L

0.60-1.50 g/L

Lipoprotein (a) concentration in plasma was measured by an immunoturbidimetric
method based on Levine et al (1992) by using SPQ TM kit, SPQ Calibration / Control:
includes Standards 1-5 and Controls Levels 1 and 2, (INCSTAR Corportion, Stillwater,
Minnesota, USA) on a Cobas-Fara analyzer. The immunoturbidimetric method is based
on the formation of insoluble antigen-antibody complexes, light scattering is measured,
following an 10 minutes incubation of sample and reagents, compared to a known
standard curve at 340 nm.
A calibration curve is produced by a series of standards with known concentrations of
lipoprotein (a) and using the instrument’s data reduction capability or manually plotting
the change in absorbance versus concentration.

Reference Values:

Control Level 1

19 mg/dL

Control Level 2

46 mg/dL
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3.4.2 Non-esterified fatty acids (NEFA)
Concentrations of non-esterified fatty acids in plasma were measured by the Wako
enzymatic method with reagent from Wako Pure Chemical Industries, Osaka, Japan.
Oleic acid 1.0 mM was used as the NEFA standard solution (Wako Pure Chemical
Industries, Ltd, Japan).

The method relies upon the acylation of co-enzyme A (Co-A) by the fatty acids in the
presence of added acyl Co-A synthetase. The acyl Co-A is oxidized by added acyl Co-A
oxidase with generation of hydrogen peroxide. Then, hydrogen peroxide in the presence
of peroxidase permits the oxidative condensation of 3-methyl-N-p hydroxyethylene
aniline (MEHA). MEHA condenses with 4 amino antipyrine to form a purple colored
product which can be measured colorimetrically at 550 nm.

Reference Values:

Plasma NEFA Concentration
0.20-1.08 mEq/L

3.4.3 Isolation of VLDL and IDL
VLDL and IDL were isolated from fresh plasma by sequential ultracentrifugation after
progressively raising the solvent density according to Havel et al (1955). KBr solutions
were made in 100 ml of deionized water and contained 0.02% sodium azide.
1.0 mL normal saline (0.15M NaCl, density 1.006 g/mL) was added to 4 mL of fresh
plasma in a quick-seal polyallomer ultracentrifuge tube (100.4, Beckman Instruments
Inc, USA).
Normal saline was added very carefully on top of plasma to avoid mixing (a syringe was
used) and then the tube was sealed.
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A Beckman TL-100 tabletop ultracentrifuge with a fixed angle, TLA -100.4 rotor
(Beckman, USA) was used.

The sample was subjected to ultracentrifugation for 25

minutes, 100,000 rpm, at 4°C. The VLDL fraction was isolated as the supernatant by
tube slicing.

Crystalline KBr was used to raise the solvent density. The amount of KBr to be added
was calculated by the following formula (Hatch and Lees, 1968) :

KBr (g) = Vi ( df- dj) / l-(v x df)

Vi = initial volume (mL)
df = density final (g/mL)
dj = density initial (g/mL 3-2)
v = value from Table 3-2

Table 3-2 R e q u ir e d s o lid K B r f o r m aking d iffere n t d e n sity so lu tio n s in 1 0 0 m L d is tille d
(d e -io n ize d ) w a te r (Hatch and Lees, 1968)

Final density of KBr
solution (g/ml)

V

KBr (g) added to 100 ml
distilled water

1.

1.019

0.2875

2.68722

2.

1.055

0.2923

7.9523

3.

1.063

0.2936

9.1582

4.

1.07

0.2943

10.2175

5.

1.09

0.2966

13.2997

6.

1.10

0.2977

14.8692

7.

1.12

0.2993

18.0509

8.

1.13

0.3003

19.6772

9.

1.14

0.3042

21.4325

10.

1.125

0.2997

18.8583

11.

1.21

0.3052

33.2959

12.

1.25

0.3084

40.6834

13.

1.27

0.3096

44.4951
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The infranatant was collected in a cylinder and the volume was measured. The sample
was then adjusted to a density of 1.19 g/mL by adding solid KBr, according to the
formula in Table 3-2.

After adjustment, the sample was poured into a quick-seal

centrifuge tube and filled by KBr solution density 1.019 g/mL. The IDL fraction was
isolated as the supernatant after centrifugation at 65,000 rpm for 16 hours at 4°C. The
infranatant was frozen immediately at -85°C.

Estimation of total cholesterol (TC), triglycerides (TG), and free cholesterol (FC)
concentrations were carried out on fresh VLDL and the IDL fraction.

Cholesterol ester (CE) was calculated in both VLDL and IDL as the difference between
total cholesterol and free (non-esterified) cholesterol.

Apo B concentration was

measured immunoturbidimetrically.

3.4.4 Isolation of HDL
ApoB-containing lipoproteins were precipitated with dextran sulfate-Mg2+ (Wamick et
al, 1982) and HDL-C

and HDL-apoA-I concentrations were measured in the

supernatant. The procedure for isolation of HDL from plasma lipoproteins is described
in detail in Appendix II.

3.4.5 Isolation of all lipoproteins for determination of HDL and LDL particle sizes
Plasma samples were adjusted to density 1.25 g/mL for isolation of all lipoproteins.
0.5 mL. fresh plasma was added to 0.1985 g KBr in a T L -100.1 Beckman centrifuge
tube. It was mixed well and subjected to ultracentrifugation in a T L A -100.1 rotor at
100,000 rpm for 16 hours at 4°C.
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After ultracentrifugation, 50|iL (yellow-top layer) was recovered and collected in a snaptop plastic tube and stored at 4°C for electrophoresis of lipoproteins. It was diluted 1:4
with TBS buffer (Appendix II) for electrophoresis.

Electrophoresis was carried out on a M icrograd II Electrophoresis Apparatus (Gradipore
Ltd Australia) using non-denaturing gradient gels (3-30% and 3-13%, Gradipore Ltd
Australia) and a 24 slot comb. 3-30% gel and 3-13% gels were used for identification of
HDL and LDL sub-populations, respectively.

3.4.6 Determination of HDL particle size by electrophoresis
HDL sub-populations were identified by electrophoresis using non-denaturing 3-30%
polyacrylamide gradient gels. Samples were applied in a volume of 10|iL containing 4
parts by volume of the density = 1.25 g/mL fraction and 1 part of a solution consisting of
sucrose and bromphenyl blue (Appendix II).

A reference protein mixture was used for calibrating particle size radius.

Each gel

contained the reference protein mixture in 3 lanes and 6 samples (Figure 3-1).

The

reference protein mixture used for calibrating particle size radius included thyroglobulin
(8.5 nm radius), apo-ferritin (6.10 nm radius), lactate dehydrogenase (4.08 nm radius),
and bovine serum albumin (3.55 nm radius) (High molecular weight (HMW) Calibration
Kit, Pharmacia LKB, Biotechnology AB, Uppsala).

Figure 3-1 Pattern of sample loading in 3-30% gel for identifying

HDL sub-populations
a a HM W a 1a 2a 3a HM W a 4a 5a 6a HM W a a
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Samples were electrophoresed at 170 V (constant voltage), 10°C for 17 hours in a buffer
containing 90 mM Tris base, 80 mM boric acid, 3 mM Na2EDTA and 3 mM sodium
azide (pH = 8.35).
Gels were fixed in 10% sulfosalicylic acid (Appendix II) for 0.5 hour immediately after
electrophoresis. After fixation, gels were stained for 3 hours in Coomassie Brilliant Blue
dye (R-250) (Appendix II) and then destained in 5% acetic acid (Appendix II). Gels were
rotated during fixing, staining, and destaining procedures,. Each gel was then put in a
small plastic bag with a few mL of 0.02% sodium azide solution (Appendix II) and
sealed.
Stained gradient gels were scanned with an Ultrascan XL Enhanced Laser Densitometer
(LKB Bromma Sweden) at wavelength 663 nm.

The migration distances (peak Rf

values) of the reference proteins of known radius were measured and a standard curve of
particle radius (nm) against Rf was constructed. The particle radius of the samples was
determined by reference to the standard curve.
The software package (LKB 2400 Gel Scan XL, Bromma) determined the peaks, and
calculated position (mm), and relevant area under the curve as a % of the total % for
each protein.
Gradient gel electrophoresis resolves human HDL into five subfractions.

Two of the

subfractions (HDL2b and HDL2a) correspond to HDL2 and three of the subfractions

(HDL3a, HDL3b, and HDL3c) correspond to HDL3 isolated by ultracentrifugation
(Converse and Skinner, 1992). HDL sub-populations were identified according to the
size ranges suggested by Nichols et al (1987).
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3.4.7 Determination of LDL particle size by electrophoresis
The procedure for identifying LDL particle size by electrophoresis is identical with that
for HDL, except that 3-13% non-denaturing polyacrylamide was used and calibration
was performed using 19 nm (radius) calibrated latex microspheres (carboxylated latex
beads, Duke Scientific Palo Alto, CA) as well as the HMW calibration kit (Pharmacia
LKB, Biotechnology AB, Uppsala, Sweden) for construction of the standard curve. The
calibration mixture was applied at the beginning of gels and after loading three samples
(Figure 3-2).

Figure 3-2 Pattern of samples loading in 3-13% gel for identifying

LDL particles
AAHMWABeadsAlA2A3AHMW/\BeadsA4A5A6AA

Fixation, staining and destaining procedures were the same as with 3-30% gels and the
same equipment was used for scanning.

3.4.8 HDL radiolabelled in the cholesteryl ester moiety
Radiolabelled HDL3 was prepared in the density range of 1.13-1.21 g/mL by using
tritium [3H] cholesterol ester as described by Albers and Tollefson (1984) (procedure in
Appendix II). One preparation of radiolabelled HDL3 was used for all CETP activity
assays.

3.4.9 Cholestryl ester transfer protein activity (CETP activity)
CETP activity was measured in plasma (thawed after storage at -85°C for 6 months) by
using the Abbey and Nestel method (1993). The assays were done in duplicate. All
assays contained as quality controls a positive control (a plasma sample from a normal
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healthy person) and a control for the estimation of non-specific transfer (not mediated by
CETP).

The CETP assay was done three times with and without (5,5-dithiobis [2-nitrobenzoic
acid]) but the results were not statistically different. As a result DTNB was not used
routinely for this assay. The procedure is presented in Appendix II.

3.4.10 LDL-C Calculation
LDL-C was calculated according the modified Friedewald equation.

The m o d ified F rie d e w a ld equation:

LDL-C (mmol/L) = Total cholesterol (mmol/L) - HDL-C (mmol/L) - TG (mmol/L) /
2.18
TG is an estimate of the concentration of cholesterol in VLDL particles in fasting
plasma. This is based on the assumption that all the plasma TG is associated with VLDL
and that the molar ratio of TG to cholesterol in VLDL is 2.18:1 (Samman and Truswell,
1993).
There are three restrictions in the use of the method presented by Friedewald et al for
estimating plasma LDL concentrations.
Firstly, it is not applicable to the fed state, when the ratio of TG to cholesterol in VLDL
and chylomicrons is likely to be higher, so that the standardised molar ratio of TG to
cholesterol in VLDL is not 2.18:1, and if the formula is used in these circumstances, it
results in overestimation of VLDL-C and hence an underestimation of the LDL-C
concentration. All participating subjects in this study were in the fasting state.
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Secondly, the technique gives erroneously high results in patients with type III
hyperlipoproteinemia, because the Friedewald equation assumes that IDL-C is negligible.
The lipid results did not suggest type HI hyperproteinemia in any subjects.
Thirdly, LDL-C can not be accurately estimated when the plasma triglyceride
concentration is more than 4.5 mmol/L (Samman and Truswell, 1993).

None of the

subjects had a plasma triglyceride concentration more than 4.5 mmol/L.

3.4.11 LDL-apoB Calculation
LDL-apoB values were calculated according to this formula:
LDL-apoB = total apoB - (VLDL-apoB + IDL-apoB).

3.5 Tests related to carbohydrate metabolism
Fasting blood glucose, fasting blood insulin and HbAlc were measured by standard
procedures described as follow:

3.5.1 Fasting blood glucose (FBG)
FBG was determined by a colorimetric method based on Trinder, 1969 and Curme et al,
1978 on an Ektachem 700 XR analyzer (Kodak, NY, USA) using the Kodak Ektachem
Clinical Chemistry Slide (GLU).
The Kodak Ektachem Clinical Chemistry Slide (GLU) is a dry, multilayered analytical
element coated on a clear polyester support. Kodak Ektachem Calibrators 1, 2, and 3
were used as calibrator. Kodac Ektachem Control was also used (Range for serum =
1.11-34.69 mmol/L).
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A 10 (iL drop of patient blood is deposited on the slide. It diffuses into the underlying
reagent layer. The oxidation of glucose in the sample is catalyzed by glucose oxidase to
form hydrogen peroxide and gluconate.
This reaction is followed by an oxidative reaction catalyzed by peroxidase in the presence
of chromogens (4-aminoantipyrine + 1,7-dihydroxynaphthalene) to produce a red dye.
The intensity of the red dye is measured by reflected light (wavelength = 540 nm)
(Kodak Ektachem Clinical Chemistry Products’ manual, 1992).

Expected Values in Serum:
Male (18-44 yr)

4.2-6.1 mmol/L

Female (18-64 yr)

3.6-5.8 mmol/L

3.5.2 Fasting blood insulin (FBI)
FBI was measured by microparticle enzyme immunoassay (MEIA) based on Travis 1980
method on an Abbot IMX analyzer (Abbott Diagnostics, Chicago, USA). In the IMX
insulin assay, an antibody-insulin complex is formed by incubating the patient’s serum
sample with coated microparticles. Then the anti-insulin:alkaline phosphatase conjugate
is added to the antibody-insulin complex and binds to it.

The substrate (4-

methylumbelliferyl phosphate) is added to the complex and the end product of the
reaction (the fluorescent product) is measured by the MEIA optical assembly (Abbott
Diagnostic, 1994).

The IMX insulin assay shows no cross-reactivity with proinsulin

(Abbott Diagnostic, 1994).
The IMX Insulin Calibrators contain insulin (human) prepared in buffer at six different
concentrations (0.000, 0.003, 0.010, 0.030, 0.100, and 0.300 mU/mL).
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The IMX Insulin Controls contain insulin (human) prepared in buffer to yield the
following concentration ranges.

Insulin concentration (mU/mL)

Bottle

Range (mU/mL)

L

0.008

0.006-0.010

M

0.040

0.032-0.048

H

0.120

0.096-0.144

3.5.3 HbAlc
H bA lc was determined by high performance liquid chromatography (HPLC), on a
Pharmacia M ono S HR 5/5 column (Pharmacia LKB Technology, Almeda, CA) (Bio
Rad Haemoglobin A le Micro-column Test Instruction Manual, 1990).
Lyphocheck Glycated Haemoglobin BioRad (Cat No C-555) level 1 and 2 were used as
quality control material.

Expected levels
> 10%

Poor degree of glucose control

9-10%

Fair

"

"

"

8-9%

Good "

"

"

7-8%

Excellent "

"

"

< 6% (4.2-5.9 %)

Non-diabetic level

3.6 Haematological Tests

3.6.1 Fibrinogen
Fibrinogen was determined in fresh citrated plasma (one part citrate solution, 0.106
mol/L sodium citrate + nine parts blood) by the Corrivea and Fritsma method (1988).
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Principle of test: In the presence of a high concentration of thrombin, the thrombin
clotting time is inversely proportional to the fibrinogen concentration of plasma.

The reference range for fibrinogen is 2.0-4.0 mg/L at all ages, including full-term and
premature newborn.
ARP or Uniplasmatrol Normal is used as control plasma.

Calibration: CSL Human

Thrombin (dried) 2500 U is mixed with 5 mL of distilled water to give a resulting
concentration of 500 U/mL. 4 mL Owems buffer is added to 1 mL of thrombin 500
U/mL to make a final concentration of thrombin of 100 U/mL. Six different dilutions
(1:5, 1:7.5, 1:10, 1:15, 1:20, and 1:30) are assayed directly on the MLA and the
corresponding thrombin times used in the construction of a standard curve.

3.6.2 Factor V n
Factor VII activity assay was performed on the MLA 1000C automated coagulation
analyzer (Baxter Diagnostics, MLA 1000C) on citrated plasma. This assay is based on
Seegers and Walz, 1986, Bajaj et al, 1981.

Factor VII activity was measured by a

clotting method utilizing the prothrombin time test (Baxter Diagnostic, MLA 1000C
operator’s manual, USA, 1988).
Immuno ads orbed Factor VII Deficient Plasma (human) with different concentrations
(1:10, 1:20, ..., 1:160, 1:320) was used in the construction of a standard curve. Factor
Assay Reference Plasma (Cat No B4234-30) and Ci-Trol Coagulation Control Level 1
(Cat No B4224-10) also were used. The result was calculated as % of activity. Factor
VII activities over 100% is considered as higher than normal.
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Note: There are several different methods available to evaluate plasma factor VII level
such as factor VII coagulant activity (measurement of factor VII activity via a clotting
method utilising the prothrombin time test), activated factor VII (factor Vila)
(quantitation of activated factor VII levels in plasma by using a tissue factor mutant
selectively deficient in promoting factor VII activation), and factor VII antigen (factor
VIIAg) (Baxter Diagnostic, Manual, 1988, Morrissey et al, 1993, respectively).

We

used factor VH coagulant activity method, because this method is commonly used in the
region pathology laboratories.
This method is traceable to Centers of Disease Control (CDC).

3.6.3 Von Willebrand Factor (vWF) antigen
vWF antigen was measured in frozen citrated plasma by the ELISA method based on
Cejka (1982) using Dakopatts rabbit’s anti-human von Willebrand Factor (Cat No.
A082). Dakopatts rabbit anti-human von Willebrand Factor conjugated with horseradish
peroxidase (Cat No. P 226) supplied by Bio Scientific Pty Ltd was used in the
construction of a standard curve.
Principle of method: Dilutions of patients and pool reference plasma are incubated in
microwells that have been coated with antibody to human vWF antigen raised in rabbits.
The vWF antigen in the diluted samples and reference plasma is bound by the
immobilized antibody. The microwells are then washed and a second antibody to human
vWf antigen conjugated to horseradish peroxidase is added and the samples incubated.
A peroxidase substrate (TMB) was added after post-incubation washing. The substrate
developed colour in the presence of conjugated enzyme. The absorbency of each well
was read at 450 nm using the MR 5000 microtitre plate reader.
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The vW f antigen concentration of the unknown patient sample is determined by reading
off the standard curve the value corresponding to each patient’s absorbance.

3.7 Hormonal Tests
3.7.1 Total testosterone
Total testosterone

was

determined

in

fresh

serum

using

a solid

phase

125I

radioimmunoassay based on testosterone-specific antibody immobilized to the wall of a
polypropylene tube (Coat-A-Count, Total testosterone, Diagnostic Products Corporation
Los Angeles, CA).
125I-labelled testosterone competes for a fixed time with testosterone in the patient
sample for antibody sites. The tube is then decanted, to separate bound from free, and
counted in a gam m a counter. The amount of testosterone present in the patient sample is
determined from a calibration curve (DPC manual, 1995).
Human serum-based calibrators (TTC3-8) having testosterone concentrations ranging
from 0.2-16 ng/mL (which is equivalent to 0.7-55 nmol/L or 20-1600 ng/dL) were used.
These were provided by Diagnostic Products Corporation (DPC).

Reference Values: 4-1600 ng/dL = 0.7-55 nmol/L.

3.7.2 Sex hormone binding globulin (SHBG)
SHBG was m easured in fresh serum using the Farmos SHBG IRMA test procedure
based on the principles of a non-competitive ‘liquid-phase’ immunoradiometric assay Sex
Hormone Binding Globulin [125I] Immunoradiometric Assay Kit (Farmos Group Ltd,
Oulunsalo, Finland).
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SHBG Standards (A-F) contain 6.25, 12.5, 25, 50, 100, and 200 nmol SHBG/L (Farmos
Group Ltd, Finland) were used.

SHBG standard was made from human pregnancy

serum diluted in bovine serum.

Two SHBG controls (low and high) were used and expected values are as follows:

Reference Values:

Quality Control L (Low)

Quality Control H (high)

9.0-12.2 nmol/L

81.0-106 nmol/L

3.8 Albumin in Urine
The amount of albumin in urine was measured by rate nephelometry (micro ALBUMIN
(MA), Reagent, P/N 441450) on a Beckman Array 360 analyzer. The method measures
the rate of increase in light scattered from particles suspended in solution as a results of
complexes formed during an antigen-antibody reaction (Beckman MA micro ALBUMIN
manual, 1990).
It is recommended that pooled urine or commercially available nephelometric quality
control material with known concentrations of albumin be included in each set of
determinations.

In this test, pooled urine with known concentration of albumin was

used.

Expected Value for Albumin in Urine: < 20 mg/dl

3.9 Anthropometry
All anthropometric measurements were carried out in accordance with the WHO
standards (WHO, 1987).
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The

following measurements were made: height against a fixed scale, weight using a
calibrated digital balance, hip circumference at the widest point of the hip by a new fabric
tape measure, and waist circumference at the level of the umbilicus without compression
of the skin by a fabric tape measure.
All skinfolds were measured on the right side of the body using a Harpendon calliper.
Those were made at four sites on all subjects, at the biceps, triceps, subscapular, and
suprailiac areas (Dumin and Wormersley, 1974).
Biceps skinfold was measured above the center of the cubital fossa, at the midpoint of
the biceps muscle.
Triceps skinfold was measured halfway between the inferior border of the acromion
process and the tip of the olecranon process and in line with the point on the elbow and
the acromion process.
Suprailiac skinfold was measured above the superior iliac crest in the midaxillary line.
Subscapular skinfold was measured just below the tip of the scapula.

Table 5-5 Body fat % calculation (Siri, 1956)
Age bracket (years):
20-29 D = 1159.9-71.7 Log (XI)
30-39 D = 1142.3-63.2 Log (XI)
40-49 D = 1133.3-61.2 Log (XI)
where:

D = body density
XI = sum of biceps, triceps, subscapular, and suprailiac skinfold
thicknesses

Body fat percentage was determined according to the formula:
% Body Fat = [(4950/D)-4.5] x 100
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Body mass index (BM I) as a measure of body adiposity was calculated as BM I = weight
(kg)/ height (m)2 (Quetelet, 1869).

The ratio of waist to hip circumferences (W/H ratio) was calculated as a measure of
central or abdominal adiposity and the skinfold ratio (subscapular / triceps ratio) was
employed as a m easure of upper-body fat (Cassano et al, 1992).

Body fat % was calculated by using Siri’s equation (1956).

3.10 The Dietary and Health Questionnaire Booklet
The booklet was explained completely to subjects.

The subjects was asked to fill it

carefully (at home) and return it by post as soon as possible.

Dietary intake was assessed using a self-administered, semi-quantitative food frequency
questionnaire.

This questionnaire has been used frequently in previous dietary intake

studies in Australia and has been shown to have high repeatability (Baghurst et al, 1988).
This questionnaire was open-ended both with respect to the foods included and the usual
serve size of the respondent. Subjects were instructed to indicate how often they usually
have each of the foods and beverage (ie never, rarely, or so many times per day, per
week, and per month). For m ost of the foods listed in the questionnaire, standard serve
sizes were assum ed (Baghurst et al, 1988).
In addition to these food frequency questions, there were a number of questions dealing
with their health, family medical history, current medication, their dietary changes,
physical activity, smoking, age, occupation status, income, country of birth, and marital
status (Appendix III).
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Daily nutrient intake was calculated using a modified version of the Frequan computer
program (a computerized dietary analysis system for use with diet diaries or food
frequency questionnaires, CSIRO Division of human Nutrition, Adelaide) (Baghurst and
Record, 1984).

% energy intake Calculation for different macronutrients:
* % Energy intake from total carbohydrate intake =

(Total carbohydrate (g) x 16 x 100 )/ Total energy intake (KJ)

* Energy intake from total fat intake =

(Total fat intake (g) x 37 x 100) / Total energy intake (KJ)

* Energy intake from protein intake =

(Protein (g) x 17 x 100) / Total energy intake (KJ)

3.11 Data collection - validity
Every study in medicine must involve an interaction between the observer and the patient
or object being observed. Measurement bias is a factor that every researcher must be
wary of (Daly et al, 1991). To avoid this problem, the study protocol was piloted twice
on volunteers by the researcher and her colleagues.

Quality control was checked for

each run of tests.
Data were extracted from demographic forms and all dietary questionnaires were coded
by the researcher.

The coded dietary questionnaires were sent to CSIRO and were

analyzed by staff at the Division of Human Nutrition, CSIRO, Adelaide.
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Then all results were entered on a spreadsheet associated with the JM P statistical
package (SAS Institute Inc) on a Macintosh Quadra 650 computer.

The data were

checked several times to detect any mistakes and then statistical analysis was carried out.

3.12 Statistical Analysis

Statistical analysis were performed using the ‘JM P’ statistical package (SAS Institute
Inc, NC, USA, Version 3). All statistical comparisons were two tailed. Variables were
tested for normality (a Gaussian distribution) using the Shapiro-Wilk W test (because n <
2000).

Several variables were not distributed normally and data transformation,

commonly to the logarithm, was used to reduce skewness.

A significant cut-off level for the p value of 0.05 was used for all statistical analysis. The
0.05 level means that an obtained result that is significant at the 0.05 level should occur
by chance only 5 times in 100 trials.

The 0.05 level corresponds fairly well to two

standard deviations from the mean of a normal probability distribution.

Student’s t-test (unpaired) was employed to assess the significance of differences in
group means. The data were presented as mean ± standard deviation.

The chi-square (Pearson) test was used in this research for determining the relationship
between nominal variables.
Cross-correlation used to determine the possible correlations between variables.

Simple and multiple regression analysis is a method of analyzing the variability of a
dependent variable on one or more independent variables. These statistical techniques
were used in this study.
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The advantage of multiple regression over other techniques used is that it shows the
combined effects of a set of independent variables and the separate effects of each
independent variable controlling for the others.

The P coefficient of each independent variable and the coefficient of multiple
determination (denoted by r2), which are two statistics that often accompany the report
of the multiple regression, are used in this research for describing the relationships
between the response variable (Y) and independent factors (Xs) in different models.

We chose nine variables (age, fasting insulin concentration, BMI, family history of
diabetes mellitus, use of an oral contraceptive pill, smoking, fat and alcohol intake, and
exercise) as independent variables for multiple regression analysis in this study. Subjects
as a whole were entered in the models and identified as a variable named groups (coded
as 1 = GDM subjects and 0 = control subject).
Nine different models were determined for BMI, fasting insulin, total cholesterol, total
triglyceride, and NEFA concentrations, CETP activity (%) in plasma, serum SHBG
concentration, systolic blood pressure, and the concentration of albumin in urine. The
result is presented in Table 4-9 in Chapter four.
In multiple regression analysis, there is a nominal variable (X = independent variable) for
a interval variable (Y = response variable) model. The model translates this specification
into a linear model as follows.

The nominal variables define a sequence of ‘dummy’

variables, which have only values 1, 0, and -1. For example, suppose you want to lit the
response Y to a nominal variable group with three levels. The linear model is written

yi —Po + Pi Xn + P2X2i + £i
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The first dummy variable is labeled group [1-3] in the report, which denotes that group =
1 contributes a value 1 and group = 3 contributes a value -1 to the dummy variable.

x ii

1

if group = 1

<0

if group = 2

1-1 if group = 3
The second dummy variable is labeled group [2-3] in the report and is given values

0

if group = 1

1

if group = 2

-1

if group = 3

The last level does not need a dummy variable because in this model its level is found by
substracting all the other parameters. Therefore, the coefficients sum to one across all
the levels.
The estimates of the means for the three levels in terms of this parameterization are

M
-i = Po+ Pi
fii-po + P2
M-3 =Po — Pi — P2
Solving for P yields
p0= ((J.J+ (i2 + p.3) / 3 = |d (the average over levels)

p2 = H2 “ H
p3 - Pi - P2 = Us - MThus, if the indicator coding is each level minus the previous level, the parameter coding
is each level minus the mean of all levls (JMP Package Manual, 1994).
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Each model will be fully described in their own sections.
Subgroups determination:

We determined several subgroups.

We used a cut-off point of fasting insulin

concentration > 1 1 , BM I > 25 kg/m2 for overweight persons, NEFA > 0.6 mmol/L, and
family history of diabetes mellitus as positive (+) and negative (-) to determine the
subgroups. ).

Subjects who had plasma NEFA levels > 0 .6 mmol/L, positive family history of diabetes,
and BMI > 25 kg/m2 determined as subgroup (A).
Subjects who had plasma NEFA levels > 0 .6 mmol/L, positive family history of diabetes,
and BMI < 25 kg/m2 determined as subgroup (B).
The GDM group with fasting plasma insulin < 10 IU/L were distinguished from those
with fasting insulin > 10 IU/L and named as hyperinsulinémie subgroup or subgroup C.
Each subgroup were compared with the residual GDM group and residual control group
using Student’s t test.

CHAPTER FOUR
RESULTS
4.1 Comparison o f Study and Control Populations
The overall response rate was 81.25% in the GDM group and 72.22% in the control
group (Table 4-1). The uncorrected chi square test indicated that there is no significant
difference between the response rate in the GDM and the control groups (Table 4-1).
Table 4-1 Response per groups
GDM

C ontrols

Expected

80

90

Responded

65

65
X2 = 6.26
p = 0.61

4.1.1 Dem ographic Data of the Study
The results showed there is no significant difference in age between the GDM and the
control groups (Table 4-2 and Figure 4-1).
Subjects who had had GDM were more likely to have a positive history of diabetes in
their first degree relatives (mother, father, sister, and brother) (Table 4-2).

The

frequency o f familial diabetes mellitus in the maternal side (17%) was not significantly
more than paternal side (18.5%) between the GDM subjects (Table 4-3).
The GDM individuals also were more likely to have a positive history of cardiovascular
disease (CVD) in their first degree relatives (Table 4-2).
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O ne G D M subject had had fiv e abortions’, w hen she w as excluded from the data, no
significant differences w ere found in parity, number o f deliveries, number o f abortions,
and history o f stillbirth b etw een G D M and controls (T able 4-2).

Table 4-2 Demographic Data
Variable

Number

GDMs

Controls

Age

M ean

31.52

31.39

Std D ev

4.95

4.22

N o history

21 (32.3% )

43 (66.2% )

First degree relative

25 (38.5% )

8 (12.3% )

Second degree relative

1 9 (2 9 .2 % )

14(21.5%)

N o history

38 (58.5% )

42 (64.6% )

First degree relative

24 (36.9% )

1 0 (1 5 .4 % )

Second degree relative

3 (4.6% )

13 (20% )

Parity

2.35 ± 1.6

2.71 ± 1.3

D elivery

1.95 ± 1.15

2.32 ± 1.13

A bortion

0.23 ± 0.72

0.32 ± 0 .6 2

Stillbirth

0.08 ± 0 .2 1

0.05 ± 0 .2 1

Last baby w eight

3410 ± 567

3304 ± 514

M ean

24.81

22.31

Std D ev

5.20

2.83

M ean

26.05

22.75

Std D ev

5.50

2.90

M ean

0.85

0.82

Std D ev

0.007

0.007

M ean

38.8

35.1

Std D ev

4.81

3.73

Fam ily history o f D M

Fam ily

history

of

P

**

CVD

O bstetrics history

Pre-pregnancy B M I

Current B M I

WHR

B od y Fat %

**

**

**

*

**

Std D e v = Standard deviation, B M I = B od y m ass index, W H R - W aist /H ip Ratio, * p < 0 .0 5 , ** = p < 0.01, blank space = N o significant.
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The m ean birth-w eight w as slightly greater in babies o f G D M subjects than in babies o f
control subjects but the difference w as not significant (Table 4-2 and Figure 4-2).
W om en w h o had had G D M w ere more likely to be fatter, both pre-pregnancy and one
year after delivery, than controls.

The G D M subjects have also a significantly greater

W H R and B od y fat % than controls (T able 4-2, Figures 4-3, 4-4, 4-5, 4-6).

Figure 4-1 Means comparison o f age in GDM and control subjects (the difference
between means is not significant)

Figure 4-2 M eans comparison o f baby birth-weight between GDM and controls
(the difference between means is not significant)
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Figure 4-3 M eans comparison o f pre-pregnancy B M I in GDM and control subjects
(the difference between means is

significant)

Figure 4-4 M eans comparison o f B M I in GD M and control subjects (the difference
between means is

significant)
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Figure 4-5 M eans comparison o f WHR in GD M and control subjects
(the difference between means is

significant)

Figure 4-6 M eans comparison o f body fa t % in GDM and control subjects
(the difference between means is

significant)
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Table 4-3 Frequencies offamily history o f diabetes mellitus in the GDM and control
group
Frequency of DM in relatives

GDM

Controls

N o p o sitiv e fa m ily history

21 (32.3% )

43 (66.2% )

M o th er

11 (16.9% )

2 (3 .1 % )

Father

1 2 (1 8 .5 % )

3 (4.6% )

Sister

2 (3 .1 % )

2 (3 .1 % )

B rother

0 (0.0% )

1 (1.5% )

Grandm other (m other side)

11 (16.9% )

2 (3 .1 % )

G randm other (father side)

0 (0.0% )

1 (1.5% )

Grandfather (m other side)

1 (1.5% )

2 (3 .1 % )

Grandfather (father side)

2 (3 .1 % )

2 (3 .1 % )

U n c le (m other sid e)

2 (3.1% )

2 (3 .1 % )

U n c le (father side)

0 (0.0% )

2 (3 .1 % )

A unt (m oth er sid e)

0 (0.0% )

0 (0.0% )

A unt (father sid e)

1 (1.5% )

1 (3.1% )

C ousin (m other side)

0 (0.0% )

2 (3.1% )

C ousin (father side)

2 (3 .1 % )

0 (0.0% )

4.1.2 Physiological Data of the Study
Plasm a cholesterol concentrations w ere significantly higher in the G D M group than in
the control group (T able 4-4 and Figure 4-7).

The G D M subjects had significantly

higher plasm a T G le v e ls than controls (T able 4-4 and Figure 4-8).
The p lasm a apoB le v e ls w ere sign ificantly higher in the G D M group than in the control
group (T able 4 -4 and Figure 4 -9 ), but there w as no significant difference b etw een the
G D M and control group m eans o f plasm a apo A -I concentrations (T able 4-4).
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Plasm a N E F A concentration after an overnight fast w as significantly higher in the G D M
subjects than in the control subjects (T able 4-4 and Figure 4-10).
C haracteristics o f V L D L in subjects outlined in Table 4-4.

V L D L -T G concentration

w as significantly higher in the G D M group than in control group. D ifference betw een
m eans for other asp ects o f V L D L com p osition w ere not significant b etw een the tw o
groups (T able 4 -4 and Figure 4-11).

Characteristics o f the EDL fraction are outlined in T able 4-4. IDL-C , IDL-FC, and IDLTG (but not ID L -C E and ID L -apoB concentrations) were significantly higher in the
G D M group than in control group (T able 4-4 and Figure 4 -12).

C alculated LD L -C lev els w ere significantly higher in the G D M subjects than in controls
(Table 4 -4 and Figure 4-1 3 ).

Calculated L D L -apoB w as significantly greater in G D M

subjects than in control subjects (T able 4-4 and Figure 4-14).

LD L -I particle sizes w ere smaller in G D M group than in the control group (Table 4-4
and Figure 4-1 5 ). LD L-II and LDL-III also w ere sm aller in the G D M group than in the
control group but not significantly sm aller (T able 4-4).

There is no difference b etw een plasm a H D L -C level in G D M subjects and in controls
(T able 4-4). H D L -ap oA -I also w as not significantly low er in the G D M than in control
group (T able 4-4). H D L 2 area % / H D L 3 area % ratio (using electrophoresis scans) did
not sh ow any sign ificant difference betw een the G D M and the control groups (Table 4 
4).

H D L 2 and H D L 3 sub-population com p on en ts (H D L 2b, H D L 2a, H D L 3a, H D L 3b, and
H D L 3c) w ere com pared b etw een tw o groups (G D M

and controls) using unpaired
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t test. H D L 3b and H D L 3c w ere sign ifican tly sm aller in G D M subjects than in

con trols but not other sub-population com p on en ts (T able 4-4 , and Figures 4 -1 6 , 4 -1 7).

There is n o sign ificant difference in the Lp(a) le v els b etw een G D M and control subjects
(T able 4 -4 ).

Plasm a C ETP activity % (C E T P .A %) w as significantly higher in the

G D M group versu s the control group (T able 4 -4 and Figure 4 -18).

Table 4-4 Summarized data from lipoprotein metabolism related tests o f study
V a r ia b le s

p v a lu e
**

i
Plasm a C holesterol (m m ol/L )

GDM

C o n tr o ls

4 .9 4 ± 0 .9 5

4 .4 4 ± 0 .8 8

Plasm a TG (m m ol/L )

1.07 ± 0 .5 0

0 .8 7 ± 0 .3 9

Plasm a apoB (g/L )

1.05 ± 0 .2 4

0 .88 ± 0 .2 2

Plasm a apo A -I (g/L )

1.50 ± 0 .2 7

1.54 ± 0 .2 5

N E F A (m m ol/L )

0 .68 ± 0 .2 2

0 .5 4 ± 0 .2 3

V L D L -C Ounol/L)

518.3 ± 30.6

4 8 9 .4 ± 3 2 .6

V L D L -T G (|im o l/L )

4 4 6 .8 ± 3 3 .7 8

3 2 6 .5 8 ± 3 3 .7 7

V L D L -F C (|jin ol/L )

2 0 4 .6 ± 16.2

184.0 ± 16.30

V L D L -C E (fim ol/L )

3 3 3 .6 ± 28.1

305.5 ± 2 8 .2

V L D L -apoB (g/L )

0 .1 3 6 ± 0 .12

0 .1 0 9 ± 0 .0 7

ID L-C (jim ol/L )

9 1 .8 2 ± 6 .5 6

67.03 ± 6 .5 1

ID L -T G (Mmol/L)

130.06 ± 10.39

82.63 ± 10.39

ID L-FC (Mmol/L)

4 2 .0 2 ± 2 9 .5

2 7 .5 9 ± 2 0 .1

ID L -C E (ttm ol/L )

4 9 .81 ± 3 .9 6

3 9 .5 0 ± 3 .9 3

ID L -apoB (g/L )

0 .0 2 8 ± 0 .0 1 2

0.025 ± 0 .0 1 0

L D L -C (m m ol/L )

3 .3 2 ± 0 .9 4

2 .7 9 ± 0 .7 5

**

L D L -apoB (g/L )

1.05.3 ± 0 .2 3 6

0 .8 8 2 ± 0 .2 1 8

**

L D L -I size (nm )

3 0.7 ± 0 .9 8

3 1.4 ± 0 .9 9

L D L -II size (nm )

2 9 .4 ± 0 .9 9

2 9 .7 ± 1.00

L D L -III size (nm )

2 8 .2 ± 0 .1 6

28.5 ± 0 .1 3

L D L -C / H D L -C R atio

2 .55 ± 0 .12

2 .0 6 ± 0 .1 2

H D L -C (m m ol/L )

1.32 ± 0 .0 4

1.38 ± 0 .0 4

*
**

**

*

**
**
**

*

**

TG = triglycerid e, apo = apolipoprotein, * = p < 0 05, ** = p < 0 .0 1 , blank sp ace = N o
significant.
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T ab le 4 -5 (con tin u ed )

V ariab les

GDM

C o n tro ls

H D L -a p o A -I (g /L )

1.39 ± 0 . 0 3

1.41 ± 0 . 0 3

H D L 2 (%) / H D L 3 (% )

0.81 ± 0 . 0 9

0. 97 ± 0 . 1 0

H D L 2b s iz e (n m )

10.91 ± 0 . 0 4

11.0 ± 0 . 0 4

H D L 2a s iz e (n m )

9 .2 8 ± 0 . 0 4

9. 34 ± 0 . 0 4

H D L 3a s iz e (n m )

8 .4 6 ± 0 . 0 3

8. 54 ± 0 . 0 3

H D L 3b s iz e (n m )

7. 92 ± 0 . 0 1

7. 98 ± 0 . 0 1

**

H D L 3c s iz e (nm )

7. 59 ± 0 . 0 2

7 .6 6 ± 0 . 0 2

**

P lasm a Lp (a) (m g/d l)

1 9 .64 ± 16.8

23. 71 ± 2 2 . 9

C ETP activity (% )

19.51 ± 1.07

15. 78 ± 1.06

p value

*

Lp = lip op rotein , * = p < 0 .0 5 , ** = p < 0. 01, blank sp ace = N o sign ifican t.

7-

6-

5“

4“
3“

GDM

control

Figure 4-7 M eans comparison for plasm a cholesterol concentration between GDM and
control groups (difference between means is significant\ p = 0.0021)
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Figure 4-8 M eans comparison for plasm a triglyceride concentration between G D M and
control groups (difference between means is significant, p = 0.0153)

Figure 4-9 Comparison between mean values o f plasm a apoB concentrations in GDM
and confrol groups (difference between means is significant, p = 0.0000)
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Figure 4-10 Comparison between mean values o f plasm a NEFA concentrations in GDM
and control groups (difference between means is significant, p = 0.0013)

Mean(VLDL-C(|amol/L))
Mean(VLDL-TG(|j.mol/L))
Mean(VLDL-FC(|amol/L))
Mean(VLDL-CE(|imol/L))

Figure 4-11 M eans comparison fo r VLDL composition levels between GD M and
controls (there is only a significant difference between means o f VLDL-TG)
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Mean(IDL-C(pmol/L))
Mean(IDL-TG(jumol/L))
Mean(IDL-FC(pmol/L))
Mean(IDL-CE(pmol/L))

0

50

I
100

1 50

Figure 4-12 M eans comparison fo r 1DL-C, IDL-TG, and ID L F C concenfrations
between the G D M subjects and controls (means are significantly different)

Figure 4-13 Comparison o f m eans o f plasm a LD L-C concentration between G D M and
confrol subjects (there is a significant difference between means, p = 0.0006)

C hapter F o u r

R esu lts

1 .4
1.3“
1.2“
1.1“
1. o -

110

■
■
■
■
---#-B
■

■
■
■
■
1

1
^

3

0.9 —

<§
Q_
7
_i

0.8 -

-i

0.6“

t

[
0.7“

0.5

■
1

0.40.3

■

0. 2 ^ ----------------- ------------------ ------------------

GDM

control

Figure 4-14 Comparison o f m eans o f LD L-apoB between G D M and control subjects
(there is a significant difference between means, p = 0.0000)

Figure 4-15 Comparison o f means ofLD L-1 (size) between G D M and control subjects
(there is a significant difference between means, p = 0.0006)
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Figure 4-16 M eans comparison o f H D L3 b (diameter) between G D M and control groups
(there is a significant difference between means, p = 0.0188)

Figure 4-17 M eans comparison o f H D L3c (diameter) between G D M and control groups
(there is a significant difference between means, p = 0.0028)
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Figure 4-18 M eans comparison for plasm a CETP activity % between GD M and controls
(there is a significant difference between means, p - 0.0190)

The fastin g b lo o d g lu co se concentration w as not significantly higher in G D M subjects
than in con trols (T ab le 4-5 ).

F astin g in su lin le v el w a s sign ifican tly higher in G D M patients than in controls (T able 4 
5 and F igure 4 -1 9 ). In addition, the ratio o f fasting insulin level / fasting g lu co se level (as
a marker o f insulin resistance) w as significantly higher in G D M subjects (T able 4-5 and
Figure 4 -20).

G ly co sy la ted h a em o g lo b in ( H b A lc ) le v e ls w ere sim ilar in the G D M and control groups
(T ab le 4 -5 ).

T he m ean p lasm a fibrinogen concentration, factor VII coagulant activity (factor V ile),
and vonW illebrand factor (v W F ) a ctivity (% ) w ere slig h tly higher in the G D M than in
con trols but did not d iffer sig n ifica n tly (T able 4-5).
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significantly

different plasm a

SH B G

concentrations (T able 4-5 and Figure 4-2 1 ).

The G D M

group w ith a low er concentration o f S H B G had a slightly

but not

significantly higher plasm a testo stero n e concentration than the control group (Table 4 
5)-

The testo stero n e / S H B G ratio w a s significantly greater in G D M

than in control

subjects (T able 4 -5 , Figure 4 -2 2 ).

B oth sy sto lic and d iastolic b lood pressures w ere sign ificantly higher in the G D M group
than in the control subjects (T able 4-5 and Figures 4 -2 3 , 4-2 4 ).

M ean arterial pressure

(M A P ) w a s sign ifican tly higher in G D M subjects than in controls (T able 4-5 and Figure
4 -2 5 ). H ow ever, the pulse pressure w as sim ilar in G D M subjects and in controls (Table
4-5). The am ount o f album in in urine (m g/L ) w as significantly greater in G D M subjects
than in controls (T able 4-5 and Figure 4 -26).

Figure 4-19 M eans comparison for fasting blood insulin between GDM and control
groups (there is a significant difference between means, p = 0.0008)
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Table 4-5 Summarised data from other physiological tests o f the study
Variables

GDM

Controls

F.blood g lu co se (m m ol/L )

4 .5 9 ± 0 .4 4

4.55 ± 0 . 4 0

F asting b lo o d insulin (IU /L )

7.53 ± 5 .2 3

5.14 ± 1.96

Insulin / G lu co se R atio

1.20 ± 0 .4 1

1.02 ± 0 . 2 7

H b A lc (%)

5 .30 ± 0 .6 2

5.28 ± 0 . 5 0

Fibrinogen (g/L )

3.11 ± 0 .8 4

2 .9 6 ± 0 .7 3

Factor V II activity (%)

100.1 ± 19.5

93.95 ± 2 1 .9

vW F (%)

80 .3 8 ± 3 0 .3

77.25 ± 2 7 .3 1

S H B G (nm ol/L )

4 5 .0 5 ± 2 9 .0 2

5 7 .69 ± 3 3 .3

T estosteron e (n m ol/L )

1.04 ± 0 .5 5

0.91 ± 0 .3 5

T estosteron e / S H B G R atio

0 .0 3 4 ± 0 .0 2 9

0.021 ± 0 .0 1 5

S ystolic B P (m m H g)

110.15 ± 1.55

105.08 ± 1.55

*

D ia sto lic B P (m m H g)

7 6 .6 7 ± 5 .9 4

7 2 .77 ± 5.45

**

M A P (m m H g)

87.23 ± 7 .7 6

83.43 ± 7 .0 1

P u lse pressure (m m H g)

34.35 ± 9 .2 5

32.31 ± 9 .3 2

A lbum in in urine (m g/L ) (L og)

1.10 ± 0.05

0.95 ± 0 .0 5

p value

**
**

*

**

**

*

F = fastin g, M A P = m ain arterial pressure, * = p < 0 .0 5 , ** = p < 0 .0 1 , blank space =

N o significant.
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Figure 4-20 M eans comparison for insulin / glucose ratio between G D M and control
groups (the difference between means is significant, p = 0.0020)

Figure 4-21 M eans comparison fo r plasm a SHBG level between G D M and control
subjects (there is a significant difference between means, p = 0.0239)
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Figure 4-22 M eans comparison for Testosterone / SHBG ratio between G D M and
control groups (the difference between means is significant, p = 0.0021)
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Figure 4-23 M eans comparison o f systolic blood pressure in GDM subjects and controls
(there is a significant difference between means, p = 0.0225)
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Figure 4-24 M eans comparison o f diastolic blood pressure in G D M subjects and
controls (there is a significant difference between means, p = 0.0026)

Figure 4-25 M eans comparison o f mean arterial pressure (MAP) in G D M subjects and
controls (there is a significant difference between m eansp = 0.0045)
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Figure 4-26 M eans comparison for microalbuminuria between GD M and control
subjects (there is a significant difference between means, p = 0.0171)

T able 4 -6 sh o w s the m ean v a lu es o f m easured dietary factors in this study.
P oly-un satu rated fat and vitam in E intakes w ere sign ificantly greater in G D M subjects
diet than in controls (F igures 4 -2 7 , 4-2 8 ).
Other dietary variables w ere not sig n ifica n tly different b etw een G D M and controls.
T he m ean o f alcohol con su m p tio n w as not statistically different b etw een the G D M
group and controls (T ab le 4-6 ).

4.1.3 C ateg orical D ata of the Study
T here w as n o significant difference in u se o f an oral contraceptive b etw een the G D M
and control groups (T ab le 4 -7 ).
Sm oking status w a s not sign ificantly different b etw een G D M
(T ab le 4 -7 ).

and control subjects
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There is no statistically significant difference between different measures o f exercise
(frequency, duration, and intensity) between the GDM and control groups (Table 4-7).

Table 4-6 Dietary data o f the study
Variables

GDM

Controls

Total Energy Intake (KJ)

9568 ± 2 6 2 2

9603 ± 3273

Total D ietary Fat (g)

89 ± 2 4

88 ± 3 5

% Energy Intake (Total fat)

3 5.4 ± 4 .3

33.8 ± 5.5

Saturated Fat (g)

35.3 ± 11

3 8.4 ± 19

% Energy (Saturated fat)

14 ± 2 . 6

14.3 ± 3 . 2

Unsaturated Fat (g)

47 ± 1 4

4 4 ± 17

% Energy (Unsaturated fat)

18.5 ± 3

17 ± 3

Polyunsaturated Fat (g)

16.3 ± 8

14 ± 6

% Energy (Polyunsaturated fat)

6.4 ± 2 .5

5.5 ± 2 . 0

M onounsaturated Fat (g)

30.2 ± 8.6

30.0 ± 13

% Energy (M onounsaturate fat)

12 ± 1.5

12 ± 2 . 0

Protein (g)

98 ± 3 1

101 98 ± 40

% Energy (Protein)

97 .6 ± 2 . 9

100.9 ± 4 .0

Total Carbohydrate (g)

266.3 ± 74

2 7 5 .2 ± 9 7

% Energy (total carbohydrate)

4 4 ,7 ± 5.6

4 5 .4 ± 5.5

C om plex Carbohydrate (g)

130 ± 34

122 ± 3 8

% E nergy (C om p, carbohydrate)

22.5 ± 4

2 1 .6 ± 5

Sugars (g)

130 ± 4 7

138 ± 47

% Energy (Sugars)

22.5 ± 5

2 1.6 ±4

Fibre (g)

25 ± 7

25 ± 9

W ater (g)

2 4 8 6 ± 690

2306 ± 7 5 5

Retinol (m eg)

659 ± 5 2 2

555 ± 4 2 7

p-carotene (m eg)

3144 ± 1628

3443 ± 1772

Vitamin D (m eg)

2.63 ± 1.3

2.45 ±1.3

Vitamin E (m g)

10.6 ± 4 .3 8

9.0 + 4 .1 9

Vitamin C (m g)

174 ± 7 8

172 ± 80

Thiam ine (m g)

1.45 ± 0 . 5

1.37 ± 0.5

R iboflavin (m g)

2.35 ± 0 . 7

2 .3 4 + 0.8

* = p < 0.05, blank space = No significant.

p value

*

*
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T ab le 4 -6 (con tin u ed )

Variables

GDM

Controls

V itam in B -6 (m g)

1.88 ± 0 . 6

1.84 ± 0 . 7

N ico tin ic A cid (m g)

2 1 .9 ± 6.6

21.11 ± 6 .1

V itam in B -1 2 (m g)

4 .4 ± 2 .1

4 .3 7 ± 2 . 2

F o lic A cid (m eg)

253 ± 8 0

2 5 2 ± 10

B iotin (m eg)

2 2 .5 5 ± 8

2 3 .1 0 ± 10

Pantothenic A cid (m g)

6 .6 ± 1.7

5.8 ± 2 . 3

Sodium (m g)

2865 ± 7 1 3

2 6 5 7 ± 790

Chloride (m g)

4793 ± 1340

4641 ± 1735

P otassiu m (m g)

3582 ± 9 9 6

3 9 0 6 ± 110

M agnesium (m g)

331 ± 8 8

330 ± 9 5

Calcium (m g)

1089 ± 3 7 6

1064 ± 4 0 4

P h osp horus (m g )

1582 ± 5 2 1

1560 ± 6 0 9

Iron (m g)

14 ± 4

14 ± 5

Z inc (m g)

13.4 ± 4.3

13.8 ± 6 .1

C opper (m g )

1.9 ± 0.6

2.0 ± 0 . 7

Sulphur (m g)

785 ± 2 8 7

826 ± 423

A lcoh ol (g)

2 .0 6 ± 3 . 6

2 .6 4 ± 3 .5

p value

D ata is presented as m ean ± standard deviation. There is no sign ificant d ifference
b etw een tw o groups in the ab ove dietary variables.
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Figure 4-27 M eans comparison for dietary polyunsaturated fat between GDM and
controls (there is a significant difference between two groups, p - 0.0433)

Figure 4-28 M ean comparison for dietary vitamin E between GDM and confrols ((ther
is a significant difference between two groups, p = 0.0386)
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Table 4-7 Summarized categorical data o f the study
Variable

Category

GDMs

Controls

Oral con tracep tiv e

1 = Current use

28 (22% )

2 0 (1 5 % )

2 = Former or Never use

37 (28% )

45 (35% )

0 = Non smoker

38 (29% )

3 6 (28% )

1 - Smoker

1 0 (8 % )

1 4 (1 1 % )

2 = Ex-smoker

1 7 (1 3 % )

15 (12% )

0 = Not at all

1 8 (1 4 % )

1 6 (1 2 % )

1 = Less than once a week
2 = Once or twice a week

1 7 (1 3 % )

11 (9% )

1 4 (1 1 % )

1 7 (1 3 % )

3 = Three times a week

1 6 (1 2 % )

20(16% )

0 = Not at all

1 8 (1 4 % )

1 6 (1 2 % )

1 = Less than 20 minutes

1 6 (1 2 % )

1 2 (9 % )

2 = 20-30 minutes

1 9 (1 5 % )

1 4 (1 1 % )

3 = More than 30 minutes

12 (9% )

2 2 (1 7 % )

0 = No exercise
1 = None of exercise session

18 (14% )

1 6 (1 2 % )

6 (5% )

4(4% )

2 = Some of exercise session
3 = Most or all of exercise
session

30 (23% )

33 (26% )

11 (11% )

1 0 (8 % )

A

4 4 (72% )

37 (62% )

B

1 7 (2 8 % )

23 (38% )

Sm oking

Freq o f E xercise

D ura o f E xercise

Inten o f E xercise

L D L P h en o ty p e

p value

Freq — freq u en cy, D ura = duration, Inten — in ten sity. There is no significant difference
b etw een the G D M and control groups in the ab ove variables.

4.1.4 Cross-correlation Between Different Variables
T ab le 4 -8 sh o w s correlation co efficien ts b etw een different variables in the G D M group
in this study. T he underlined v a lu es h ave sign ifican t correlation (p < 0.0 5 ).

Age sh o w ed on ly a n egative and sign ificant correlation w ith concentration o f album in in
u rin e in th e G D M group.
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Total ch olestero l concentration w a s p o sitiv e ly and sign ificantly correlated w ith plasm a
TG , a p o A -I, ap oB , L D L -C , V L D L -T G concen trations, and CETP activity in plasma.
Plasm a ch olesterol w a s a lso p o sitiv e ly and sign ificantly correlated w ith factor V ile,
d iastolic b lo o d pressure, and m arkers o f o b esity (B M I, b od y fat %), but the correlation
b etw een p lasm a ch olesterol concentration and W H R did not reach significance level.
Total ch olesterol level w a s also sign ificantly and p o sitiv e ly
pregnancy B M I.

correlated with

pre

P lasm a cholesterol concentration w a s not sign ificantly related to

plasm a insulin lev el, fasting blood g lu co se, H b A lc , exercise, sm oking, cholesterol intake
or total fat intake (T ab le 4 -8 ).

F asting plasm a insulin, apo B concentrations, factor V ile , B M I, b od y fat %, and CETP
activity in p lasm a w ere p o sitiv ely and sign ifican tly related to plasm a T G concentration.
Plasm a T G level w a s n egatively and sign ificantly correlated w ith H D L -C and LDL1
particle siz e (T ab le 4 -8 ).
Plasm a apo A -I concentration w as sign ificantly related to plasm a H D L -C , N E F A ,
S H B G con centrations and alcohol con su m p tion. Plasm a apoB level w as p o sitiv ely and
sign ificantly related to L D L -C , ID L -C , and V L D L -T G concentrations
activity in plasm a as o n e m igh t exp ected and n egatively to H D L -C .

and CETP

Plasm a apoB level

also w as p o sitiv e ly correlated w ith fasting insulin level, factor VII, B M I, and body fat
% (T ab le 4-8 ).
Plasm a N E F A concentration w a s n egatively and sign ificantly correlated w ith blood
pressure, alco h o l intake, and am ount o f album in in urine. Plasm a N E F A concentration
w a s also n eg a tiv ely correlated w ith C ETP activity in plasm a (T able 4-8 ).
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H D L -C w as n eg a tiv ely and significantly correlated w ith plasm a TG, apoB , V L D L -T G ,
ID L -C concentration, and C ETP activity in plasm a.

There is a p o sitiv e and significant

association b etw een H D L -C lev el and alcohol consum ption. H D L 3c w as p o sitiv ely and
sign ificantly correlated w ith H b A lc (T able 4-8).

D ata sh ow ed a relationship b etw een L D L -C concentration and V L D L -T G level and
CETP activity in plasm a, as one m ight expect. L D L -C also is correlated w ith fasting
plasm a insulin lev el, B M I, and body fat %. There are several dietary factors w hich are
negatively related to L D L -C .

A negative linear relationship w as b etw een LD L-I

(particle size) and a set o f variables including plasm a TG and apoB , V L D L -T G , IDL,
in sulin concentrations, B M I, and body fat %, h ow ever L D L -I had a p o sitiv e correlation
w ith H D L -C (T ab les 4-8).

Statistical a n a ly sis sh o w ed that V L D L -T G w as p o sitiv ely

correlated w ith

CETP

activity in plasm a, fasting plasm a insulin concentration, B M I, and body fat %, w hile
there w as a n egative correlation betw een V L D L -T G and LDL1 particle size (Table 4-8).
ID L -C has p o sitiv e correlation w ith CETP activity in plasm a, B M I, and body fat.
There w as a p o sitiv e correlation b etw een ID L-C level and fasting plasm a insulin level,
but it w as not sign ifican t (T able 4-8).

Plasm a

Lp

(a)

concentration

w as

negatively

and

significantly

correlated

w ith

concentration o f album in in urine (T able 4-8).

Plasm a C E T P .A % w as related to total cholesterol, TG, apoA -I, apoB , V L D L -T G ,
ID L -C , L D L -C and N E F A concentrations.

C ETP activity in plasm a w a s correlated

p o sitiv ely and sign ifican tly w ith fasting insulin level, B M I, body fat.

The relationship
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b etw een C E T P activ ity in p lasm a and a lco h o l intake w a s negative and significant (T able
4 -8 ).

-

T here is a p o s itiv e and sign ificant a sso c ia tio n b etw een fasting b lood g lu co se level and
factor Vile.

F a stin g insulin concentration w a s p o s itiv e ly and sign ificantly w ith total

ch o lestero l, T G , ap oB , L D L -C , V L D L -T G , testo ste ro n e con cen trations, CETP activity
in p lasm a, factor V ile , b lood p ressure, m icroalbum inuria, and ob esity .

There is a

n egative and sig n ifica n t association b etw een plasm a insulin level and LD L1 particle size
(T able 4 -8 ).

_

Plasm a fibrinogen level w a s p o s itiv e ly

and

sign ificantly

w ith

o b esity ,

d iastolic b lood pressure, and n eg a tiv ely and sign ificantly w ith fiber intake.

Plasm a

fibrinogen level a lso w as correlated p o sitiv e ly w ith ID L-C .
significant correlation b etw een factor V ile and B M I.
sign ifican tly

correlated

w ith

p lasm a

ch olesterol,

a ssociated

T here is a p o sitiv e and

Factor V ile w as p o sitiv ely and
TG,

ap oB ,

glucose,

insulin

con cen trations. V on w illebrand factor w a s p o sitiv e ly and sign ificantly associated w ith
total fat in tak e (T ab le 4 -8 ).

S H B G level in serum w as n eg a tiv ely and sign ificantly correlated w ith fasting ap oA -I,
in su lin , testo ste ro n e con cen trations and o b esity .

Serum testo stero n e concentration w as

p o sitiv e ly and sig n ifica n tly a sso cia ted w ith fa stin g insulin lev el, and ob esity (T able 4-8).

B lo o d p ressu re w a s p o sitiv e ly and significantly correlated with lip id s and lipop rotein

(total

c h o le ster o l, T G , N E F A , and L D L -C le v e ls), insulin concentrations, and B M I

(T able 4 - 8).
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M arkers o f o b e sity (B M I, W H R , and b o d y fat %) w ere sign ifican tly associated w ith
p lasm a lip id s and lip o p ro te in s (p lasm a ch o lestero l, TG , ap oB , V L D L -T G , ID L -C , and
L D L -C le v e ls), in su lin , fibrinogen, factor V ile , and testo stero n e con centrations, blood
p ressure, and C E T P a ctiv ity in plasm a.

O b esity a lso w a s n egatively and significantly

correlated w ith p lasm a S H B G , L D L particle s iz e (T ab le 4-8 ).

T he con cen tration o f album in in urine w a s sign ificantly and p o sitiv e ly correlated w ith
p lasm a N E F A and in su lin con cen trations, h ow ever, T he concentration o f album in in
urine w a s sig n ifica n tly and n eg a tiv ely correlated w ith age (T able 4 -8 ).

T here is o n ly a sign ificant and p o sitiv e correlation b etw een baby w eig h t and p re
pregn an cy B M I (T a b le 4 -8 ).

A lco h o l co n su m p tio n w a s p o sitiv e ly and sign ificantly a ssociated w ith p lasm a ap oA -I,
N E F A , H D L -C con cen tration. T he correlation b etw een alcoh ol con su m p tion and C E T P
activity in plasm a w as n eg a tiv e and sign ifican t (T able 4-8).

T he am ou n t o f fibre in d iet w a s n egatively and sign ificantly correlated w ith both
sy sto lic and d ia sto lic b lo o d pressure, plasm a fib rinogen concentration, and B M I.

D ietary fib re intake w a s a lso correlated w ith plasm a total cholesterol, apo B , and L D L C concen trations, but the correlation did not reach the sig n ifica n ce lev el (T able 4-8).

D ietary fat intake w a s not correlated w ith any o f biochem ical tests

ex cep t v W F .

D ietary fat intake and all other dietary factors w ere correlated w ith W H R , but not other
variables (T ab le 4-8 ).
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Table 4-8 Cross-correlation beh \ een different variables in this study

.---- ;----C
o
r
r
e
l
ations
__________________ /

r

V a r ia b le
Age
TC
TG
A p o A -I
A poB
NEFA
HDL-C
LDL-C
V LD L-TG
ID L -C
Lp(a)
CETP
H D L3b
HDL3c
H D L 2 /H D L 3
LDLI
FBG
In s u lin
Hb A1 c
F ib
F a c V II
vW F
SHBG
T e s to s
SBP
DBP
PB Ml
BMI
WHR
B . Fat %
A lb u
B aby W (q)
A lc o h o l
F ib e r
Na
E n e r . ln
F a t .I n
C h o i.In
S Fat
U SFat
C a r b .In
P r o t e in

Age

TC

0 .0592
0.1075
0.0758
0.1428
0.1038
0.1541
0.0582
0.1213
0.0700
0.1022
0.0407
0.0555
0.0402
0.0309
0.0182
0.0307
0.1315
0.0089
0.0268
0.1259
0.1119
-0.0116
0.0956
0.1157
0.1448
0.1082
0.0895
0.1389
0.0787
-0.2380
0.0030
0.0607
0.1425
0.0986
0.0886
0.1013
0.0330
0.0574
0.1584
0.0271
0.0822

0.3388
0.4416
0.8571
0.0367
0.0597
0.9983
0.3242
0.1821
0.0781
0.3997
0.0197
-0 .0 8 7 6
-0 .0 4 3 0
-0 .15 8 8
0.0702
0.2247
0.0393
0.1183
0.2230
-0.0691
-0.0231
0.0816
0.2218
0.2970
0.2823
0.3723
0.0933
0.3479
0 .1 0 6 7
0.1338
0.0405
-0 .1 6 5 5
0 .0 8 8 9
0.1581
0 .1 1 6 0
0 .1 3 7 2
-0.1121
0 .0 3 8 2
0 .1 6 5 4
0 .2 2 0 4

TG

-0 .0 2 9 4
0.4769
0.1142
-0 .29 9 6
0.3015
0.7365
0.6313
0.1176
0.4108
-0 .01 4 9
-0 .00 7 8
-0 .07 5 0
-0.2261
0.0702
0.4143
0.0517
0.2160
0.2346
0.1307
-0 .07 4 9
0.0765
0.2078
0.2106
0.2418
0.3808
0.1901
0.3120
0.1432
0.0492
0.0868
-0 .0 4 2 4
0.0267
-0.0743
0 .0 4 0 4
0.0 3 28
0.0 4 28
0.0 7 25
0.0 9 35
0.0 4 53

A p o A -i

A poB

N E FA

0.2231
0.2335
0.6166
0.4398
-0.0204
0.0073
0.0120
-0.2282
0.2140
0.0207
0.1864
-0.0410
0.0550
-0.0936
-0.0798
0.0492
0.0641
-0.0357
0.3637
-0.1383
0.1253
0.1098
0.0340
-0.0164
0.0190
0.0738
0.0417
0.0396
0.3363
-0.0664
0.0042
0.0637
0.0142
-0.0647
-0.0590
0.0201
0.0950
0.1500

0.0278
-0.2512
0.8499
0.5042
0.3395
0.0564
0.5930
-0.0251
-0.1331
-0.1365
-0.2109
-0.0033
0.2798
0.0457
0.1647
0.2692
-0.0605
0.0398
0.0004
0.2653
0.3470
0.3235
0.4178
0.0260
0.3331
-0.0243
0.0794
0.0103
-0.1759
0.1363
0.1964
0.1968
0.1818
0.1491
0.1279
0.1671
-0.2593

0.1292
0.0392
-0.0860
-0.0700
-0.1396
-0.2372
0.0023
-0.0271
0.0554
-0.1316
0.1705
0.1070
-0.1080
0.0677
-0.1794
0.1274
0.0355
0.0373
0.3467
0.3325 .
0.0383
0.0094
0.0588
0.1052
0.4049
0.0959
0.2801
-0.0148
0.1163
0.0183
0.0319
0.0184
0.0251
0.0269
0.0493
-0.0487

HDL-C

0.0635
-0.3485
-0.2762
0.1206
-0.4782
0.2175
0.1729
0.2995
0.2479
0.1975
-0.1288
0.063“
0.056“
0.0457
-0.0345
0 .1 6 K
-0.0327
•0.026C
-0.004C
-0.1237
-0.1 982
-0.0043
-0.148C
-0.0792
-0.0147
0.2556
0.0213
0.0180
0.0050
0.0454
0.0002,
-0.0068
0.0660
0.0885
0.0129
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Table 4-8 (Continued)

V a r ia b le
Age
TC
TG
A p o A -I
A poB
NEFA
HDL-C
LD L-C
V LD L-TG
ID L -C
Lp(a)
CETP
HDL3b
HDL3c
H D L 2 /H D L 3
LDLI
FBG
In s u lin
Hb A1 c
F ib
F a c V II
vW F
SHBG
T e s to s
SBP
DBP
PB MI
BMi
WHR
B . Fat %
A lb u
B aby W (q)
A lc o h o l
F ib e r
Na
E n e r .In
F a t.I n
C h o i.In
S Fat
U SFat
Ca r b . ln
P r o t e in

L D L -C

.0.2923
0.1304
0.0739
0.3872
0.0208
-0.0868
-0.0455
-0.1549
0.0670
0.2165
0.0387
0.1027
0.2096
-0.0762
-0.0267
0.0821
0.2256
0.3010
0.2804
0.3655
0.0883
0.3376
-0.1 110
0.1375
0.0362
-0.1 690
0.0910
0.1528
0.1135
0.1351
0.1111
0.0326
-0.1570
-0.2188

V L D L -T G

0.6469
0.0602
0.4892
0.0215
-0 .01 2 7
-0.1674
-0.2290
0.0353
0.3331
0.0476
0.0785
0.2301
-0.0779
-0 .09 7 2
0.0813
0.1483
0.1963
0.3142
0.4064
0.0775
0.3246
0.0476
0.1200
-0.0493
-0.0529
0.0199
0.0446
0.1290
0.0104
0.0582
0.0874
0.0090
0.0163

ID L - C

Lp(a)

0.0528
0.3800
-0.0646
-0.1252
-0.0577
-0.2151
-0.0085
0.1945
-0.0358
0.2260
0.1122
0.0835
0.0715
-0.0034
-0.0163
0.0019
0.1571
0.2265
0.0878
0.2472
0.1107
-0.0520
0.0115
-0.0402
0.0343
•0.0905
0.0578
0.0813
0.0309
0.0897
0.1049
0.0615

0.0085
0.1025
0.0113
0.0643
0.0713
-0.0689
0.1154
-0.0500
0.1236
0.1384
0.0592
-0.0128
0.0289
0.1655
-0.0004
0.0388
0.0806
0.1311
0.0155
-0.2740
0.0694
0.1998
0.0421
0.1005
0.1102
0.1155
0.0450
0.0996
0.1152
0.1296
0.0514

C ETP

-0.0809
-0.1161
-0.1906
-0.2098
-0.0929
0.2679
0.0810
0.0228
0.1598
-0.0769
-0.0939
0.0780
0.0506
0.0925
0.2322
0.2994
0.1410
0.2747
-0.1821
0.0770
-0.2699
-0.0492
-0.0256
0.0114
0.0324
0.0012
0.0335
-0.0103
0.0356
0.0044

Fib = fibrinogen, Albu = albumin, W = weight, S = saturated, US - un-saturated, Carb
carbohydrate.
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Table 4-8 (Continued)

V a r ia b le
Age
TC
TG
A p o A -l
A poB
NEFA
H D L-C
LD L -C
V LD L-T G
ID L - C
L p (a )
C E TP

H D L3b

HDL3c

0.4685
-0 .20 5 4
-0.0599
-0.0746
-0.0043
-0 .05 2 5
-0 .04 4 0
-0.0744
-0 .15 1 9
0.1007
-0 .15 2 3
-0 .03 6 7
-0 .03 0 4
-0 .03 5 0
-0.0098
-0 .08 0 7
-0 .0 4 2 7
-0 .18 1 2
-0 .07 2 4
0.1695
0 .1412
-0 .04 3 0
-0 .08 5 4
-0 .06 2 9
-0 .12 0 9
-0.0971
-0 .0 4 6 2
-0 .09 4 6
-0 .0 7 0 7

0.0323
0.1678
0.0301
-0.1601
0.2698
0 .0 5 7 7
0.0137
0 .1 8 2 0
0.0113
-0 .1 5 2 3
-0 .1 3 3 0
-0 .0 2 5 8
-0 .1 7 2 8
-0.1681
-0 .0 8 4 2
-0 .1 9 4 8
-0 .0 3 8 8
-0 .1 2 4 9
0.0429
0.0993
0.0094
0.0797
0.0720
-0 .0 9 6 8
0.0822
0.0401
0.0989
0.0258

H D L 2 /H D L 3

LDLi

FBG

HDL3b
HDL3c
H D L 2 /H D L 3
LDLI
FBG
In s u lin
HbA1 c
F ib
F a c V II
vW F
SHBG
T e s to s
SBP
DBP
PB M l
BMI
WHR
B .Fat %
A lb u
B a b y W (g)
A lc o h o l
F ib e r
Na
E n e r .In
F a t.In
C h o i.In
S Fat
USFat
C a r b . In
P r o t e in

0.1329
0.0105
-0 .12 9 5
0.0736
0.0360
-0 .22 1 6
-0 .04 9 9
0.0616
. 0.1506
-0 .01 6 6
0.0265
-0 .16 3 4
-0 .17 4 7
-0.0531
-0 .18 1 7
0.0053
0.0514
0.1294
0 .0 4 37
0 .0286
0.0735
0.1168
0.1386
0.1254
0.0243
0.0422
0.0503

0.1813
-0.2641
0.0534
-0.0046
0.0556
0.0006
0.1879
-0 .07 3 5
-0.2799
-0.1735
-0.2525
-0.2466
-0.11 60
-0.2571
-0.1381
-0.1403
0.0505
0.1422
0.0176
0.1130
0.0971
0.0387
0.1268
0.0986
0.0636
0.1162

•

0.1668
0.1612
0.0984
0.2610
0.1389
-0.1457
0.1605
0.0348
0.1910
0.0188
0.0090
0.0209
0.0655
0.1199
0.1663
0.1169
-0.1367
0.0177
0.0486
0.0303
0.0829
0.0289
0.0295
0.0949
0.0426
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Table 4-8 (Continued)

V a r ia b le
Age
TC
TG
A p o A -l
A poB
NEFA
H D L -C
L D L -C
V L D L -T G
ID L -C
L p (a )
CETP

In s u lin

H b A1 c

F ib

F a c V Il

vW F

0.1154
0.0785
0.2208
-0 .04 2 7
0.0403
0.0822
0.0014
0.0972
0.1051
0.0858
0.1398
0.0338
0.0844
0.0921
-0 .0 8 7 5
-0 .01 5 2
-0.0041
-0 .00 6 6
-0 .14 1 3
-0.0281
0.0350
0.0405
0.0404

0.1857
0.1915
-0.0393
0.0709
0.1921
0.2527
0.1379
0.2428
0.1555
0.2575
0.1047
0.0936
0.1254
-0 .25 0 2
0.0008
0.1250
0.1118
0.1 0 72
•0.0439
0.0 2 97
0.1721
0.1 6 02

0.0448
-0 .14 5 2
0.0206
0.0359
0.0053
0.1345
0.2419
0.0242
0.1743
0.1 8 82
0.0907
0.1126
-0 .07 2 3
0.0 8 17
0.1148
0.0779
0.0223
0.0439
0.0556
0.1908
0 .1 2 04

-0.0448
0.0992
0.0565
0.0204
0.0180
0.0675
0.0519
0.0631
0.0615
0.0785
0.0422
0.0889
0.1527
0.1756
0.2270
0.1845
0.2144
0.1854
0.0860
0.1942

HDL3b
H DL3c
H D L 2 /H D L 3
LD LI
FBG
In s u lin
H b A1 c
F ib
F a c V II
vW F
SHBG
T e s to s
SBP
DB P
P B Ml
BMI
WHR
B .Fat %
Al b u
Baby W
A lc o h o l
F ib e r
Na
En e r.I n
F a t.I n
C h o l. I n
S Fat
USFat
C a rb .In
P r o te in

(g)

0.0424
0.0214
0.2211
0.0116
-0.3736
0.3107
0.3205
0.2177
0.5511
0.5713
0.2175
0.4782
0:2601
0.0137
0.0601
-0.1736
0.0337
0.0583
0.0067
0.0944
0.0115
-0.0501
0.0896
0.0319
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Table 4-8 (Continued)

V a r ia b le
Age
TC
TG
A p o A -I
ApoB
NEFA
H D L -C
L D L -C
V L D L -T G
ID L -C
L p (a )
CETP
H D L3b
HDL3c
H D L 2 /H D L 3
LD LI
FBG
in s u lin
H b A1 c
F ib
F a c V II
vW F
SHBG
T e s to s
SBP
DBP
PBM I
BMI
W HR
B .Fat%
A lb u
Baby W
A lc o h o l
F ib e r
Na
E n e r . ln
F a t.I n
C h o i. I n
SFat
USFat
Ca rb .In
P r o te in

(g)

SH BG

-0.3881
-0.1327
-0.1030
-0.3226
-0.3617
'-0 .1 9 3 9
-0.3073
-0.0010
-0 .05 1 2
0.1960
0.0679
-0 .05 4 2
-0 .07 5 2
-0.0639
-0.1449
-0.1075
-0 .05 8 9
-0 .05 7 8
-0 .13 6 7

T e s to s

SBP

DBP

PB Ml

0.1122
0.1127
0.3150
0.3275
0.3717
0.2340
0.0265
0.0299
0.0068
-0 .11 5 3
0.0313
0.0388
0.0076
0.0822
0.0270
0.0007
0.0604
0.0321

0.7257
0.3548
0.3997
0 .0 0 57
0.3092
0.1759
0.1292
0.1413
-0 .28 3 6
-0.1330
0 .1 2 00
0.1 6 43
0.0294
0.1311
0 .1 0 77
0.0611
0.1 3 59

0.3435
0.3833
0.1165
0.2411
0.1022
0.0865
0.1836
-0.3087
0.1096
0.0963
0.1064
0.0149
0.1151
0.0287
0.0704
0.1110

0.9049
0.2675
0,7515
0.1423
0,2344
0.0656
-0 .21 8 7
0.0 6 45
0.0469
0.0 9 77
0.0019
0.0599
0.1041
0.0055
0 .0 7 07
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Table 4-8 (Continued)

V a r ia b le
Age
TC
TG
A p o A -1
A po B
N E FA
HDL-C
LD L-C
V LD L-T G
ID L - C
L p(a)
CETP
H DL3b
H DL3c
H D L 2 /H D L 3
LDLI
FBG
In s u lin
Hb A1 c
F ib
F a c V ll
vW F
SHBG
T e s to s
SB P
DBP
P B Ml
BMI
WHR
B .Fat %
A lb u
B ab y W (g)
A lc o h o l
F ib e r
Na
E n e r .ln
F a t .I n
C h o i.In
S Fat
U SFat
C a r b . ln
P r o t e in

BMI

W HR

B .F a t%

A lb u

0.3334
0.7990
0.0540
0.2165
0.0358
-0 .25 6 5
0.0898
0.0798
0.0948
0.0163
0.0608
0.1054
0.0568
0.0799

0.2763
0.0188
0.0940
0.1088
0.0221
0.2188
0.2942
0.2963
0.2138
0.3244
0.2380
0.2595
0.2453

0.0492
0.2004
0.0719
0.1392
0.0882
0.0000
-0.0018
0.0971
0.0119
0.0293
0.0025
0.0433

0.0007
0.0177
0.0583
0.1417
0.1011
0.1054
0.1114
0.0596
0.0555
0.1295
0.0789

B aby W (g)

0.1073
0.0074
0.0274
0.0384
0.0976
0.0836
-0.0654
•0.0403
0.1387
0.0163
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Table 4-8 (Continued)

V a r ia b le
Age
TC
TG
A p o A -I
ApoB
NEFA
H D L-C
L D L -C
V LD L-T G
ID L - C
L p (a )
C E TP
H D L3b
HDL3c
H D L 2 /H D L 3
LDLI
FBG
In s u lin
Hb A1 c
F ib
F a c V II
vW F
SHBG
T e s to s
SBP
DBP
PBM I
BMl
WHR
B .Fa t %
A Ib u
B a b y W (g)
A lc o h o l
F ib e r
Na
E n e r .In
F a t.In
C h o i.In
S Fat
USFat
C a r b . ln
P r o t e in

A lc o h o l

-0 .05 0 3
-0 .04 9 9
-0.0930
-0 .07 7 9
-0 .16 1 5
-0 .15 5 0
-0.0295
-0 .10 4 3
-0 .19 6 3

F ib e r

0.5736
0.6341
0.4900
0.2802
0.4293
0.4976
0.6344
0.6137

Na

0.8775
0.8126
0.4913
0.7788
0.8173
0.7737
0.7706

E n e r . ln

0.8949
0.6180
0.8934
0.8674
0.9235
0.8706

F a t .I n

0.5858
0,9030
0,8499
0.7214
0,7889
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Table 4-8 (Continued)

V a r ia b le
Age
TC
TG
.
A p o A -I
ApoB
NEFA
H D L -C
L D L -C
V L D L -T G

C h o 4 In

SFat

USFat

0 .7 8 77
0 .7 2 7 3
0 .7 9 0 7

0 .7 0 72
0.7 1 82

C a rb .In

ID L -C
L p (a )
CETP
HDL3b
HDL3c
H D L 2 /H D L 3
LDLI
FBG
I n s u lin
H b A1 c
F ib
F a c V II
vW F
SHBG
T e s to s
SB P
DBP
PB MI
BMI
WHR
B .Fat%
A lb u
Baby W
A lc o h o l
F ib e r
Na
E n e r.In
F a t.I n
C h o i. I n
S Fat
USFat
C a rb .In
P r o te in

(g )

0.6621
0.4739
0.4835
0.7487

0 .7 2 06

Protein
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Most of the correlations between plasma lipoprotein and lipoprotein constituents could
be predicted with a knowledge of the physiology of plasma lipid and lipoprotein
metabolism.
Note: Other correlations indicated that relationships could be further explored by two
techniques, multiple regression analysis of a group o f apparently related variables, and
subgroup analysis (eg of a subgroup with particularly well-developed insulin resistance
syndrome).

4.1.5 M u ltiple R egression A nalysis
Multiple regression was used to investigate relationships between BMI, fasting insulin,
total cholesterol and triglyceride, NEFA, and SHBG concentrations, CETP activity in
plasma, systolic blood pressure, and microalbuminuria and their possible determinants.

Age, Groups (1= GDM

group and 0 = control group), fasting plasma insulin

concentration, BMI, family history of diabetes mellitus, use of a contraceptive pill,
alcohol, fat, and protein intake, and exercise were chosen as independent variables in
different multiple regression model. The results are presented in Table 4-9.

The multiple regression model for BMI showed that group (as 1 - GDM subjects and 0
= controls) and fasting insulin concentrations are significant determinants of BMI in this
study (Table 4-9).
The multiple regression model for fasting insulin concentration indicated that BMI is the
most im portant determinant in the variance o f fasting insulin concentration in this

investigation (Table 4-9).
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Regression analysis showed that group (as 1 - GDM subjects and 0 = controls), BMI,
family history of diabetes, and exercise are the significant determinants for the total
cholesterol levels (Table 4-9).
T able 4 -9 R esu lts fr o m the m u ltip le r e c e s s i o n a n a ly ses

BMI

Insulin

TC

TG

NEFA

CETP

SHBG

SBP

Albu

N

130

130

130

130

130

130

130

130

130

Adj R2

0.28

0.24

0.17

0.24

0.16

0.12

0.35

0.18

0.12

Intercept

25.33

-2.65

3.57

0.063

0.59

2.299

4.22

85.56

1.53

Age

-0.10

-0.02

-0.003

0.01

-0.002

-0.0003

0.01

0.01

-0.02*

Groups [0-1]

-1.03*

-0.66

-0.23*

-0.03

-0.07*

-0.10

0.13*

0.48

0.05*

Insulin

0.48*

(-)

0.01

0.04*

0.01

0.03

-0.003

0.62*

0.03*

BMI

(-)

0.39*

0.05*

0.02

-0.004

0.01

-0.03*

0.73*

-0.01*

FH.DM [0-2]

0.08

0.55

0.14

0.02

-0.14

0.11

0.03

-0.36

-0.03

FH.DM [1-2]

-0.25

0.36

-0.22*

0.04

-0.0003

-0.07

-0.05

0.01

0.03

C.Pill [0-2]

-0.18

0.38

-0.12

0.14

-0.05

0.08

-0.23*

-3.41

-0.04

C.Pill [1-2]

-0.11

-0.19

0.15

-0.01

0.05

0.01

0.39*

2.34

0.09

Smoking [0-2]

-0.23

0.01

-0.01

0.013

0.02

0.08

-0.11

0.50

-0.03

Smoking [1-2]

-0.08

0.03

-0.06

0.05

0.05

-0.012

0.17*

0.05

0.10

Alcohol

0.32

0.03

0.28

0.15

0.20*

-0.25*

0.15

5.21*

0.02

Fat in

-0.01

-0.001

-0.002

0.0001

0.001

-0.0004

-0.001

-0.03

0.001

Fre.Exer [0-3]

0.67

0.72

0.31*

-0.06

-0.05

0.13

0.08

0.41

0.02

Fre.Exer [1-3]

0.29

0.32

0.16

0.10

0.004

-0.06

0.02

-2.22

0.02

Fre.Exer [2-3]

0.02

-0.77

0.01

-0.06

0.02

0.07

-0.10

3.23

-0.05

The regression coefficients and their significant level of the relevant variables in the
regression model are presented. N = number of observations, FH.DM = family history
of diabetes mellitus, C.Pill = contraceptive pill, in = intake, Fre = frequency, Exer =
exercise, Dur = duration, Int = intensity, (-) = not included in the model, albu =
Albuminuria. “Note: the explanation of [ ] is in Chapter Three”.

In the final regression analysis, fasting insulin concentration was shown significantly

associated with plasma TG concentration (Table 4-9).
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M ultiple regression analysis showed that group (as 1 = GDM subjects and 0 = controls)
and alcohol consumption are significant independent variables in the plasma NEFA
levels (Table 4-9).
CETP activity (%) in plasma was significantly associated with alcohol consumption in
the multiple regression analysis (Table 4-9).
The multiple regression model for serum SHBG concentration indicated that group (as
1= the GDM subjects and 0 = controls), BMI, use of an oral contraceptive, and smoking
are the significant determinants for serum SHBG model (Table 4-9).
Fasting insulin concentration, BMI, and alcohol consumption

were significantly

associated with systolic blood pressure in the multiple regression analysis (Table 4-9).
Regression analysis showed that age, group (as 1 = GDM subjects and 0 = controls),
fasting insulin concentration, and BMI are the most important determinants of the
amount of albumin in urine (Table 4-9).

4.2 Sub-population Analysis:

4.2.1 The Definition of Subgroups
The multiple regression models suggested that sub-populations with sub-clinical or
overt disease may exist.
The populations (both GDM and controls) were categorised according to three factors:
plasma NEFA concentration, family history of diabetes, and BMI. The frequencies are
presented in Table 4-10).
In addition, another subgroup was determined according to fasting insulin concentration
(hyperinsulinemic subgroup or subgroup C). Data suggested that a number of subjects
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in the GDM group might have the insulin resistance syndrome. The defining feature of
the insulin resistance syndrome was taken to be fasting hyperinsulinemia.

On initial

analysis of fasting plasma insulin concentrations, it was clear that there was a group of
GDM women who had a higher plasma insulin than the control group.

The control

group had a mean fasting plasma insulin 5.14 IU/L (range 1.1-9.8, 95% within range
1.36-9.54).

The GDM group with fasting plasma insulin < 10 IU/L were distinguished from those
with fasting insulin > 1 0 IU/L. There were 65 women in the control group, 52 in the
GDM group with fasting insulin <10 IU/L who were assessed not to have developed
insulin resistance and 13 (ie 20% of the GDM group) who were assessed as having
insulin resistance.
Table 4-10 Frequencies for different subgroups
Subgroups
h.NEFA , (+) FH , OW
h.NEFA , (+) FH
h.N E F A , OW
(+) FH , OW
h.NEFA
(+) FH
OW
None
h.NEFA = high plasma NEFA level, FH - family

GDM
14
15
3
8
6
7
7
5
history, OW

C ontrol
0
8
5
3
8
11
4
26
= overweight.

4.2.2 Subgroup (A) Results
Sub-group (A): Sub-population includes subjects who are overweight and have high
plasma NEFA concentrations and a positive family history of diabetes.
There were no differences in age between the subgroup (A) and residual GDM group

and controls (Table 4-11).
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The subgroup (A) had slightly higher plasma cholesterol and apoB than residual GD M
subjects, but significantly higher than controls (Table 4-11).

The subgroup (A) tended to have higher plasma TG,

VLDL-TG, and IDL-C

concentrations than the residual GDM or control groups. There was a tendency for the
subgroup (A) to have a slightly higher LDL-C than the residual GDM group, and a
significantly higher LDL-C than controls (Table 4-11).

All three subgroups were similar in the HDL-C concentrations. HDL particle sizes and
the HDL2 /HDL3 ratio were similar in the three groups (Table 4-11).

The subgroup (A) tended to have slightly smaller LDL-I then the residual GDM group
and significantly smaller than the control group (Table 4-11).

The subgroup (A) also tended to have slightly higher CETP activity in plasma then the
residual GDM group, but CETP activity in plasma was significantly higher in the
subgroup (A) than controls (Table 4-11).

Fasting blood glucose means were similar in the three groups. However, fasting insulin
levels were significantly higher in the subgroup (A) than other two groups (Table 4-11).

The mean systolic and diastolic blood pressures were slightly higher in subgroup (A)
compared with the residual GDM subjects, and significantly higher in subgroup (A)
than controls (Table 4-11).
The subgroup (A) showed a greater concentration of albumin in urine than both the
residual GDM group and controls. The subgroup (A) had slightly greater amount of
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albumin in their urine than the residual GDM group and significantly greater than the
control group (Table 4-11).

The subgroup (A) tended to be fatter before they became pregnant (as described by pre
pregnancy BMI) than both the residual GDM and control groups (table 4-11).

Table 4-1 1 C o m p a riso n o f su b g ro u p (A) Math the resid u a l G D M p o p u la tio n a n d co n trols

(Continuous Data)
V a ria b le

R.G D M
(n - 51)
31.4 ± 4 .7
4.9 ± 0.9

Pi

Age
TC

S ubgroup (A)
(n - 14)
32.1 ± 6.1
5.2 ± 1.0

TG (log)

1.06 ± 0.02

1.04 ± 0.02

**

ApoB

1.12 ± 0.2

1.03 ± 0.3

VLDL-TG (log)

6.3 ± 0.6

5.8 ± 0.7

IDL-C (log)

4.7 ± 0.5

4.2 ± 0.6

HDL-C (log)

1.05 ± 0.01

1.05 ± 0.01

1.06 ± 0.02

LDL-C

3.5 ± 1.0

3.3 ± 0.9

2.8 ± 0.7

HDL3b Size

7.92 ± 0.10

7.92 ± 0.11

7.97 ± 0.11

HDL3c Size

7.62 ± 0.16

7.59 ± 0.16

7.65 ± 0.13

‘ 0.85 ± 0.18

0.91 ± 0.19
30.88 ± 1.06

0.92 ± 0.21
31.39 ± 1.00

*
*

H D L2 /H D L 3

*
*

C o n tro ls
(n = 65)
31.4 ± 4.2
4.4 ± 0.8

P2

1.04 ± 0.02

**

*

*

0.88 ± 0.2

* *

5.6 ± 0.7

*

*

4.1 ± 0.6

*

*

*

*

LDL-I Size

30.34 ± 0.83

CETP.A (log)

3.0 ± 0.49

2.8 ± 0.60

2.6 ± 0.66

FBG (log)

1.54 ± 0.08

1.50 ± 0.10

1.50 ± 0.09

Insulin

10.9 ± 6.5

6.6 ± 4.5

SBP

114.5 ± 12.1

DBP

5.1 ± 2.0

**

109.6 ± 12.7

105.5 ± 11.7

**

76.9 ± 5.5

76.0 ± 6.0

73.2 ± 5.4

*

Microalb (log)

1.16 ± 0.33

1.09 ± 0.37

0.9 ± 0.38

P.BM I

26.8 ± 5.2

24.1 ± 4.5

Baby weight

3573 ± 547

3366 ± 569

3304 ± 5 1 3

Alcohol in (log)

0.34 ± 0.40

0.28 ± 0.36

0.40 ± 0.41

Sodium intake

7.95 ± 0.34

7.96 ± 0.26

7.87 ± 0.37

Fat intake

103.5 ± 57.5

93.14 ± 31.0

90.78 ± 28.4

**

*

22.3 ± 2.8

*

**

Data presented as mean ± standard deviation. R.GDM = the residual GDM group, P! =
p values o f comparison o f subgroup (A) Vs the residual GDM group, P2 = p values of
comparison o f subgroup Vs controls, in = intake, log = Natural logarithm (base e), * = p
< 0.05, ** = p < 0.01, and blank space in the P x and P2 columns = No significant
difference.
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T he b a b ies o f th e subgroup (A ) m others tended to be slightly heavier than the babies o f
the other tw o groups.

Fat, alcohol and sodium con su m p tion w ere sim ilar in three

grou p s.(T ab le 4 -1 1 ). There w ere no significant differences b etw een use o f an oral
con tracep tive, sm oking, and exercise b etw een the subgroup (A ) and other tw o groups
(T able 4 -1 2 ).

T able 4 -1 2 C o m p a riso n o f su b g ro u p (A) w ith r e s t o f the G D M p o p u la tio n a n d co n tro ls
(C a te g o ric a l D a ta )

V ariable

Subgroup

C.Pill

Current use
F or N use

(n = 14)
7 (50%)
7 (50%)

R .G DM
(n = 51)
22 (43%)
29 (57%)

Smoking

N on-sm oke
Smoker
E x-sm oke

9 (64%)
0 (0%)
5 (36%)

29 (57%)
10 (20%)
12 (24%)

36 (55%)
14 (22%)
15 (23%)

Fre.Exer

0
1
2
3

5
3
2
4

(36%)
(21%)
(14%)
(29%)

13
14
12
12

(26%)
(27%)
(24%)
(24%)

16
12
17
20

(25%)
(19%)
(26%)
(31%)

Dur.Exer

0.
1.
2.
3.

5
4
3
2

(36%)
(29%)
(21%)
(14%)

13
12
16
10

(26%)
(24%)
(31%)
(20%)

16
13
14
22

(25%)
(20%)
(22%)
(34%)

Int.E xer

0123-

5
0
7
2

(36%)
(0%)
(50%)
(14%)

13 (26%)
6 (12%)
23 (45%)
9 (18%)

(A )

Pj

C o n tr o ls
(n = 65)
21 (32%)
44 (68%)

P2

17 (26%)
5 (8%)
33 (51%)
10 (15%)

R .G D M = rest o f the G D M group, Pi - p v a lu es o f com parison o f subgroup (A ) versu s
rest o f G D M group, P 2 = p values o f com parison o f subgroup versu s controls, F =
form er, N = never, S m oke = sm oker, 0 = N o t at all, 1 = L ess than o n ce a w eek , 2 = O nce
or tw ic e a w eek , 3 = Three tim es a w eek , 0. = N o t at all, 1. = L ess than 20 m inutes, 2. =
2 0 -3 0 m in u tes, 3. = M ore than 30 m inutes, 0- = N o exercise, 1- = N o n e o f exercise
sessio n , 2 - = S o m e o f exercise sessio n , 3- = M o st or all o f exercise, and blank space in
the P i and P 2 colu m n s = N o sign ifican t difference.
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4.2.3 S u b g ro u p (B) Results
S u b -g ro u p (B): Sub-population in clu d es su bjects w h o have high plasm a N E F A
con cen trations and p o sitiv e fam ily history o f diabetes.
There w ere no sign ificant d ifference for a g e b etw een subgroup (B ) and other tw o groups
(the residual G D M and control grou p s) (T a b le 4 -1 3 ).

The subgroup (B ) had slightly lo w er p lasm a cholesterol than the residual G D M group,
but not sign ifican tly. Plasm a ch olesterol m eans w ere similar b etw een the subgroup (B )
and con trols (T able 4-13).

The

subgroup

(B ) had sign ificantly lo w er

concentration than the residual G D M

group.

plasm a TG ,

V L D L -T G ,

and

IDL-C

T h ose three variables w ere similar

b etw een the subgroup (B ) and controls (T ab le 4 -1 3 ).

There w a s a ten d en cy for the subgroup (B ) to have a sligh tly low er L D L-C than the
residual G D M group, and a similar m ean o f L D L -C concentration w ith controls (Table
4 -1 3 ).

A ll three subgroup w ere similar in the H D L -C concentrations.

H D L 3c particle siz e s

w ere sign ificantly smaller in the subgroup (B ) than the control group, but were not
sig n ifica n tly sm aller com pared w ith the residual G D M subjects (T able 4-13).

T he H D L 2 / H D L 3 ratio w ere sim ilar in the three groups. L D L -I particle size also w ere
sim ilar b etw een three groups (T able 4 -1 3 ).

T he subgroup (B ) also tended to h ave slig h tly lo w er CETP a ctivity in plasm a then the
residual G D M and control groups, but not sig n ifica n tly lo w er (T ab le 4-13).
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H o w ev er, fasting insulin

levels w ere sign ificantly low er in the subgroup (B ) than the residual G D M group, and
sligh tly lo w er than the control group (T able 4-1 3 ).

The m ean sy sto lic and d iastolic blood pressures w ere slightly higher in the subgroup (B )
com pared w ith the residual G D M , but the subgroup (B ) tended to have significantly
higher d ia sto lic b lo o d pressure than the control group (T able 4-1 3 ).

Subgroup (B ) tended to have sim ilar S H B G concentration with the control group and to
have sign ificantly higher SH B G concentration than the residual G D M group (Table 4 
13).

T estosteron e concentration w ere significantly low er in the subgroup (B ) than in the
residual G D M

group, but there is no significant difference betw een testo steron e

concentrations in the subgroup (B ) and controls (T able 4-13).

The subgroup (B ) sh ow ed significantly greater concentration o f albumin in urine than
the controls, but the difference b etw een m eans for concentration o f albumin in urine
b etw een the subgroup (B ) and the residual G D M w ere not sign ificant (T able 4-1 3 ).

The subgroup (B ) tended to be slim m er before they becam e pregnant (as described b y
pre-pregnancy B M I) than both the residual G D M and control groups.

The difference

b etw een m ean s o f the residual G D M group and subgroup (B ) w as significant (Table 4 
13).

The b ab ies o f the subgroup (B ) m others tended to be slightly lighter than the babies o f

the other two groups (Table 4-13).
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Fat, alco h o l and sodium con su m p tion w ere sim ilar in three groups.(T able 4-13).

T able 4 -1 3 C o m p a riso n o f s u b g ro u p (B) w ith the r e s id u a l G D M p o p u la tio n a n d r e sid u a l
c o n tr o ls ( C on tin u ou s D a ta )
V a r ia b le
Age

TC

S u bgroup
(n = 15)
29.7 ± 4.4

(B )

± 1.1

R.GDM

p,

(n = 50)
32.1 ± 5.0

R .C o n tr o ls
(n = 57)
31.5 ± 4.0

5.0 ± 0.9

4.4 ± 0.8
*

TG

0.84 ± 0.4

1.13 ± 0.5

ApoB

0.10 ± 0.3

1.1 ± 0.3

VLDL-TG (log)

5.47 ± 0.7

6.01 ± 0.6

IDL-C (log)

3.9 ± 0.6

4.4 ± 0.60

HDL-C (log)

1.06 ± 0.01

1.05 ± 0.01

1.06 ± 0.01

LDL-C

3.11 ± 1.12

3.38 ± 0.88

2.79 ± 1.12

HDL3b Size

7.92 ± 0.11

7.92 ± 0.11

7.97 ± 0.11

HDL3c Size

7.57 ± 0.14

7.60 ± 0.16

7.64 ± 0.13

HDL2 /

0.90 ± 0.15

0.89 ± 0.20

0.92 ± 0.21

LDL-1 Size

30.9 ± 0.95

30.7 ± 1.06

31.4 ± 1.00

CETP.A (log)

2.48 ± 0.73

2.94 ± 0.49

FBG (log)

1.50 ± 0.14

1.51 ± 0.07

Insulin

4.51 ± 2.39

8.45 ± 5.52

SBP

111.1 ± 10.9

110.5 ± 13.2

105.5 ± 11.7

DBF

77.1 ± 4.7

75.9 ± 6.1

73.2 ± 5.4

SHBG (log)

3.92 ± 0.63

3.59 ± 0.54

*

3.92 ± 0.50

Testostero (log)

1.03 ± 0.02

1.05 ± 0.02

*

1.04 ± 0.01

Microalb (log)

1.19 ± 0.37

1.08 ± 0.36

P.BMI

22.03 ± 2.36

25.64 ± 5.5

*

22.31 ± 2.8

Current BMI

22.07 ± 2.20

27.15 ± 5.66

**

22.75 ± 2.95

WHR

0.81 ± 0.05

0.86 ± 0.07

*

0.82 ± 0.06

Baby weight

3202 ± 530

3473 ± 567

3304 ± 514

Alcohol in (log)

0.24 ± 0.30

0.31 ± 0.38

0.40 ± 0.40

Sodium intake

8.07 ± 0.26

7.93 ± 0.28

7.87 ± 0.37

Fat intake

92.82 ± 32.9

96.14 ± 39.6

90.78 ± 38.4

hdl3

p2

0.87 ± 0.4
0.88 ± 0.2
*

5.55 ± 0.7

**

4.1 ± 0.60

*

* *

2.58 ± 0.66
1.52 ± 0.09

**

5.15 ± 1.96

0.95 ± 0.38

*

*

R = resid u al, T estostero = testosteron e, M icroalb = m icroalbum inuria , * = p < 0.05, **
= p < 0 .0 1 , blank sp ace = N o sign ifican t. D ata presented as m ean ± standard deviation.
M o st (60% ) o f subjects in the subgroup (B ) w ere using oral contraceptive pill, at tim e
o f stu d y, com pared w ith other tw o

groups, but on ly the difference b etw een the

subgroup (B ) and controls w as sig n ifica n t (T able 4 -1 4 ), lo g = natural logarithm (base e).
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T able 4 -1 4 C o m p a riso n o f su b g ro u p (B) w ith the resid u a l G D M p o p u la tio n a n d resid u a l
co n tro ls (C a te g o rica l D a ta )
V a r ia b le
C.Pill

Current use
F or N use

S ubgroup
(n = 15)
9 (60%)
6 (40%)

Smoking

N on-sm oke
Smoker
Ex-sm oke

7 (47%)
6 (40%)
2 (13%)

31 (62%)
4 (8%)
15 (30%)

2
1
7
5

(13%)
(7%)
(47%)
(33%)

16 (32%)
16 (32%)
7 (14%)
11 (22%)

2
2
5
6

(13%)
(13%)
(33%)
(40%)

16
14
14
6 (

2
0
9
4

(13%)
(0%)
(60%)
(27%)

16 (32%)
6 (12%)
21 (42%)
7 (14%)

Fre.Exer

0
1
2
3

Dur.Exer

0.
1.
2.
3.

Int.E xer

0
1

-

23-

(B )

R .G DM
(n = 50)
20 (40%)
30 (60%)

(32%)
(28%)
(33%)
12%)

Pi

*

*

*

R .C o n tr o ls
(n - 57)
16 (28%)
41 (72%)

P2
*

29 (50%)
14 (25%)
14 (25%)

14
10
17
16

(25%)
(18%)
(30%)
(28%)

14
11
13
19

(25%)
(19%)
(23%)
(33%)

15 (26%)
3 (5%)
31 (54%)
8 (14%)

R .G D M = rest o f the G D M group, Pj = p values o f com parison o f subgroup B versus
rest o f G D M group, P 2 = p values o f com parison o f subgroup B versus controls, F =
form er, N = never, Sm oke = sm oker, 0 - N ot at all, 1 = L ess than once a w eek, 2 - Once
or tw ice a w eek , 3 = Three tim es a w eek, 0. = N ot at all, 1. = L ess than 20 m inutes, 2. =
2 0 -3 0 m inutes, 3. = M ore than 30 m inutes, 0- = N o exercise, 1- = N o n e o f exercise
sessio n , 2 - = Som e o f exercise session , 3- = M o st or all o f exercise, * - p < 0.05, and
blank sp ace in the

and P2 colum ns = N o significant difference.

The subgroup (B ) tended to sm oke m ore than both other groups, but only the difference
b etw een subgroup (B ) and the residual G D M group w as statistically significant (Table
4 -1 4 ).
T he three com p on en ts o f exercise (frequency, duration, and in ten sity) w ere similar
b etw een the subgroup (B ) and controls. H ow ever, the subgroup (B ) tended to do more
ex er cise than the residual G D M group (T able 4-14).
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4.2.4 H yperinsulinem ic subgroup (Subgroup C) Results
There w ere n o d ifferen ces in age b etw een the three groups.

T he in su lin resistan t group had sign ifican tly higher plasm a ch olesterol level than the
other tw o groups. T h e in su lin resistant group tended to be m ildly hypertriglyceridem ic
(range 0 .8 -2 .8 m m o l/L , m edian 1.4 m m ol/L ), and as a group, they had higher plasm a T G
v a lu es than residual G D M or control groups.

Plasm a ap oB , V L D L -T G , ID L -C , L D L -C , and N E F A w ere higher in insulin resistant
group then other tw o groups.

There w as a ten d en cy for the insulin resistant group to have a sligh tly low er H D L -C
than the other tw o groups, but this w a s not sign ifican t. C ETP activity w as significantly
h igher in the in su lin resistant group than in other tw o groups.

H D L 3 particle siz e s w ere sim ilar in three groups, h o w ev er L D L I particle size slightly
sm aller in the insulin resistant group than in the residual G D M group and significantly
sm aller than in controls (T ab le 4 -1 5 ).

T he m ean sy sto lic and d iastolic b lood p ressures w ere sign ificantly higher in the insulin
resistant group than in the other tw o groups (T ab le 4 -1 5 ).
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T able 4 -1 5 C o m p a riso n o f su b g ro u p (C ) w ith r e s t o f the G D M p o p u la tio n a n d co n tro ls

_______________________________ (C o n tin u o u s D a ta ) ______
V ariab le
S u bgroup (C ) R .G D M
C o n tr o ls
p.
_("
=
52)
(n = 65)
(" = 13)

P2

Age

30.9 ± 7,1

31.7 ± 4.3

TC

5.4 ± 0.8

4.8 ± 1.0

*

4.39 ± 0.76

**

TG

1.06 ± 0.02

1.04 ± 0.02

**

1.03 ± 0.02

**

A poB

1.23 ± 0.22

1.01 ± 0.22

**

0.88 ± 0.22

**

NEFA

1.029 ± 0.008

1 .0 2 8 ± 0.01

1.023 ± 0.01

*

VLDL-TG (log)

6.54 ± 0.49

5.72 ± 0.61

5.55 ± 0.70

**

IDL-C (log)

4.50 ± 0.58

4.28 ± 0.64

4.05 ± 0.60

*

HDL-C (log)

1.05 ± 0.02

1.06 ± 0.02

1.06 ± 0.01

LDL-C

3.78 ± 0.80

3.20 ± 0.95

HDL3b Size

7.93 ± 0.12

7.92 ± 0.10

7.97 ± 0.11

HDL3c Size

7.61 ± 0.19

7.59 ± 0.15

7.65 ± 0.13

HDL2 / h d l 3

0.86 ± 0.17

0.90 ± 0.19

0.92 ± 0.21

LDL-I Size

30.43 ± 0.83

31.39 ± 1.00

*

CETP.A (log)

3.22 ± 0.36

30.85
±
1.06
2.74 ± 0.60

2.58 ± 0.66

**

FBG (log)

1.54 ± 0.06

1.50 ± 0.10

SBP

121.5 ± 6.9

DBP

79.6 ± 5.2

108.0
±
12.3
75.4 ± 5.7

SHBG (log)

3.47 ± 0.72

Testoste (log)

31.39 ± 4.22

**

*

**

2.79 ± 0.75

**

1.52 ± 0.09
**

105.5 ± 11.7

**

*

73.2 ± 5.4

**

3.71 ± 0.53

3.92 ± 0.50

*

1.05 ± 0.03

1.04 ± 0.02

1.04 ± 0.01

**

Testoste / SHBG

0.31 ± 0.07

0.28 ± 0.04

0.27 ± 0.04

**

Microalb (log)

21.89 ± 10.6

13.22 ± 14.2

*

P.BM I

31.06 ± 4.75

**

22.31 ± 2.83

**

Current BMI

32.59 ± 4.53

**

22.8 ± 2.95

**

Baby weight

3460 ± 488

17.02
±
18.3
23.25
±
4 .0 2
24.32
±
4 .3 8
3398 ± 589

A lcohol in (log)

0.24 ± 0.31

0.31 ± 0.38

0.40 ± 0.41

Sodium intake

7.93 ± 0.29

7.97 ± 0.28

7.87 ± 0.37

Fat intake

96.41 ± 40.3

95.11
3 7 .7

±

*

3304 ± 514

90.78 ± 38.4

Testoste = testosterone, P.BM I = pre-pregnancy BMI, * = p < 0.05, ** - p < 0.01,
blank space = No significant difference. Data presentes as mean ± standard deviation.
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N o study su b ject w a s h y p erten siv e: in the in su lin resistant group the h igh est s y s to lic
b lo o d pressure w a s 130 m m H g, in the residual G D M group it w a s 140 mm H g and in
the control group it w a s 130 m m H g. T h e h ig h est d ia sto lic b lo o d pressure in the insulin
resistant and th e residual G D M grou p s w a s 9 0 m m H g and in the control group it w a s
80 m m H g. F astin g b lood g lu c o se le v e ls w ere sim ilar in three groups.

T he group w ith in su lin resistan ce ten d ed to be fatter than either the control or the
residual G D M group, w ith all b ein g o v erw eig h t (B M I > 2 5 ) or o b ese (B M I > 30) (T able
4 -1 5 ).

T he m inim um B M I in the insulin resistant group w a s 2 6 .6 , and 9 o f the 13 in

this group (ab o u t 70% ) w ere ob ese.

On the other hand, on ly one o f the 65 control

subjects w a s o b e se (B M I = 3 4 ) and 11 (17% ) w ere overw eight.

O f the residual (n on 

in su lin resistant) G D M group 16 (31% ) w ere o v erw eig h t and 3 (6% ) w ere ob ese.

P re-pregnancy B M I w a s sign ifican tly higher in the insulin resistant group than other
tw o grou p s (T a b le 4 -1 5 ).

T he in su lin resistant group sh o w a greater am ount o f album in in urine (T able 4-1 5 ).

A lco h o l, sod iu m , and fat intake w ere not sign ificantly different b etw een three groups
(T ab le 4 -1 5 ).

There w ere n o sig n ifica n t d ifferen ces b etw een u se o f an oral contraceptive, sm oking, and
e x er cise b etw een the subgroup (C ) and other tw o groups (T able 4 -1 6 ).
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T able 4 - 1 6 C o m p a r is o n o f s u b g r o u p (C ) w ith the r e s id u a l G D M p o p u la tio n a n d c o n tr o ls
(C a te g o r ic a l D a ta )
V a r ia b le
C.Pill

Current use
F or N use

Smoking

N o n -sm o k e
Sm oker
E x -sm o k e

8 (62%)
0 (0.0% )
6 (46%)

29 (56%)
10 (19 %)
13 (25%)

36 (55% )
14 (22% )
15 (23% )

Fre.Exer

0
1
2
3

5
2
3
3

(39%)
(15%)
(23%)
(23%)

13
14
13
12

(25%)
(27%)
(25%)
(23%)

16
12
17
20

(25% )
(19%)
(26% )
(31%)

Dur.Exer

0 .

5
3
3
2

(39%)
(23%)
(23%)
(15%)

13
13
16
10

(25%)
(25%)
(31%)
(19%)

16
12
14
22

(25%)
(19%)
(22%)
(34%)

5
1
6
1

(39%)
(8%)
(46%)
(8%)

13 (25%)
6 (12%)
23 (44%)
10 (19%)

1.

2.
3.

Int.E xer

0-

1-

(C )

R.GDM

S u b g ro u p
(n = 13)
7 (54%)
6 (46%)

(n = 52)
22 (42 %)
30 (58%)

C o n t r o ls
(n = 65)
21 (32% )
44 (68% )

p,

p2

17 (26% )
5 (8%)
33 (51%)
10 (15%)

23R .G D M = rest o f th e G D M group, Pj = p v a lu es o f com p arison o f subgroup C v ersu s
rest o f G D M grou p , P 2 - p v a lu es o f com p arison o f subgroup C versu s con trols, F =
form er, N = n ever, S m o k e — sm oker, 0 = N o t at all, 1 = L ess than o n ce a w eek , 2 = O nce
or tw ic e a w e e k , 3 = T hree tim es a w eek , 0. = N o t at all, 1. — L ess than 2 0 m in u tes, 2. =
2 0 -3 0 m in u tes, 3. = M o re than 30 m inutes, 0- = N o exercise, 1- = N o n e o f exercise
sessio n , 2 - = S o m e o f e x er cise sessio n , 3- = M o st or all o f e x ercise, blank sp ace in the P t
and P2 co lu m n s = N o sign ifican t difference.
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DISCUSSION
The objective of this chapter is to discuss the finding of the present study on women with
previous GDM one year after delivery compared with controls.

In this study, age was not significantly different between the GDM and control groups.
GDM is most common in women over 30 years old (Wiess, 1988). This discrepancy
may be due to sample size of this study.

5.1 Family Medical History in Women with Previous GDM
GDM subjects gave a history of diabetes mellitus (n = 25, 38.5%) and / or CVD (n = 24,
36.9%) in their first degree relatives more often than in controls (n = 8, 12.3% and n =
10,15.4%, respectively).
Haffner et al (1988) have suggested that fasting insulin concentrations are significantly
higher in normoglycemic persons who have diabetic parents than in persons with no
diabetic relatives.

In addition, Eriksson et al (1988) have found that persons with

positive family history of diabetes have decreased non-oxidative glucose disposal
compared with persons with no family history of diabetes.
Weisser et al (1993) have reported that there is a correlation between insulin and blood
pressure in subjects with a positive family history of diabetes or hypertension and this
genetic influence may be related to insulin resistance.
Aerts et al (1990) have reported that 35% of patients with GDM are offspring of diabetic
mothers versus only 5% of normoglycemic women, and GDM occurs more frequently in
the offspring of diabetic mothers (35%) than in offspring of diabetic fathers (7%).
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A history of diabetes on the m other’s side has been reported to be a more important and
frequent factor for developing diabetes in offspring than a history of diabetes in the
father’s side. Our finding are in agreem ent with these reports.

Several metabolic abnormalities may occur in adulthood including NIDDM and obesity
in the offspring of mothers with G D M (Pettitt et al, 1988, Pettitt et al, 1987,
respectively).

Our finding in GD M subjects in this study is consistent with these

findings.
Van Assche et al (1991) suggested that even mild diabetes mellitus induces an abnormal
intra-uterine milieu that causes

morphological and

functional changes

in fetal

development with consequences for later life. Intra-uterine factors may be responsible
for the transmission of diabetes mellitus from one generation to another. The incidence
of NIDDM is much higher in the offspring of diabetic mothers than in normal mothers
(Aerts et al, 1990).
GDM subjects had more frequently significant and positive family histories of CVD in
comparison with control subjects. Bell et al (1990) previously reported a similar finding
in GDM subjects.
Our findings also indicate that the GD M subjects are more likely to have a diabetic
mother than controls and that the GD M subjects are more likely to have history of
diabetes in the m other side in father side. The GDM subjects also are more likely to
have a first degree relative with CVD.
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5.2 Obstetrics History in Women with Previous GDM One Year after Delivery
Fetal risks accompanying diabetes in the m other include spontaneous abortion, prenatal
death, and malformation (Crandall, 1987). In our study, there is a similar incidence of
those and other complications in patient who have had GDM and controls.

This good outcom e is possibly due to intensive diet management and insulin therapy to
maintain euglycemia.

Caesarean delivery was more common in GDM but not

statistically different between two groups.

Our finding is in agreement with similar

findings by Goldman et al (1991).

GDM subjects did not have greater parity than controls; our findings in this agree with
those of M olsted-Pedersen et al (1989).

Three GDM subjects had had GDM in previous gestations. They were obese, and they
required insulin to achieve normoglycemia in their most recent and previous pregnancies.
Gaudier et al (1992) reported that women with a history of GDM and BMI > 35 kg / m2,
if they required insulin therapy during pregnancy, were at increased risk (52%) of
recurrence of GDM.

5.3 Oral Contraceptive Use in Women with Previous GDM One Year after Delivery
There is no significant difference in use of an oral contraceptive between the GDM and
control groups.
In our study, current use of oral contraceptive was not significantly associated with
plasma cholesterol, LDL-C, HDL-C, NEFA, and insulin concentrations. Our results are
consistent with those of Kjos et al (1990) who reported that low-dose oral
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contraceptives in women with prior GDM did not seem to have any adverse effect on
carbohydrate or lipid metabolism.

Current oral contraceptive use was positively and significantly correlated with plasma
cholesterol, apoB, and apo A-I concentrations. Lussier-Cacan et al (1991) reported that
apoB and apoA-I both were higher during oral contraceptive therapy.
The serum concentration of SHBG is known to be increased by estrogen, tamoxifen,
phenytoin, or thyroid hormone administration and by hyperthyroidism and cirrhosis.
SHBG also is decreased by exogenous androgen, glucocorticoids or growth hormone
and by hypothyroidism. Only one GDM subject was excluded from analysis, because she
was taking replacement thyroxine (Braunstein, 1994). There is a positive and significant
correlation between oral contraceptive pill and SHBG in our study.

SHBG is

synthesized in the liver, and its synthesis is stimulated by estrogens and inhibited by
androgen (Goldfien and Monroe, 1994).
Normal and healthy women taking oral contraceptive pills have a slightly increased risk
of cerebrovascular and cardiovascular disease, and the risk is higher for the diabetic
patients (Rapkin, 1987).

5.4 Obesity in Women with Previous GDM One Year after Delivery
In our study, subjects who have had GDM have significantly greater WHR, BMI, and
body fat % than control subjects. W HR seems to be the simplest and most reproducible
measure of central obesity (Haffner et al, 1987) and it is strongly associated with visceral
fat mass (Ashwell et al, 1985).
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Factors affecting percent body fat include age, gender, level of energy balance,
composition of the diet, level of physical activity, and a variety of social factors including
smoking and alcohol intake (Bouchard et al, 1990). In this study, we examined these
factors in GDM populations.
Metabolic disorders in obesity have been shown to be correlated with abdominal obesity
(Kalkhoff et al, 1983, Larsson et al, 1984, Ohlson et al, 1985). In addition, Ashwell et al
(1985) have found a strong correlation between the intra-abdominal fat:subcutaneous fat
area ratio and WHR by using CT scanning at an umbilical level. Shimokata et al (1989)
have reported that WHR is strongly affected by age and BMI. WHR has a positive
correlation with age and BMI.

Our data also indicates that WHR has a positive

correlation with age and BMI, too.
Central obesity is positively associated with overall adiposity, particularly in females. In
our study, GDM subjects also represent a higher BMI in

company with higher WHR

and body fat %.
Insulin resistance occurs in both NIDDM and obesity, and most NIDDM patients are
obese. In fact, obesity precedes the development of NIDDM in more than 80% of cases
in Pima Indians (Seely and Olefsky, 1993).

In the present study, GDM subjects had

higher BMI and higher insulin levels leading to dyslipidemia (Table 4-8).
Multiple regression analysis showed that fasting insulin concentration is the strongest
determinant of BMI in the GDM subjects (Table 4-9).
WHR, BMI, and body fat % showed a positive and significant correlation with fasting
plasma insulin level and insulin / glucose ratio. Baynes et al (1991) reported a similar
result in both diabetic males and females.

Hyperinsulinemia may develop through
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progressive development of insulin resistance, presumably due to post-receptor site
alterations (Lillioja and Bogardus, 1988, Olefsky et al, 1988).
Women are resistant to insulin action at an average body fat % of 37.7% (in GDM
subjects mean was 38.79 %), while men develop an equivalent condition at an average
body fat % of 23.9% (Plaisted and Istfan, 1994).
In mildly hyperinsulinemic obese subjects, only a decrease in insulin sensitivity exists. As
the hyperinsulinemia worsen, a post-receptor defect also occurs. Furthermore, there is a
direct association between degree of insulin resistance or hyperinsulinemia and the
magnitude of the post binding defect (Seely and Olefsky, 1993).
Glucose oxidation is lower in obese subjects than normo-weight controls, but lipid
oxidation is 30% higher in obese subjects than controls in the fasting state. Thus, there
is a negative correlation between glucose oxidation and lipid oxidation which may be
explained by the glucose-fatty acid cycle (Seely and Olefsky, 1993).
The association between insulin and hypertriglyceridemia has been shown in Figure 5-1.
Insulin resistance causes increased insulin secretion, and increased flux of NEFA to the
liver (where they stimulate TG synthesis), and increasing hyperinsulinemia (Durrington,
1995). Hyperinsulinemia, in turn, can be a cause of overproduction of hepatic TG and
increased hepatic VLDL secretion, and as a result cause hypertriglyceridemia (Olefsky et
al, 1974) (Figure 5-1).
GDM subjects in this investigation have a significantly higher plasma NEFA
concentration than controls. NEFAs are thought to increase insulin resistance in muscle
and liver and increase hepatic gluconeogenesis and lipoprotein synthesis and perhaps
decrease hepatic removal of insulin (Bjomtorp, 1992).

NEFAs are a determinant of
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V L D L production. H igh N E F A levels m ay g iv e rise to high plasm a V L D L , L D L , apoB 100, and g lu co se concentrations, and perhaps secondarily, hypertension (B jom torp,
1992). A ll th ese variables have been sh ow n to be raised w hen plasm a N E F A is raised in
our investigation. A ll these variables w ere significantly and positively related to obesity
among the G D M group.

Increased blood glucose

Increased
NEFA release

Increased insulin

Increased hepatic TG

secretion (if possible)

synthesis

Increased hepatic VLDL
secretion

Figure 5-1 Alternative hypothesis to explain the association between insulin and
hypertriglyceridemia (Data from Durrington, 1995 and Olefsky et al, 1974). TG —
triglyceride, NEFA - non-esterified fatty acid.
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two

basic

mechanisms

for the

hypertriglyceridemia of obesity: overproduction of VLDL-TG and impaired lipolysis of
the TG-rich lipoproteins. The high plasma TG concentrations in subjects (GDM) may be
due to a reduction in VLDL catabolism, through the decreased plasma post-heparin LPL
activity, and / or an increased VLDL synthesis (Despres et al, 1990 b).
Stromblad and Bjomtorp (1986) have reported that high FFA concentrations in portal
blood are associated with reduced hepatic insulin clearance in rat with dietary-induced
obesity.
In addition, Svedberg et al (1990) have demonstrated that elevated FFA levels inhibit
insulin binding and degradation in isolated rat hepatocytes. Thus, central obesity and
high FFA concentrations may increase insulin resistance and thus hyperinsulinemia.
BMI showed a significant and negative correlation with LDL particle size in this study.
The correlation of abdominal obesity with denser and smaller LDL was reported
previously (Harris-Peeples et al, 1989). BMI and WHR were positively associated with
LDL-C but it did not reach significant level.
HDL-C may be decreased in obese subjects, either through direct clearance of HDL-C
from circulation by the adipose tissue or through separation of the lipid from its apo A-I
or its cholesterol ester (Grundy and Barnett, 1990). In the present study, BMI was not
significantly correlated to HDL-C but WHR was significantly and negatively associated
with plasma HDL-C concentration.
CETP was a significandy and positively correlated with BMI and body fat % in the
GDM group.

Increased CETP activity is associated with increased lipid exchanged

between VLDL and HDL in abdominal obesity (Despres et al, 1992).
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There was a significant and positive correlation between BMI and systolic blood
pressure, diastolic blood pressure, and mean arterial pressure.

Previous studies have

reported a similar correlation between obesity and both systolic and diastolic blood
pressure in obese subjects (Van Gaal et al, 1988, Peiris et al, 1989).

Obesity is a strong predictor for the development of hypertension (Sowers et al, 1991).
Although the mechanisms by which obesity cause hypertension are not fully understood,
hypercaloric intake, hyperinsulinemia, insulin resistance, enhanced metabolic activity of
visceral adipose tissue, enhanced sympathetic activity, and even the greater body mass
present in obese patients are all thought to be involved mechanisms (Plaisted and Istfan,
1994).

5.5 Carbohydrate Metabolism in Women with Previous GDM One Year after
Delivery
Data from a study on Nauruans indicated that subjects with higher post-load serum
insulin levels, presumably indicative of insulin resistance, at base line tended to develop
IGT or diabetes over a six year period (Sicree et al, 1987). It is generally accepted that
insulin resistance plays an important role in the pathogenesis of NIDDM (Alzaid and
Rizza, 1993).
Reduced glucose clearance, accompanied by compensatory hyperinsulinemia, is present
one or two decades before NIDDM is diagnosed in the offspring of diabetic parents. It
indicates that the primary defect is in the peripheral tissue response to insulin and
glucose, not in the pancreatic cell (Warram et al, 1990). The same authors suggested
that a low glucose clearance rate and hyperinsulinemia are the best predictors of the
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subsequent development of diabetes in the offspring of diabetic parents (Warram et al,
1990).
Several studies have showed that fasting hyperinsulinemia is a good predictor for the
development of NIDDM in different populations such as in Nauruans (Sicree et al,
1987), Pima Indians (Knowler et al, 1990, Saad et al, 1988, Lillioja et al, 1988), Mexican
Americans (Haffner et al, 1990 b), Swedish women (Lundgren et al, 1990), the offspring
of diabetic parents in America (Warram et al, 1990), and French policemen (Charles et
al, 1991). The cellular mechanisms involved in the alteration of insulin function are still
unclear (Knowler et al, 1993). It may be applicable for GDM subjects and say that high
fasting insulin level is a predictor of the development of diabetes mellitus in these
population.
The current hypothesis is that as a result of chronic insulin resistance, compensatory
hypersecretion of insulin develops to maintain glucose homeostasis and that eventually
diabetes mellitus develops when pancreatic hypersecretion fails (Haffner et al, 1990 b).
The present study showed that 20% of the GDM subjects had developed insulin
resistance (as defined by fasting hyperinsulinemia) one year post-partum.

They were

overweight or obese and they tended to have mild dyslipidemia. They also tended to
have a higher blood pressure, lower SHBG concentration, and microalbuminuria.
BMI was the unique determinant factor in the insulin multiple regression model (Table 4
9).
There is considerable evidence to suggest that insulin resistance is caused (at least in
part) by excess availability of fatty acids. Randle has suggested that elevated plasma
FFA levels impair glucose metabolism.

Increased uptake of free fatty acids and
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subsequent oxidation inhibits glucose oxidation and glycogen synthesis (Randle et al,
1963).
Infusion of FFA into normal subjects using the insulin clamp technique to measure insulin
resistance and indirect calorimetry showed that increased FFA concentrations may result
in mild insulin resistance, reduction in glucose transport, and a reduction in both glucose
oxidative and non-oxidative metabolism (Ferrannini et al, 1983, Yki-Jarvinen et al,
1991).
Haffner et al (1992) have demonstrated that increased fasting insulin concentrations
predict a cluster of metabolic disorders including dyslipidemia, hypertension, and
NIDDM, and other have previously shown that fasting insulin predicts NIDDM (Saad et
al, 1988, Haffner et al, 1990 a, Charles et al, 1991, Zimmet et al, 1992).
Subjects who have GDM have an increased risk of developing NIDDM later in life and
more than 50% of these women develop NIDDM within 25 years (O’Sullivan, 1975).
Women with GDM who need insulin treatment during pregnancy have a higher risk of
later development of diabetes mellitus than those who have been controlled by diet alone
(Henry and Beischer, 1991).
In our study, 17% (11 cases) of GDM patients have received insulin for control their
blood glucose levels during pregnancy and 83% (54 cases) have been treated only by diet
to achieve an acceptable level of glucose. GDM subjects who received insulin treatment
during pregnancy had a higher BMI before and after pregnancy and dyslipidemia (higher
plasma cholesterol and LDL-C).
None of the GDM subjects including those with insulin resistance were sufficiently
hyperglycaemic to elevate glycosylated haemoglobin (as % of blood haemoglobin).
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As a result, the severity of insulin resistance appears to be predicted by factors such as
antecedent glycemic control, level of fitness, age, obesity, body fat distribution, and
hypertension (Alzaid and Rizza, 1993).
Our study showed that a subgroup of those women who have a history of GDM have
hyperinsulinemia and mild hypertriglyceridemia.

They tended to be fatter, to be

dyslipidemic (higher plasma cholesterol and TG concentrations), to have a higher blood
pressure, to have a greater amount of albumin in urine, and to have lower plasma SHBG
concentrations, but not to be older.
Alterations in lipid metabolism associated with insulin resistance are outlined in Table 5
1 (Frayn, 1993). In the present study all these changes were found in the GDM group,
particularly those with insulin resistance.

Table 5-1 A lte ra tio n s in lip id m eta b o lism com m on ly a s so c ia te d w ith insulin resistance

Elevated plasma TG concentration (particularly VLDL-TG)
Decreased plasma HDL-C concentration (particularly HDL2-C)
Elevation NEFA
Small, dense LDL particles

5.6 Lipoprotein Metabolism in Women with Previous GDM One Year after Delivery
Plasma cholesterol and apoB concentrations in the women with prior GDM tend to be
significantly higher than in women with no history of GDM of the same age. Apo B
level has been reported as a more effective marker for coronary artery disease than LDL
or total cholesterol level (Levinson and Wagner, 1992). As shown in recent study, apo
B level may be measuring the atherogenic potential of both VLDL and LDL (Grundy and
Vega, 1992).
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The plasma cholesterol concentration was not related to cholesterol intake and
cholesterol intake was similar between two groups.

Elevated TG levels may result from overproduction or defective removal. The latter may
be due to genetic or acquired deficiency of LPL or apoC-II (the activator of LPL), or an
excess of apoC-IH which inhibits apoC-II activity and (3-VLDL uptake (Kashyap, 1991).

A clinically im portant aspect of HTG is that it signals the presence of other metabolic
disorders (Vergani et al, 1990). In addition to HTG and low level of HDL, affected
subjects frequently have one or more of the following: overweight, insulin resistance
with fasting hyperinsulinemia and glucose intolerance, hypertension, and hyperuricemia.
Different terms have been used to define this syndrome: ‘plurimetabolic syndrome’,
‘overweight-hyperlipidemic-hyperuricemic

syndrome’,

‘glucose

intolerance-obesity-

hypertension condition’, and ‘symptom complex’ (Vergani et al, 1990). The name most
used now is ‘insulin resistance syndrom e’. The syndrome is strongly related to coronary
heart disease (Vergani et al, 1990).
According to Zavaroni and Reaven, an increase in the plasma triglyceride concentration
and a decrease in the plasma HDL-C concentration are the expected results of insulin
resistance and hyperinsulinemia (Vergani et al, 1990).
In the current investigation, GDM subjects have HTG, but not a low level of HDL-C
compared with controls. In these subjects HTG seems statistically to be related with
hyperinsulinemia, high plasma NEFA concentration, NEFA, and smoking. Interestingly,
BMI and alcohol consumption were not strong predictors in the subjects. This lack of
correlation might be due to considerable homogeneity in the subjects.
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Reaven and Greenfield have suggested that HTG associated with insulin resistance is
related to plasma insulin concentration and / or free fatty acids (Reaven and Greenfield,
1981).

In impaired glucose tolerance states, subjects exhibit insulin resistance and a

compensatory hyperinsulinemia.

The hyperinsulinemia causes an increased rate of

synthesis and secretion of VLDL-TG and perhaps HTG due to impaired clearance
capacity (Nikkila, 1984). On the other hand, high plasma FFA concentration derived
from VLDL metabolism give rise to hypertriglyceridemia (Galton and Krone, 11991).
Genetic studies have suggested that the high concentration of apoB in circulation can be
a strong coronary risk factor (Douste-Blazy and Kloer, 1989). In human, apoBlOO is a
protein constituent of VLDL, IDL, and LDL.

Each of these lipoprotein particles

contains but a single copy of apoBlOO (Innerarity, 1990).

In our study, the GDM

subjects exhibited a higher level of plasma apoB and LDL-apoB concentrations than
controls, and they also had slightly higher levels of VLDL-apoB and IDL-apoB than
controls but not to an exact that was statistically significant.

Plasma FFA (NEFA) concentration is a function of rates of both input and removal from
the plasma concentration. Inflow of FFA is governed by the rate of lipolysis in adipose
tissue and also the release of FFA during the hydrolysis of circulating TG-rich particles,
particularly in the postabsorptive state (Taskinen et al, 1985). The rate of FFA removal
is determined by both esterification (or re-esterification) and lipid oxidation. It has been
generally accepted that plasma FFA concentration is controlled mainly by FFA
production (ie by the rate of lipolysis), whereas the efflux rate of FFA is secondary to
changes in plasma FFA concentration. This concept implies that the removal of FFA
from plasma is not controlled independently (Taskinen et al, 1985).
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As is shown by simple regression, intensity of exercise is related positively to NEFA
level. The activation of lipase and subsequent lipolysis and mobilization of FFA from
adipose tissue is increased by the hormones epinephrine, norepinephrine, glucagon, and
growth hormone.

Because plasma concentrations of these hormones are increased

during exercise, this mechanism for lipase activation provides the muscle with a supply of
a potent energy substrate. Alterations in lipase activity may partly explain the enhanced
utilization of fat observed with aerobic exercise training (McArdle et al, 1991 a).
The most substrates used by the heart for energy are glucose, fatty acids, and lactic
acids. During exercise the myocardial metabolism of FFAs rises to approximately 70%
of the total energy requirement (McArdle et al, 1991 a).
Emphasis has recendy been placed on abnormalities not only in lipid and apolipoprotein
concentrations but also in lipid and apoprotein composition of different lipoproteins in
diabetic as well as in non-diabedc individuals (Steinberg et al, 1989).
Compared with non-diabetic people, diabetic patients have decreased clearance of both
VLDL-apoB and VLDL-TG, and increased production of VLDL-TG. Obese subjects
have increased production of both VLDL-apoB and VLDL-TG and more VLDL of
normal composition (Howard et al, 1987).

Study on VLDL turnover showed that

production of both VLDL-apoB and VLDL-TG were significantly correlated with insulin
concentrations, and the rates of clearance of both were significantly correlated with
plasma glucose levels (Howard et al, 1987).
In GDM subjects, it may be said that clearance of both VLDL-TG and VLDL-apoB are
decreased and also the production of VLDL-TG is increased. It explains significant
elevation in the level of VLDL-TG and a slightly higher (but not significantly higher)
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concentration o f VLDL-apoB but not significant in the GDM group compared with
controls.

Saheki et al (1993) reported that VLDL from diabetic patients are a poor

substrate for LPL compared with norm al VLDL.

IDL particles are thought to be associated with increased atherosclerosis risk (Tatami et
al, 1981, Steiner, 1981). This supposition is supported by the observation that particles
with size and flotation similar to those of human cholesterol-enriched IDL have been
associated with a predisposition to coronary atherosclerosis in the cholesterol-fed
monkey and that elevated levels of IDL mass and IDL-C have been related to increased
risk of coronary disease in human (Krauss, 1987).
On this basis, Fielding et al (1984) have suggested that the block to cholesteryl ester
transfer to VLDL and LDL in NIDDM patients is mediated by their increased free
cholesterol (FC) content and may be related to the increased risk of these patients for
developing atherosclerosis.
In the GDM group as a whole, the plasma LDL-C and LDL-apoB concentrations were
significantly greater in the GDM subjects than in controls.
Elevated levels of LDL-C might be secondary to either an increase in the synthesis rate
of LDL-C or a decrease in the rate of its catabolism and clearance from plasma (Barter,
1994). A down-regulation of the B/E receptor may be involved in the decreased rate of
LDL-C catabolism (Barter, 1994). On this basis, a defect in VLDL degradation possibly
due to LPL activity disorders and an enhanced synthesis of VLDL from the liver can be a
cause of HTG and combined HTG and hypercholesterolemia (Barter, 1994), and thus a
greater level of LDL-C in plasma.
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Deckelbaum et al have suggested that transformation of IDL and larger LDL to smaller,
denser LDL subspecies can result from the combined effects of TG hydrolysis and lipid
transfer (Musliner et al, 1991).

The factors that determine the size and composition of LDL are not fully known.
Investigations have shown that genetic factors are involved in the size of LDL. Studies
have demonstrated that environmental factors or other disease states may also influence
the size and composition of IDL (Feingold et al, 1992).

Firstly, age has a positive

correlation with LDL phenotype B. Secondly, weight loss induced by exercise decreases
the concentration of small, dense LDL, and thirdly, studies have recently found that in
subjects with acquired immunodeficiency syndrome (AIDS) the prevalence of the LDL B
phenotype B is increased 2.5 fold (Feingold et al, 1992).
Krauss and Burke (1982) suggested that the TG-enriched LDL found in the larger and
less dense subfractions may give rise to smaller, dense LDL subspecies via lipolysis and
loss of core TG and other lipids.

However, in the smallest and most dense LDL

subspecies, LDL-TG is increased, suggesting that another metabolic pathway is involved
in their formation.

Some of the smaller, denser subspecies may also conceivably be

precursors of larger, less dense LDL subspecies formed as a result of transfers of lipid
and protein components to and from these particles (Krauss and Burke, 1982).
McNamara et al (1987) have found that the presence of small LDL particle is associated
with increased age, plasma cholesterol and TG concentrations, and lower HDL-C and
apoA-I levels. On the other hand, Barakat et al (1990) have found that LDL particles
are smaller and denser in patients with IGT and NIDDM. LDL size was correlated with
plasma insulin concentrations independent of plasma TG level, age and BMI. In addition,
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this does not necessarily testify a causal relationship and it is difficult to identify the
mechanisms that govern the alterations in LDL particle size. It may be a link between
hyperinsulinemia and atherosclerosis (Barakat et al, 1990).

Smaller LDL particle size is prevalent in subjects with IGT and NIDDM but not in
normoglycemic obese subjects whose plasma insulin concentrations are normal. It seems
the presence of small LDL may be related to the degree of resistance of tissues to insulin
action. LPL also may play a role in the alteration in LDL size (Barakat et al, 1990),
because adipose tissue and lipoprotein metabolism

are associated with insulin (Eckel,

1989).
Feingold et al believe that whether HTG itself leads to the formation of small, dense
LDL or whether those who inherit the LDL B phenotype are more susceptible to the
development of HTG is unresolved (Feingold et al, 1992).
HDL consists of a heterogenous group of particles defined either by size or by their
apolipoproteins (Silverman et al, 1993).

Data from this study suggests that HDL-C is not significantly lower in GDM subjects
and also the HDL2 %:HDL3 % mass ratio (the HDL2 area %:HDL3 area % ratio
measured after gel electrophoresis separate the HDL subfractions) is not increased,
resulting in no evidence for impaired LCAT activity.

Silverman et al suggested that

transfer of CE via CETP, followed by lipolysis of TG by HPL, results in the conversion
of HDL2 into HD L3 (Silverman et al, 1993).
It is thought both HDL2 and HDL3 are acceptors of phospholipid, FC, and apoCs from
VLDL and chylomicrons, but the major acceptor particles are probably HDL3. With
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higher substrate concentrations the HDL3 decreases and may be completely transformed
to the density of HDL 2 (Nikkila et al, 1987).
Deckelbaum et al (19884) have reported that there is a positive correlation between
plasma TG

concentrations

and TG

content of HDL in normolipidemic and

hypertriglyceridemic subjects.
TG-enriched HDL3 particles show a positive relationship with posprandial lipemia and
the evidence suggests that they serve also as substrate for hepatic lipase and are
converted to particularly small, dense HDL3 (Patsch et al, 1987).
Behr et al (1981) have reported that an immunologically mediated blockage of the effect
of LPL (by influencing antibodies to LPL) in the chicken resulted in accumulation of TGrich lipoproteins, a higher TG content of HDL, and the replacement of the larger HDL2
by smaller, denser HDL3.
Largost (1992) have suggested that CETP promotes a reduction in the size of HDL3
when HDL3 was incubated with purified CETP at 37°C for 24 hours.

In addition,

NEFAs have been reported to modulate the redistribution of particle size in HDL3 by
CETP even in the absence of any other lipoprotein classes (Largost and Barter, 1991).
In hypertriglyceridemia, the fractional catabolic rate (FCR) for apoA-I is increased, and
low plasma concentrations of apoA-I and HDL-C are presumed secondary to the
increased FCR (Tribble and Krauss, 1993).

In present study, GDM subjects were

moderately hypertriglyceridemic in comparison with controls and their HDL-C and HDL
apoA-I levels were slighdy lower than controls but not to a statistically significant extent.
In the GDM group Lp (a) concentration in plasma was not significantly different
between GDM and control subjects. Plasma Lp (a) concentration was not associated
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with plasma cholesterol, TG, VLDL-C, IDL-C, LDL-C, apoB, smoking, blood pressure,
and dietary factors, these being other risk factors for atherosclerosis, but it was
significandy correlated with plasma insulin concentration and markers of obesity in this
study. Lp (a) also was associated with amount of albumin in urine (Table 4-8). It seems
likely that obesity and hyperinsulinemia are associated with higher plasma Lp (a)
concentrations, but the underlying mechanisms are not clear.

Steinmetz et al (1993)

reported that Lp(a) and atherosclerosis are associated, but the underlying mechanism is
not clear.
In conclusion, it can be said that a number of metabolic and pathophysiological
mechanisms may modulate the concentration of Lp (a) and that these are not yet fully
understood.
In this investigation, CETP activity % was higher in the GDM group than in control
group. Studies have suggested that increased CETP activity may promote atherogenesis
by stimulating enhanced transfer of CE to LDL in patients with low plasma HDL
concentrations (Sparks et al, 1991).
The CETP mediated transfer of cholesteryl esters from HDL to apoB-containing
lipoproteins can be potentially atherogenic, particularly in circumstances when plasma
concentrations of apoB-containing particles are elevated, a circumstance perhaps in
which the cholesteryl ester-rich apoB-containing lipoproteins are more likely to transfer
cholesterol to peripheral cells in the arterial wall (Albers et al, 1990).
The activity of CETP has been shown to be positively related to adiposity (Dullaart et al,
1994). The data in this study suggest that there is a positive relationship between higher
CETP activity and markers of obesity, BM I and body fat %. In addition, CETP activity
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showed a significant and negative correlation with exercise in the present study. It is
possible that obese subjects may have greater plasma CETP activity because of their lack
of physical activity, but that needs to be practically examined.

CETP plays a major role in modifying the composition of lipoproteins in the plasma
compartment (Albers et al, 1990). For example, CETP facilitates the exchange of LDL
cholesteryl ester for VLDL triglyceride. By this process, the TG-enriched LDL formed
can then subsequendy undergo lipolysis, leading to the formation of smaller, dense LDL
(Albers et al, 1990).

McPherson et al (1991) have reported that plasma CETP concentrations are elevated in
patients with hypercholesterolemia, sometimes
hyperchylomicronemia.

in combination with HTG and

Correction of the abnormal lipoprotein phenotype by dietary

therapy caused significant reductions in plasma CETP concentrations in patients with
hypercholesterolemia (McPherson et al, 1991).
In light of the above information, it seems a number of the GDM group demonstrate a
syndrome of dyslipidemia compared with controls. The dyslipidemic syndrome in the
GDM subjects includes hypercholesterolemia, hypertriglyceridemia, higher plasma apo B
and NEFA concentrations, alterations in VLDL, IDL, and LDL compositions (ie higher
VLDL, IDL-C, IDL-C, LDL-C, and LDL-apoB in the GDM subjects compared with
controls), greater CETP activity in plasma, and denser and smaller HDL and LDL
particles.
Approximately 37% of the GDM group in the current study have the dyslipidemic
syndrome. The results showed that subjects with dyslipidemia had hyperinsulinemia and
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insulin / glucose ratio, greater BM I and body fat %, higher blood pressure (both systolic
and diastolic), and lower plasma SHBG concentration.

Plasma cholesterol and LDL-C concentrations were positively associated with insulin
levels in men but not in women (Haffner et al, 1988). Plasma insulin concentration has
been reported to be associated with smaller and denser LDL particles which seem to be
more atherogenic (Barakat et al,

1990).

In this investigation, plasma insulin

concentration and insulin / glucose ratio, as a marker of insulin resistance, were
positively correlated to plasma cholesterol and LDL-C concentrations in GDM subjects.
Gary et al (1988) have reported that insulin-mediated glucose disposal is negatively
correlated with fasting TG concentration as well as VLDL-C, VLDL-TG, and LDL-C /
HDL-C ratio. Laakso et al (1990) have found insulin resistance is associated with low
HDL-C and high total TG and VLDL-TG levels in subjects with normal and impaired
glucose tolerance and NIDDM.

In our investigation, the GDM subjects with

hypertriglyceridemia had higher fasting plasma insulin concentrations and insulin /
glucose ratio, and VLDL-TG levels, they also had slightly lower HDL-C levels but not
to a statistically significant extent.
Over all, it seems that abnormalities founded in this study in LDL composition and size
can be due to HTG and a high activity of CETP in plasma (GDM subjects represent
higher plasma TG levels and CETP activity compared with controls). These changes
may be due to insulin resistance.
In addition, LDL composition was altered ( higher LDL-C and LDL-apoB levels) in
women who had had GDM in comparison with controls.

LDL phenotype was not

significantly different in women who had had GDM than control women.

Discussion

Chapter Five

172

As a result, based on the results o f our study, it is possible to say that subjects with
previous GDM exhibit a complex of lipid and lipoprotein disorders which can be risk
factors

for

atherosclerosis.

Subjects

with

history

of GDM

presented

mild

hypercholesterolemia, hypertriglyceridemia, higher apoB and NEFA levels, and greater
CETP activity. Additionally, they had abnormal VLDL, IDL, and LDL compositions
and they possessed denser and sm aller LDL-I and HDL3b and HDL3c particles.

Subjects with dyslipidemia were overweight or obese and had hyperinsulinemia. It may
be that the dyslipidemic syndrome in a number of the GDM subjects is secondary to
insulin resistance.
Many studies recently have suggested that a profile of plasma apolipoprotein values may
be useful in the evaluation of coronary heart disease risk, although the final goal should
be to identify by means of their apolipoprotein components atherogenic and non
atherogenic lipoprotein particles (Douste-Blazy and Kloer, 1989).
Thus, abnormalities in lipid metabolism may be very important in GDM patients and
should be considered carefully by those caring for them. Lipids and lipoproteins should
be checked in following these patients up and action taken where appropriate.

5.7 H y p e r a n d r o g e n ic ity in W o m e n w ith P r e v io u s G D M O n e Y ea r a fte r D e liv e ry
In the present study, GDM patients exhibited lower plasma SHBG levels than controls
but the plasma levels of testosterone were not significantly elevated in GDM subjects.
On the other hand, total testosterone / SHBG ratio (the free androgen index) was
significandy higher in women with previous GDM than in women with history of a
normal pregnancy (p = 0.0048).
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GDM subjects demonstrated a significant negative correlation between plasma SHBG
concentration and the plasma level o f testosterone. Rosenfield (1975) reported the same
linkage between low level of SHBG and higher level of free testosterone in pre
menopausal

and

post-menopausal

women.

It

is

considered

a

marker

of

hyperandrogenicity in women. A small increase in total testosterone in the blood (as
exist in GDM subjects) accompanied by a decrease in the concentration of SHBG may
result in a significant increase in circulating biologically active hormone (Goldfien and
Monroe, 1994).
Studies have reported an inverse relationship between body weight and the plasma
SHBG concentration (Demoore and loosens 1970), BMI and upper body obesity in pre
menopausal women (Haffner et al, 1989). In our study, we found an inverse relationship
between the plasma SHBG concentration and WHR, BMI, and body fat % in the GDM
patients.
Evans et al (1983) reported that abdominal obesity causes low SHBG and high free
testosterone levels in women. In addition, Kirschner et al (1990) demonstrated that sex
hormone production and metabolism are different in women with upper body
(abdominal) and lower body obesity. W omen with upper body obesity exhibit higher
androgen production rates, higher testosterone and estradiol (E2) levels and lower
SHBG levels. However, women with low er body obesity make increased amounts of E2
from peripheral aromatization.
Use of an oral contraceptive was strongly related to the plasma SHBG concentration.
Estrogen therapy is one of the factors which increased SHBG synthesis (Goldfien and
Monroe, 1994). The mechanism of this effect will be discussed later in this Chapter.
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Data from the present investigation show ed that SHBG has significant and positive
correlations with plasma apoA-I and H D L-apoA -I concentrations but the relationship
between SHBG and HDL-C was not significant.

Previously, Haffner et al (1989) reported that SHBG is positively correlated with HDL
C in pre-m enopausal wom en and Longcope et al (1990) found that SHBG is significantly
related to HD L-C and apoA-I in women. The numbers of subjects in our study may not
have been great enough to dem onstrate statistical significance for the relation of SHBG
and HDL-C.

Longcope et al (1990) suggested that the positive associations between SHBG and
HDL-C, HD L2, and apoA-I are related to the fact that these proteins are synthesized in
the liver, and their syntheses may be stimulated through similar mechanisms.

Insulin is known as a regulator of SHBG production in v itro and in v iv o (Peiris et al,
1993). Insulin is capable of suppressing SHBG production in a hepatic cell line and may
also prom ote hepatic secretion of TG-rich VLDL (Longcope et al, 1990).

It is possible

therefore that hyperinsulinemia in the GD M patients decreases the production of SHBG
and has an independent effect on lipoprotein synthesis.

Lindstedt et al (1991) have suggested that low plasma SHBG concentration is a strong
independent risk factor for the developm ent of NIDDM in women.

Whether the low plasma SHBG concentration or the high testosterone / SHBG ratio we
have found in wom en who have had G D M can be regarded in any way as a causative
factor for GD M is uncertain.
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In conclusion, epidemiological studies have suggested that obesity is an independent risk
factor for cardiovascular disease and related mortality (Bray and Gray, 1988 and Manson
etal, 1990).

Most studies have shown that there is a positive correlation between obesity and
prevalence of NIDDM (Ashley and Kannel, 1974, Knowler et al, 1981, Stem et al,
1983). Finally, it can be said that GDM patients are more likely to develop NIDDM than
controls.

In

addition,

hyperandrogenicity,

as

assessed

by

decreased

SHBG

concentrations, is an important independent risk factor for NIDDM in women (Haffner
et al, 1993 b).
In general, obesity is a heterogenous condition. The regional fat distribution seems to be
an important determinant of the metabolic complications that have been associated with
obesity.
In this study, women with previous GDM exhibit higher WHR, BMI, and body fat % and
several abnormalities in lipids and lipoproteins, hyperinsulinemia and insulin resistance,
higher blood pressure, and a low level of SHBG.

5.8 Raised Blood Pressure in Women with Previous GDM One Year after Delivery
In this study, the GDM group exhibited higher systolic and diastolic blood pressure and
higher M AP than the control group.
Blood pressure was significandy correlated with BMI, plasma insulin, and insulin
resistance index (insulin / glucose ratio).

It confirms previous findings by other

researchers such as Sechi et al (1992). However, this is the first report of raised blood
pressure in subjects who have had GDM which suggests that hyperinsulinemia due to
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possible underlying mechanism.

Fasting insulin

concentration, B M I, and alcohol consum ption w ere the significant independent variables
in multiple regression analysis for systolic blood pressure.

The pathogenic role o f hyperinsulinem ia is currently unclear.

The insulin resistance-

hyperinsulinemia-hypertension hypothesis was shown in Figure 4-2.

Insulin has been

found to play an im portant role in the regulation of sodium reabsorption in the distal
tubules o f the kidney (Skott et al, 1989, DeFronzo, 1981). W ater is also reabsorbed
with sodium (Feldt-Rasm ussen et al, 1987).

The mechanism could be that insulin

activates sodium -potassium -adenosine triphosphatase activity in the distal tubules of the
kidney (Skott et al, 1989) and thus elevates plasma levels of noradrenaline and hence the
sympathetic tone (Feldt-Rasm ussen et al, 1987).

In the pathogenesis of hypertension,

impaired vasoconstriction due to imbalance of vasoactive substances and / or raised
cytosolicCa2+ and / or a structural vasculopathy is thought to be an important causative
event.

Insulin resistance in certain trans-m em branous cation exchange systems may

increasecytosolicCa2+ (W eidm ann et al, 1993).

Another possible mechanism for raised blood pressure in hyperinsulinémie subjects may
be based on som e alteration in their sm ooth muscle cells. Intracellular sodium content is
increased in erythrocytes from hypertensive patients. If this also occurs in their smooth
muscle cells, it may cause narrow ing o f the lumen of small arteries and therefore explain
the peripheral resistance existed in hypertensive patients (Beck-Nielson et al, 1990).
Figure 5-2 schematically shows the possible mechanisms for raised blood pressure in the
insulin resistance state (M eehan et al, 1993).
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Figure 5-2 The insulin resistance-hyperinsulinemia-hypertension hypothesis (Adapted
fro m M eehan et al, 1993).

Nevertheless, the role of insulin in the pathogenesis of hypertension is controversial. The
relation between hyperinsulinemia and blood pressure is not invariable. It is possible that
insulin play a role in concert with other factors in the development of essential
hypertension (Meehan et al, 1993) or insulin resistance may be due to other factors such
as obesity.
Grunfeld and colleagues have found that hyperinsulinemia precedes the onset of clinical
hypertension in a population of genetically hypertension-prone subjects such as children
of at least one essential hypertensive parent (Ferrari et al, 1991, Grunfeld et al, 1994).

In the present investigation, simple linear regression showed a significant and positive
relationship between systolic blood pressure and insulin but not between diastolic blood
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pressure and insulin. However, multiple linear regression indicated that BMI and the
plasma NEFA level are two strong contributors of the variance of both systolic and
diastolic blood pressure. As a result B M I and hyperlipidemia and perhaps other factors
may cause insulin resistance and insulin resistance could be the precursor mechanisms for
other factors in Figure 5-2

A possible explanation for finding B M I as a strong predictor of hypertension (both
systolic and diastolic ) can be found in the San Antonio Heart Study which showed that
insulin was a risk factor for hypertension predominantly in a lean group, with increasing
risk associated with rising plasma insulin level. However, no such association was seen
in an obese group. Conceivably, hypertension is heterogeneous and insulin plays a role
in its development only in lean individuals (Stem , 1983). In our study, GDM subjects
had significantly greater BMI and body fat % than controls.
From the frequently noted relation between diabetes mellitus, obesity, and hypertension,
the following pathogenic inter-relationships may be proposed (Figure 5-3) (Weidmann et
al, 1993).
Several possible mechanisms may be involved in raised blood pressure in obesity,
including an increased sympathetic tone, hyperaldosteronism, enhanced blood pressure
sensitivity to salt intake, increased cardiac output due to hypervolemia, and also an
increased in cystosolic free calcium (Ca2+) and decreased magnesium (M g'+) levels
(Weidmann et al, 1993 b).
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♦
Different factors

Figure 5-3 Inter-relationship between (predisposition to) hypertension, excess weight
and metabolic disturbances (Weidmann et al, 1993.a)
Most studies of insulin resistance have concentrated on the regulation of glucose
metabolism by insulin. A few researchers have reported impaired fatty acid regulation in
the insulin resistance state (Fraze et al, 1986, Swislocki et al, 1987).- Plasma NEFA and
TG concentrations were higher and HDL-C lower in a hypertensive group than a
normotensive group (Pollare et al, 1990).
Singer et al (1985) have reported that 24-hour metabolic profiles of patients with
hypertension suggested that insulin, glucose, and NEFA concentrations were increased,
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suggesting an impaired sensitivity to insulin for both glucose homeostasis and
antilipolysis.

Furthermore, Swislocki and Tsuzuki have reported that the serum FFA (NEFA) level is
elevated both in the fasting state and in response to feeding in the spontaneously
hypertensive rat (SHR) and they have suggested that this interesting finding is another
potential locus of insulin resistance in hypertension (Swislocki and Tsuzuki, 1993). It
may be a model for the relationship between NEFA and blood pressure in the present
study.
An important link existsbetween obesity, NIDDM, and hypertension. Hypertension is
understood to contribute to the increased cardiovascular morbidity and mortality in
patients with obesity and NIDDM (Daly and Landsberg, 1991).
Hypertension in obese individuals with or without NIDDM is clearly related to
hyperinsulinemia and hyperinsulinemia excites sympathetic nervous system (SNS)
activity.

Both hyperinsulinemia and increased SNS activity cause decreased sodium

excretion, thus elevating blood pressure (Daly and Landsberg, 1991). This is an possible
explanation for raised blood pressure in women with previous GDM.
In conclusion, based on the present information, it may be said that there are several
possible explanation for the relationship between insulin resistance or hyperinsulinemia
and hypertension.
Firstly, insulin resistance and hypertension may be causally independent but have a
common underlying mechanism, such as altered cellular electrolyte metabolism,
increased vascular resistance or decreased capacity to vasodilate (especially in skeletal
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muscles), increased sympathetic nervous system activity and, once it occurs, obesity
(Weidmann et al, 1993). It may be an explanation for our finding.

Secondly, insulin resistance may occur as a secondary modification during the
development of hypertension, not affecting its pathogenesis. Insulin resistance and / or
hyperinsulinemia, regardless of their underlying mechanism and time of occurrence, may
cause or worsen hypertension (Weidmann et al, 1993).

5.9 Microalbuminuria in Women with Previous GDM One Year after Delivery
GDM subjects exhibit a significant microalbuminuria compared to controls based upon
spot urine.
Arterial hypertension causes increased UAER. The possible mechanism for this effect is
thought an increase in hydrostatic pressure in the glomerular capillaries or a change in
permeability in the glomerular basement membrane (Parving et al, 1974, Ljungman,
1990).
Several investigations have suggested that microalbuminuria is strongly related to
increased cardiovascular disease risk (Haffner et al, 1990 a, Winocour et al, 1992) and
predicts increased mortality rate (Yudkin et al, 1988, Damsgaard et al, 1990).

Ross

hypothesised that increased UAER is a marker of endothelial dysfunction, including
increased trans-endothelial permeability of different macromolecules such as albumin
(Ross, 1986). According to the ‘response-to-injury’ hypothesis, endothelial dysfunction
is one of the early steprin the atherogenesis process (Ross, 1986).
We found a negative correlation between microalbuminuria and age and it confirms the
results reported by Watts et al (1988). The underlying mechanism is not clear.
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Microalbuminuria was also related to fasting insulin concentration and insulin / glucose
ratio (as a m arker of insulin resistance) in women with previous GDM. This association
between microalbuminuria and insulin resistance was reported previously by Nosadini et
al (1992) in NIDDM or essential hypertension patients with microalbuminuria.

In this study, there is a positive and significant correlation between BMI and
microalbuminuria in GDM subjects.

Hasslacher et al (1993) also have reported a

correlation between BMI and decline of kidney function in proteinuric NIDDM patients.
Subjects with microalbuminuria have higher arterial pressure than diabetic patients
without microalbuminuria (Feldt-Rasmussen et al, 1982).

We also found that

microalbuminuric

blood

GDM

patients

have

a

higher

systolic

pressure

than

normoalbuminuric GDM patients.
Approximately 75% of IDDM patients with nephropathy are hypertensive and 25% of
them could be normotensive.

It is thought that serious morphologic injury might be

independent of hypertension in IDDM patients (Sherman and Gosking, 1988, Mauer et
al, 1992).

_

In animal models of IDDM, increased glomerular capillary pressure generally precedes
the development of both systemic hypertension and microalbuminuria.

There are no

comparable data on NIDDM patients. Thus, increased arterial pressure may not be a
causal factor but rather the process that provokes a different underlying process (Abott
et al, 1994).
Recently, microalbuminuria was reported to be associated with hyperinsulinemia in non
diabetic subjects (Haffner et al, 1990 a).

Our study showed an association between
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microalbuminuria and increased fasting insulin level in subjects with past medical history
of GDM.

The microalbuminuric GDM subjects had significantly elevated plasma cholesterol than
normoalbuminuric subjects. Metacalf et al (1992) recently reported the same finding in
non-diabetic subjects.

Moreover, the microalbuminuric group demonstrated higher plasma TG levels than the
normoalbuminuric group, it confirming W oo’s report (Woo et al, 1992).

In the present

study, microalbuminuric GDM patients had significantly higher concentrations of VLDLC and VLDL-TG than normoalbuminuric GDM patients.
Jones et al have reported higher concentration of VLDL-C in EDDM patients and they
believe prolonged exposure to dyslipidemia and blood pressure and other risk factors
may result the increased risk of coronary heart disease (Jones et al, 1989). The reasons
for the apparent effect of hyperlipidemia on kidney function are not fully known.
Animal experiments indicate an increased uptake of lipoproteins by ‘mesangial’ and
‘epithelial’ cells

of the

glomerulus

are

a

cause

of the

negative

effect

of

hyperlipoproteinemia on kindney function (Wassermann et al, 1989, Kasiske et al, 1990,
Grone et al, 1990, Raner et al, 1990). Secondary to increased uptake of lipoproteins by
mesangial and epithelial cells, proliferation of mesangial cells and increased production of
mesangial matrix occurs.

This promotes the development of glomerulosclerosis

(Hasslacher et al, 1993).
Several investigations were performed on humans to study the effect of treatment of
hypercholesterolemia with HMG-CoA reductase inhibitors on proteinuria. Rabelmk et al
(1990) reported a decrease in protein secretion in nephrotic syndrome patients treated by
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simvastatin. However, Hommel et al (1992) reported no difference in plasma lipoprotein
and renal function during simvastatin treatment in diabetic nephropathy.

Further

experiments are necessary to clarify this.

Factor VII was significantly and positively related to microalbuminuria in the GDM
group. A significant positive correlation was found between urinary albumin excretion
rate and factor VII, by us and by Knobl et al (1993).

It may suggest that

microalbuminuria might be the expression of vascular endothelial damage associated with
a hypofibrinolytic and hypercoagulative circumstance (Gruden et al, 1994).
In the present study, fasting insulin level presents a significandy contribution in a multiple
regression model to the development of microalbuminuria in the GDM group. In this
study, our finding is similar to that of W inocour et al (1992).

Nosadini et al have

suggested that extrahepatic defects in insulin sensitivity seem to precede the development
of hypertension and microalbuminuria in NIDDM patients (Nosadini et al, 1994).
It may be hypothesised that the relationship between hyperinsulinemia as a causal factor
and microalbuminuria indicate microalbuminuria as part of the pre-diabetic state.
Subsequently, hyperinsulinemia and insulin resistance are the strong predictors of the
development of NIDDM (Bogardus et al, 1987, Saad et al, 1988). Also, raised blood
pressure and dyslipidemia precede the onset of diabetes (McPhillips et al, 1990, Medalie
et al, 1975).
The exact mechanism involved in the role of insulin in microalbuminuria is not
completely clear. Nestler et al have reported that transcapillary escape rate of albumin is
increased in non-diabetic men in response to marked pharmacological hyperinsulinemia
(Nestier et al, 1990).

Another possible mechanism behind hyperinsulinemia and
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microalbuminuria was suggested by Niskanen and Laakso (1993). They suggested that
impaired insulin action or hyperinsulinemia at the kidney level could lead intra
glomerular pathology and subsequent albuminuria.

Animal and human studies in renal disease other than diabetic nephropathy have shown
that dietary sodium intake influences

urinary albumin excretion rate (Donson et al,

1989, Tuck et al, 1990, Lax et al, 1992). Insulin

influences

renal sodium handling,

which causes the sodium retention in diabetic patients (DeFronzo et al, 1992). Sodium
intake did not show a significant correlation with microalbuminuria in this study.
The existence of microalbuminuria in non-diabetic subjects indicates that hyperglycaemia
cannot be an essential condition for its development.

The relationship between

microalbuminuria and ischaemic heart disease in both diabetic and non-diabetic subjects
propose that a similar, non-glucose related mechanism underlies this relationship in both
groups, with the role of hyperglycaemia only to increase renal protein loss and thus
progression of glomerulosclerosis to renal failure (Yudkin, 1993).
Haffner et al (1993 a) suggested that microalbuminuria may be a feature of the pre
diabetic state. This may also be the case in this population of women with history of
GDM, but follow up studies will be required to see if this is the case
Based on Stiegler’s suggestion, increased albuminuria may be a marker of early and
accelerated atherosclerosis (Stiegler, 1993).
Microalbuminuria is correlated to a hypercoagulative and hypofibrinolytic state.
Haemostatic dysfunctions could be a pathogenic link between microalbuminuria and
cardiovascular disease (Gruden et al, 1994).
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5.10 Coagulopathy in Women with Previous GDM One Year after Delivery
Numerous studies have suggested that coagulation disorders in diabetic patients, which
seem to be caused by hyperglycaemia (Ceriello, 1993), give rise to a thrombotic
tendency.

High levels of plasma fibrinogen (Coller et al, 1978, Ganda and Arkin, 1992), factor VII
(Ceriello et al, 1988), factor VIII, vW F (Osterman and Va-deLoo, 1986), factor X
antigen and low activity of factor X in plasma (Ceriello et al, 1990) have been reported
in diabetic patients and thought be due to hyperglycaemia.
The figure 5-5 shows the pathway linking hyperglycaemia and a tendency to thrombosis
in diabetic patients.

Hyperglycaemia may influence thrombosis by two mechanisms;

either by a mechanism connected with non-enzymatic glycation or by an increased
oxidative reaction (Ceriello, 1993).
Hyperfibrinogenemia was correlated with body fat % and BMI in the GDM group. A
similar result was found by Cigolini et al (1994). In addition, dietary fibre intake showed
an independent and negative correlation with fibrinogen in GDM subjects.
mechanism of this association is unclear.

The
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Figure 5-4 Pathway linking hyperglycaemia and thrombosis in diabetes mellitus.
(+ = increased and - = decreased, Adapted from Ceriello, 1993)

Oral contraceptive use has been shown by Meade et al (1979) to be associated with
raised plasma fibrinogen levels and fibrinolytic activity, whereas in our study, there was
no significant correlation between oral contraceptives and fibrinogen.
Factor Vile levels were related positively to BMI in GDM subjects.

The same

relationship was reported previously by Meade et al (1987) in subjects who had given up
smoking. In addition, Factor V ile also demonstrated significant correlations with lipid
and lipoproteins such as plasma cholesterol, TG concentrations, VLDL-TG, IDL-C, and
IDL-TG. The mechanism for these correlations is not clear.
In conclusion, in the present investigation, there were no significant haematologic
abnormalities in the GDM subjects compared with controls.
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Statistical analysis using simple regression indicates that abnormalities in the coagulation
system are correlated with aspects of lipid and carbohydrate metabolisms in the GDM
subjects.

5.11 Dietary Habits in Women with Previous GDM One Year after Delivery
GDM subjects had significantly higher PUFA and apoE intake in comparison with
controls.
Mensink and Katan (1992) have proposed that dietary fatty acids are not the sole or even
most important determinant of serum lipid concentrations.

Age, genetic background,

and degree of obesity are stronger determinants.
In our study, total energy and all macronutrients (fat, carbohydrates, and proteins) intake
were associated with WHR as a marker of obesity particularly central obesity (p < 0.001
for total energy, fat and carbohydrate intake and p < 0.01 for protein intake). Studies
indicated that weight gain resulting in obesity occurs when energy intake chronically
exceeds energy expenditure (Jequier and Schütz, 1983, Woo et al, 1985, Prentice et al,
1986).
Dietary cholesterol intake did not represent an association with plasma cholesterol in this
study. Several studies reported no linear relationship between dietary cholesterol intake
and total cholesterol levels (Shekelle et al, 1981, Katan et al, 1988), whereas others
report a positive correlation between those two (Lamon-Fava et al, 1994).
Our data demonstrated the negative correlation of dietary fibre intake and total
cholesterol, apoB, LDL-C, blood pressure, BMI and body fat %. Rouse et al (1983)
reported that both systolic and diastolic blood pressure were lower in a vegetarian
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The major differences in dietary intake

between two groups were that the vegetarian population had a higher intake of
polyunsaturated fat, fibre, potassium, magnesium, and calcium and less protein and
saturated fat intake.

In addition, other investigators have reported a negative correlation between increased
fibre from fruit and vegetables and blood pressure (Kestin et al, 1989). Our findings are
consistent with this result.
Soluble dietary fibre such as pectin and oat-bran increases faecal bile-acid excretion and
often the excretion of other faecal steroids, causing increased concentrations of hepatic
lipoprotein B/E receptors. As a result, circulating cholesterol ester-rich lipoproteins are
removed more rapidly (Williams et al, 1986), resulting in decreased plasma total
cholesterol. This is an explanation for the negative correlation between fibre intake and
total plasma cholesterol.
Dietary fibre intake was shown as an independent variable in simple regression analysis
for BMI. The mechanism by which dietary fibre influences obesity are thought to be due
to its physiological effects. Dietary fibre fills the stomach and provides a sense of satiety,
normalizes intestinal transit time, delay gastric emptying and slow the rate of digestion
and absorption of nutrients (Mahan and Arlin, 1992).
In addition, dietary fibre intake was negatively correlated with plasma fibrinogen level
and factor Vile. The mechanisms of this associations (if confirmed) are unclear.
Subjects with > 53% of energy intake as carbohydrates in their diet exhibited
significandy lower HDL-C and apoA-I levels than did subjects with lower carbohydrate
intake (Lamon-Fava et al, 1994). In the present study, subjects had ~ 45% of energy
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intake as carbohydrate. W e found a negative correlation between carbohydrate intake
and plasma total cholesterol, apoB, LDL-C, and CETP activity in plasma in GDM
subjects, and perhaps this was because of their relatively low carbohydrate and high fat
intake.

There were positive correlations between all types of energy intake (fatty acids, protein,
and carbohydrate) and markers of obesity. It is generally accepted that all sources of
energy can be stored as adipose tissue in the body.

Micronutrients are the small quantities of vitamins and minerals that play highly specific
roles in facilitating energy transfer. Vitamins contain no useful energy for the body, but
generally serve as essential links to help regulate the chain of metabolic reactions that
facilitate the release of energy bound in the food molecules and control the process of
tissue synthesis (McArdle et al, 1991 c).

The GDM subjects included significantly

greater quantity of vitamin E in their diet. It is difficult to relate this finding to NIDDM
and it m ay be a chance effect.

There was a suggestion that the intake of green leafy vegetables was lower in the insulin
resistant group of people who had had GDM than in others. W hether this observation is
a result of chance or whether it reflects reality is notclear. Nevertheless, it seems clear
that those women who are overweight and who have insulin resistance are not following
current dietary recommendations.

It may be said that the first step to improve the metabolic abnormalities in the GDM or
NIDDM subjects who are overweight or obese is weight reduction. The weight loss is
an effective tool in improving abnormalities in both carbohydrate and lipid metabolism in
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A high carbohydrate, low-fat diet such as the Mediterranean diet, is

correlated with a reduced risk of CHD (Keys et al, 1986).
The reduction in risk of CHD probably is due to contribution in lipid and lipoprotein
metabolism by these diets. A W HO study group has suggested that less than 30% of
food energy should be provided by fat and no more than 10% of energy from saturated
fat.

5.12 Alcohol Consumption in Women with Previous GDM One Year after Delivery
The significant correlation between alcohol intake and apo A-I and HDL-C levels has
previously been observed by other researchers, but this is the first report in a GDM
population.
Many studies have observed that alcohol use raised HDL-C both in males (Hubert et al,
1987, Contaldo et al, 1989, Linn et al, 1989) and in females (Linn et al, 1989, Hubert et
al, 1987, Bush et al, 1988). The positive correlation between alcohol use and plasma
apo A-I which we found is consistent with other investigators’ findings (Camargo et al,
1985, Moore et al, 1988). Alcohol-related HDL-C elevations may be due to increased
hepatic apo A-I production (Okamoto et al, 1988).
The mechanism by which ethanol influences HDL concentration remains unknown.
The mechanisms underlying the effect of ethanol on FFA is complex. The effects may
occur through several mechanisms.
(1) Increased mobilization of peripheral fat. These actions are depends on the dose of
alcohol intake and the dietary factors.
(2) Decreased hepatic fatty acid oxidation.
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(3) Increased hepatic fatty acid production.

(4) Increased formation of fatty acyl esters.

A clinical study, using some makers of

lipolysis, showed an increase of hepatic FFAs with progression of alcoholic liver injury.
Usually the free fatty acids are bound to the fatty acyl binding protein (FABP) and this
protein increase by ethanol use.

Increased formation of fatty acyl esters tends to

counteract the accumulation of free fatty acids (Lieber and Pignon, 1989).

5.13 Smoking in Women with Previous GDM One Year after Delivery
In the present study, smoking was not

correlated with plasma HDL concentration.

Subjects were not heavy smokers.
Current smoking was correlated with increased plasma TG, IDL-TG, IDL-FC, and
NEFA concentrations in our investigation. Steiner et al (1987) reported that the men
who currently smoked had higher levels of IDL-apoB and of IDL-TG in comparison
with men who never smoked or had not smoked for at least 2 years.
It has previously been postulated that smoking may play a role in the development of
atherosclerosis and it may be through elevated VLDL remnants levels due to smoking
(Topping and Turner, 1975, Topping et al, 1977).

Other investigators reported a

correlation between TG and smoking (Simons et al, 1984, Cowan et al, 1985).

Our

findings support all previous findings
Smoking was associated independently with plasma insulin levels (corrected for age,
BMI, use of contraceptive pill, etc) in GDM subjects.

The influence of smoking on

insulin sensitivity was first studied by Helve et al (1986). They suggested that smoking
has a negative effect on insulin sensitivity. Facchini et al (1992) have reported that non
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diabetic smokers are more insulin resistant, hyperinsulinémie, and dyslipidémie than non
diabetic non-smokers. Attval et al (1993) have found that smoking results in impaired
insulin action mainly due to decreased peripheral glucose uptake. This results support
the Facchini et al study.

Some studies have revealed that glycaemic control is worse among diabetic patients who
smoke than diabetic patients who do not smoke (Lundman et al, 1990, Bott et al, 1994).
Cigarette smoking has been identified as a risk factor for diabetic nephropathy
(Muhlhauser et al, 1986, Stegmayr and Lithner, 1987).
Heavy smoking (a packet or more per day) increases the risk of diabetes (NIDDM) in
women (Rimm et al, 1993), it has also been associated with higher H bA lc levels among
subjects with normal glucose tolerance (Modan et al, 1988).
The mechanism for any changes in lipids and lipoproteins by smoking is uncertain

5.14 Physical Activity in Women with Previous GDM One Year after
Delivery
Physical activity was related to plasma insulin levels and WHR in this study. Regular
physical activity improves glucose tolerance and may induces weight loss (Rauramaa,
1984) and increases insulin sensitivity (Soman et al, 1979). In addition, short periods of
exercise can increase plasma glucose concentrations by increasing peripheral and
splanchnic insulin sensitivity (Delvin et al, 1987).
Both cross-sectional and prospective studies have suggested an increase in the HDL-C
following exercise training especially after aerobic exercise (McCrory et al, 1994).
There is no significant correlation between HDL-C and exercise in our study.

This
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discrepancy might be due to a dose response relation between the amount of habitual
exercise and HDL-C elevation (Lakka and Salonen, 1992). It may be said the GDM
subjects should exercise more to achieve the beneficial metabolic effects of exercise, or it
is due to sample size.
The significant correlations between exercise and CETP activity, plasma apoA-I, VLDLTG, and NEFA may support the beneficial influence of exercise on lipoprotein
metabolism
The significant correlation between exercise and CETP activity indicates that exercise is
associated with an increase in reverse cholesterol transport (Gupta et al, 1993).
There was a significant and negative correlation between exercise and WHR. Horton
and Geissler (1994) have found that habitual exercise leads to increases daily energy
expenditure by 8-14% and increase lean body mass (and results loss of body fat and thus
WHR). Alternatively, fat persons might not like to take exercise, resulting in increased
obesity.

.

Long et al (1994) have suggested that weight loss in patients with clinically severe
obesity prevents the progression of impaired glucose tolerance to NIDDM by > 30-fold.
Both frequency and intensity of exercise were related to systolic blood pressure in GDM
subjects. Systolic blood pressure increases in proportion to oxygen consumption and
cardiac output during physical activity, whereas diastolic blood pressure remains
relatively unchanged or slightly increased. Following exercise blood pressure falls below
pre-exercise levels, and may remain lower for several hours (McArdle et al, 1991 b).
Physical activity is an effective, non-dietary, non-pharmacological option for the
management of mild hypertension. Physical activity produced average falls in blood
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pressure of 11 mmHg systolic and 6 mmHg diastolic respectively in reported series of
hypertensive patients subjected to various forms of isotonic exercise such as walking,
running, cycling, swimming and cross-country skiing (Stokes, 1992).
The beneficial effects of physical activity on serum lipids seem to be mediated partially by
a decreased serum insulin level and body adiposity (Lakka and Salonen, 1992).
In addition, regular physical activity is effective in preventing NIDDM, and the
protective benefit is particularly pronounced in subjects at the highest risk for developing
NIDDM (Helmrich et al, 1991).
Results from subgroups analysis showed that the GDM subjects who had positive family
history of diabetes mellitus, high plasma NEFA concentrations, and were overweight or
obese (BMI > 25 kg / m2) (subgroup A) had several metabolic abnormalities compared
with the residual GDM group and controls.
Subgroup A of the GDM group (those who are overweight, have high plasma NEFA
concentrations, and a positive family history of diabetes mellitus) tended to be
hyperinsulinémie and hyperlipidémie (significantly higher plasma TG, VLDL-TG, and
IDL-C concentrations) compared with the residual GDM group.
Subgroup A also tended to be more hyperinsulinémie, hyperlipidémie (significantly
higher plasma cholesterol, TG, apoB, VLDL-TG, IDL-C, and LDL-C concentrations,
and greater CETP activity in plasma) compared with controls.
The GDM subjects who had positive family history of diabetes and high plasma levels of
NEFA but not overweight (BMI < 25 kg / m2) (subgroup B) tended to have better
metabolic status than the residual GDM group and similar to controls.
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Subgroup B tended to have less insulin resistance (lower fasting insulin concentrations)
than the residual GDM group but similar to the residual controls.

In addition, subgroup B tended to have significantly lower lipids and lipoprotein
concentrations (plasma cholesterol, TG, VLDL-TG, and IDL-C concentrations) than the
residual GDM group but similar to the residual controls.

The subgroup B also had significantly lower BMI and WHR than the residual GDM, but
similar to the residual controls.

As a result, a comparison of subgroup A and B suggests that being overweight or obese
is an important factor in developing metabolic disorders in women who have positive
family history of diabetes mellitus.

CHAPTER SIX
CONCLUSION

6.1 Background
The purpose of our investigation was to test the hypothesis that certain factors are
altered in patients who have been diagnosed with GDM compared with controls.
Identification, treatment, and follow-up o f wom en with GDM are very im portant because
GDM subjects are at the risk of adverse maternal, fetal, and neonatal outcomes.
Subjects who have had GDM are at a high risk of later development of NIDDM.
The present study showed that the GDM subjects (ie subjects who had had GDM in thenlast pregnancy one year previously) were m ore overweight or obese than controls. The
GDM subjects had a family history of diabetes mellitus in first and second degree of
relatives, particularly in the maternal side.
Obesity like NIDDM is commonly characterized by insulin resistance with increased
plasma N EFA concentrations. Distribution o f excessive fat on the upper body segment
or abdomen, as measured by W HR is correlated with decreased insulin sensitivity and
increased risk for developing diabetes (Park, 1993).
The links between insulin resistance and obesity might be multifactorial and bi
directional. Insulin resistance may precede the obesity or insulin resistance may be due
to obesity (Park, 1993).
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NEFA may have an important role in the metabolic influence of obesity. Plasma NEFA
concentration is elevated and fatty acid turnover rate is increased in obesity, and these
abnormalities are more pronounced in upper body obesity than lower body obesity
(Jensen et al, 1989).
Increased NEFA concentrations result in increased fatty acid oxidation, and this may lead
to decreased glucose oxidation and thus decreased glycogen synthetase activity.
Decreased glycogen synthetase activity associates result in development of insulin
resistance in both liver and muscle.

Therefore, increased availability of NEFA is an

important link between insulin resistance and obesity (Park, 1993).
Upper body obesity is associated with large fat cells which in turn tend to be insulin
resistant.

Fat localization (upper body or central) is related to increased activity of

androgens, as manifest by lower SHBG and higher free testosterone. In turn, increased
activity of androgens is also associated with increasing WHR, increasing plasma glucose
and insulin concentrations in both fasting and in response to oral glucose challenge, and
decreased insulin sensitivity in obese pre-menopausal women (Evans et al, 1983).
Low SHBG and high testosterone concentration are caused by abdominal obesity (Evans
et al, 1983). In the present study, BMI was independently correlated with SHBG levels
in multiple regression analysis. In addition, low serum SHBG level has been suggested
as strong independent risk factor for the development of NIDDM in women (Lindstedt et
al, 1991).
The GDM subjects were overweight or obese, had family history of diabetes, high
plasma NEFA concentration, and low SHBG level. As a result, the GDM subjects were
more likely to have hyperinsulinemia and insulin resistance. The GDM subjects exhibited
higher plasma insulin levels than controls.
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Evidence suggests that insulin resistance and hyperinsulinemia may continue for many
years in a compensated state with normal glucose tolerance. It appears likely that many
of the metabolic disorders associated with insulin resistance have their onset during this
compensated state, long before glucose intolerance or frank diabetes.
Thus, insulin resistance may help explain the metabolic disorders often observed in
obesity and NIDDM, including dyslipidemia, hypertension, and atherosclerosis (Williams
et al, 1994). The present study suggests that insulin resistance secondary to obesity and
a family history of diabetes may be cause of dyslipidemia, raised blood pressure,
microalbuminuria, and impaired glucose tolerance and NIDDM in women with history of
GDM (Figure 6-1).

Figure 6-1 Hypothetical model based on the present study (DM - diabetes mellitus)
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6.2 Insulin Resistance, Dyslipidemia, and ‘GDM’

Increased availability of FFA is an important link between insulin resistance and obesity.
The possible mechanism for hyperlipoproteinemia and its related abnormalities found
with insulin resistant

might be that hyperlipoproteinemia may be caused by enhanced

FFAs flux on the insulin-resistance liver, perhaps resulting from central obesity (Park,
1993).

Most causes of insulin resistance including diet, central obesity, and physical activity
result in increased flux of FFAs and (probably) glucose to the liver.

Cambien et al

(1987) reported that hyperinsulinemia insulin is associated with elevated VLDL-TG
concentrations positively and decreased HDL-C concentration. This appears to be a
consistent relationship between hyperinsulinemia and hypertriglyceridemia in healthy,
normal-weight subjects (Zavaroni et al, 1989). The possible underlying mechanism is
outlined in Figure 6-2.

Incubation of cell lines with VLDL causes insulin resistance due to either a decrease in
insulin receptors or a post-binding defect (Hunt et al, 1989).

Thus, it seems insulin

resistance promotes dyslipidemia and dyslipidemia may induce insulin resistance.

W inocour et al (1992) have found that hyperinsulinemia is associated with a higher TG /
apoB ratio and lower HDL-C / apoA-I ratio after adjustment for BM I in women.
Despite a higher apoA-I and HDL synthetic rate in NIDDM patients than controls,
plasma HDL-C is reduced in NIDDM patients because of an increased apoA-I and HDL
fractional clearance rate (Golay et al, 1987).
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LDL is synthesized from hepatic-derived VLDL. DDL particles are produced during the
conversion of VLDL to LDL, and IDL particles are thought to be atherogenic
((Nordestgaard and Tybjaerg-Hassan, 1992).

Impaired LPL activity can reduce VLDL removal and therefore indirectly influence the
flux of material to HDL particles. Additionally, insulin resistance might inhibit CETP or
LCAT activity. Alterations in the lipolytic cascade may cause more dense LDL particles
(Howard, 1993).

From the results of this study, it may be concluded that the GDM subjects who have a
positive family history of diabetes and also are overweight or obese exhibit
hyperinsulinemia (as a compensatory response to the insulin resistance), resulting in
dyslipidemia in this population.

Dyslipidemia in the GDM subjects is characterized by hypertriglyceridemia and high
plasma concentrations of VLDL-TG, high plasma total cholesterol, IDL-C, and LDL-C
levels, slightly lower HDL-C, higher CETP activity in plasma, and smaller and denser
LDL and HDL3 particles. There is abundant evidence that hyperinsulinemia and insulin
resistance appear to be associated with frequency of atherosclerosis (Stout, 1993).
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Figure 6-2 Insulin resistance and lipoprotein abnormalities
(data from Howard, 1993, Hunt et al, 1989)

Chapter Six

Conclusion

203

6.3 Insulin Resistance, Raised Blood Pressure, and <GDM>
It has been recognized for many years that hypertension is common in people who are
obese (Havlik et al, 1983, M odan et al, 1985) and those who have NIDDM (Modan et
al, 1985, Turner, 1985). On the other hand, exercise (Maiorano et al, 1989) and weight
loss (MacMahon et al, 1985) has been reported to be effective in lowering the blood
pressure in obese and diabetic patients by improving insulin sensitivity.
DeFronzo (1982) has reported that improvement of insulin sensitivity, resulting in lower
plasma insulin concentration is correlated with a reduction in both systolic and diastolic
blood pressure in ono-diabetic obese patients.

Thus, it might be said that insulin

resistance per se, or through compensated hyperinsulinemia, results in raised systolic and
diastolic blood pressure (Manicardi et al, 1986).
Studies have proposed that hyperinsulinemia and / or insulin resistance assist sodium
retention, which plays a n important role in the development of hypertension. Sodium
retention in turn, results in w ater reabsorption in the kidney tubules (Sharma et al, 1991,
DeFronzo, 1981, Kolanowski, 1981).
Hyperinsulinemia may lead to the development of hypertension through activation of the
sympathetic nervous system (O’D ea et al, 1982, Sowers et al, 1982).
The possible mechanisms underlying raised blood pressure in the GDM subjects are
summarized in Figure 6-3.
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Figure 6-3 Relationship between insulin resistance, hyperinsulinemia, sympathetic
nervous system activity, and hypertension.
(CNS = central nervous system, DeFronzo and Ferrannini, 1991)

6.4 Insulin Resistance, Microalbuminuria, and ‘GDM’
It is thought that there is link between microalbuminuria and insulin resistance.
Angiotensin converting enzyme inhibitor agents such as captopril cause an increase in
insulin sensitivity (Pollare et al, 1989) and use of these drugs decreases microalbuminuria
irrespective of their antihypertensive effects (Parving et al, 1989).

Conclusion
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that there is an association between

microalbuminuria and a number of cardiovascular risk factors such as hyperinsulinemia,
hypertension, and hypertriglyceridemia in non-diabetic subjects.
Nestler et al (1990) have reported an increased trans-capillary escape of albumin in non
diabetic subjects.

It may be a possible link between microalbuminuria and

hyperinsulinemia. Insulin resistance and or hyperinsulinemia at kidney level may result in
intraglomerular pathology and subsequent albuminuria (Niskanen and Laasko, (1993).
In our study, microalbuminuria was correlated with plasma insulin concentration.

6.5 Insulin Resistance, IGT, NIDDM, and ‘GDM’
The pathogenesis of NIDDM can be divided into four phases: genetic susceptibility,
insulin resistance, IGT, and NIDDM itself (Bennett et al, 1988).

Figure 6-4

demonstrates briefly the pathogenesis of NIDDM.
People who have had GDM with a positive family history of diabetes mellitus have a
genetic or inherited susceptibility to NIDDM. In addition, they are significantly fatter
and hyperinsulinémie than controls in the present investigation.
Defects in insulin action may be exist in some subjects years before the onset of overt
diabetes mellitus. Impaired insulin action is present in individuals at risk for developing
NIDDM (pre-diabetic), including relatives of NIDDM patients, people with impaired
glucose tolerance, and in ethnic populations with a high prevalence of NIDDM such as
Pima Indians (Alzaid and Rizza, 1993).
As a result, we may say that women with previous GDM are likely to develop NIDDM
later and hyperinsulinemia is its hallmark.
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Several lines of evidence suggest that those who develop overt NIDDM may at first
manifest only insulin resistance. Acquired factors such as obesity and inactivity may be
additive (Seely and Olefsky, 1993).

Compensated Insulin
Resistance
(Normal or Impaired
Glucose Tolerance)

Figure 6-4 Proposed etiology fo r the development o f NIDDM (adapted from Seely and
Olefsky, 1993)
Impaired glucose tolerance (IGT) is a phase occurring after the insulin resistance phase
and before overt NIDDM (WHO, 1985). IGT subjects represent a greater degree of
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insulin resistance compared with subjects with normal glucose tolerance. Among IGT
subjects those with the greater insulin resistance are most likely to develop overt
NIDDM (Bennett et al, 1988).
NIDDM in obese subjects seems to be the end result of a series of changes that occur
over many years that culminate in the failure to maintain glucose homostasis (Bennett,
1988).
The proposed pathogenic mechanisms for NIDDM include a primary defect relating to
the development of insulin resistance and a secondary defect relating to pancreatic insulin
secretory failure (Bennett, 1988).
It seems NIDDM can be delayed or even prevented if somehow the pancreas could be
protected from failure.

It seems likely this may be achieved by diminishing insulin

resistance. W eight loss in obese and overweight subjects, regular exercise, a healthy diet
with low saturated fat and adequate fruit and vegetables, stopping smoking, and
correction of the medical problems can reduce the degree of insulin resistance degree
and may delay or prevent NIDDM in GDM subjects.
In conclusion, this study revealed that women with previous GDM are more likely to
have a family history of diabetes mellitus and be fatter than controls, resulting in
hyperinsulinemia.
hyperandrogenicity

Obesity
and

these

causes

higher

abnormalities

plasma
may

NEFA

cause

concentration

insulin

resistance

and
and

hyperinsulinemia. The GDM subjects demonstrated a cluster of abnormalities related to
insulin resistance and hyperinsulinemia including dyslipidemia (high cholesterol, TG,
VLDL-TG, IDL-C, and LDL concentrations, sm aller and denser LDL, and greater CETP
activity in plasma), raised blood pressure, and microalbuminuria.
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Recommendations for Future Research
This study has investigated the m etabolic abnorm alities in subjects with previous G D M
(post-G D M ) one year after delivery. In light o f this study, there are several areas in
which future research could be conducted:
The major areas o f interest will be to determine the crucial factors determining the
developm ent o f diabetes in these women who have demonstrated a predisposition to
diabetes, and determining ways in which this slide into diabetes could be arrested.
Two particular study areas are suggested by the work described in this thesis:
* Subgroup analysis showed that being overweight appears to be a very im portant
factor in the developm ent o f m etabolic disorders in the GDM group. A study based on
weight reduction in both post-G D M women and also in women who are at risk o f
developm ent o f GDM (women w ho have a positive family history o f diabetes and high
plasma N E FA concentrations) may show that the abnormalities associated with the
insulin resistance syndrome can be reversed.
* A nother intervention study may examine the effects o f a low fat-high fibre diet and
enough exercise in the post-G D M subjects. A low fat-high fibre diet (more fruit and
vegetable consum ption) and physical activity may induce more insulin sensitivity and
thus reduce the risk o f development o f diabetes mellitus and cardiovascular disease in
the GD M group.
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APPENDIX I
Demographic Information
F IL E :.....................

DATE:

N A M E :............................................................................................
A D D R E S S :....................................................................................

T E L E P H O N E N O :...................................................
D A TE O F B IR T H :...................................................
N am e and ad d ress of fam ily / personal doctor:

N am e and ad d ress of two relatives / friends (This will help us locate you if you move
from the above address):
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Do you presently take any medications:
(please circle correct answer)
No
Yes
(If your answer is yes- please give the name of the medications and briefly give reasons
for taking them)

Family history of diabetes, eg. parents, brothers, sisters, other relatives; and age
of onset.

W hat treatm ent for diabetes mellitus were your relatives receiving? (please tick
the relevant correct answer)
..............

Diet alone

..............

Diet and tablets

..............

Diet and insulin
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Obstetric History:
N um ber of p re g n a n c y :.................................................................................
N um ber of s tillb irth :....................................................................................
N um ber of a b o rtio n :....................................................................................
N um ber of d eliv ery :.....................................................................................
Date of birth of baby (and maturity- full-term or premature):
W eight of baby at b i r th : ..............................................................................
W ere you on insulin at any stage of your pregnancy?
(please tick the correct answer)
No
Yes (if yes, please give dosage)...................
Have you ever taken oral contraceptive pill?
No
Yes
For how long altogether have you taken the oral contraceptive pill?
less than 6 m onths................................................
between 6 months and 2 years...............................
between 2 and 5 y e ars............................................
between 5 and 10 y e ars..........................................
longer than 10 y e ars................................................
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A re you now taking the oral contraceptive pill?
Yes

No

How often do you usually d rink alcohol?
I do not drink a lc o h o l..........................................
L ess than once a w e e k ............................................
On 1 or 2 days a w e e k ............................................
On 3 or 4 days a w e e k ............................................
On 5 or 6 days a w e e k ............................................
E veryday......................................................................

On a day when you drink alcohol, how many drinks do you usually have?
1 or 2 d rin k s..............................................................
3 or 4 d rin k s................................................................
5 to 8 d rin k s.................................................................
9 to 12 d rin k s...............................................................
13 to 20 d rin k s.............................................................
M ore than 20 d rin k s...................................................

Have you ever smoked cigarettes, cigars or pipe regularly?
Yes

No

A t w hat age did you start smoking regularly?
I started sm oking regularly at..................years of age.
Have you given up smoking?
yes, I gave up sm oking i n ............................. ( month / year).
N o , I still sm ok e............................................................................
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If you have given up smoking please answer the following questions:
Now m uch did you smoke?
I used to smoke...................manufactured cigarettes a day
.................... grams ‘hand-rolled’ cigarette tobacco per
week
.....................cigars per week
..................... grams pipe tobacco per week

A nthropometric Measurements:
Usual w eight:................................................ Present weight
H eight....................
W aist m easurem ent:

1.............................................
2 .....................................................

3.........................................
Hip m easurem ent:

1.............................................
2.....................................................

3.........................................
Waist / Hip ra tio :....................
Skinfold thickness: 1............. .......... 2.............. ..........3............. .......... Triceps
1............. .......... 2.............. ..........3.............. ...........Biceps
1....................... 2 ............. .........3 ............. ......... Subscapular
1............ ...........2.............. .........3............. ..........Suprailiac
Blood pressure:

1

2

3.
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D ata Elem ents to be Collected from the patient’s medical record and from the
patient:
This part of the study will involve the collection retrospectively of data from the
patient’s medical records, and from the patient. Access to the patient’s details will be
sought after consent has been given by the patient and agreement negotiated with the
Area Health Service.
D ata to be collected:
Age:
Height:
Weight:
Waist to Hip Ratio:
Ethnicity:
Date of diagnosis:
Family history of diabetes:
Family history of cardiovascular disease:
Current dietary intake:
Glaucoma: present / not present
Diabetic retinopathy:
Evidence of peripheral vascular disease (PVD):
Evidence of renal disease (pyelonephritis, cystitis, etc):
History of cardiovascular disease in participant:
Blood glucose level:
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APPENDIX II
(Chemical Solutions and Assays)
1. G G E b u ffe r (T ris/B o ra te b u ffer)

(pH = 8.35)
Measure:
Chemical

Concentration (mili molar)

Amount in 4 litre

Trizma base(Tris)

90 mM

43.6 g

Boric acid

8 mM

19.79 g

EDTA N a2

3 mM

4.47 g

NaN3

3 mM

0.78 g

Measure 4000 ml water in a big beaker and then add solid chemicals.
This buffer can be used 5-6 times for isolated lipoproteins from plasma.

Buffer which

has been used for whole plasma samples should not be used, subsequently, for density
d=1.25 on 4-30 % gels due to albumin contamination.

2 T ris b u ffers
(a) Making 1 litre o f 1 molar Tris buffer with pH = 7.4
Calculation:
g = C V M => Amount (mass) = Concentration x Volume x M olecular Mass
g = 1 x 1 x 121.1
g = 121.1 gram Tris
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This amount o f Tris is dissolved in 1 litre distilled water in a flask.
Solution is put in beaker and pH is measured (should be pH = 7.4), if pH is higher than
7.4, 32% concentrated HCL solution should be added to reach the target pH (pH = 7.4).
This solution will be used as stock to make TBS buffer.
(b) TBS + 0.005% EDTA + 0,02% N aN , (for 5 1)
M easure:
43.83 gN aC L
0.25 g EDTA
1 g NaN3
Mix the measured chemicals with 50 ml of Tris buffer
M easure twice 2 litter o f distilled water in volumetric flask and last 1 litter
measure in cylinder (but -50 ml o f Tris) (950 ml of water).
This buffer can be used for dialysing and dilution.

2 T r a c k in g d y e
(Sucrose brom ophenol blue solution)
Measure and mix:
4 gram o f Sucrose (D-glucose)
0.001 gram o f bromophenol blue
Add 10 ml o f Tris borate buffer (TBS)

3. G G E s ta in (p ro te in )

M easure 0.4 g page blue stain (brilliant blue)
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Add 950 ml distilled water and stir 2 hours.
Then add 50 ml H C L 0 4 and stir again 2 hours.
Then filtrate and collect the solution in a labelled bottle.

4. Making 10 % sulfosalycylic acid (SSA)
Mix 10 grams o f SSA in 100 ml o f distilled water in a volumetric flask and stir it. Then
filtrate and storage at room temperature
(Note: 10% SSA solution can be reused. After each use it should be filtrated).
This solution is used as a fixer for gels in electrophoresis.

5. Making 5% acetic acid
Measure 950 ml o f distilled water in a cylinder and then add 50 ml o f acetic acid, very
slowly.

6. HDL determination in plasma
Procedure:
1.

Allow specimens and precipitation reagents to equilibrate to room temperature.

2.

Using a manual pipette, transfer 1.0 ml. aliquot of plasma into appropriately

labelled eppendrof tubes.

3.

Add IOOjiL o f the combined of detrain sulfate-Mg2+ solution to each tube.

Immediately after addition o f this reagent, mix the contents of each tube in sequence for at
least 3 seconds, with a vortex-type mixer.
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This amount o f Tris is dissolved in 1 litre distilled water in a flask.
Solution is put in beaker and pH is measured (should be pH = 7.4), if pH is higher than
7.4, 32% concentrated HCL solution should be added to reach the target pH (pH = 7.4).
This solution will be used as stock to make TBS buffer.
(b) TBS + 0,005% EDTA + 0.02% N aN , (for 5 1)
Measure:
43.83 gN aC L
0.25 g EDTA
1 g NaN3
Mix the measured chemicals with 50 ml of Tris buffer
Measure twice 2 litter o f distilled water in volumetric flask and last 1 litter
measure in cylinder (but -50 ml of Tris) (950 ml of water).
This buffer can be used for dialysing and dilution.

2. Tracking dye
(Sucrose bromophenol blue solution)
Measure and mix:
4 gram o f Sucrose (D-glucose)
0.001 gram o f bromophenol blue
Add 10 ml o f Tris borate buffer (TBS)

3. GGE stain (protein)
Measure 0.4 g page blue stain (brilliant blue)
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Add 950 ml distilled w ater and stir 2 hours.
Then add 50 ml H C L 0 4 and stir again 2 hours.
Then filtrate and collect the solution in a labelled bottle.

4. M a k in g 1 0 % s u lf o s a ly c y lic a c id (S S A )

Mix 10 grams o f SSA in 100 ml o f distilled water in a volumetric flask and stir it. Then
filtrate and storage at room temperature
(Note: 10% SSA solution can be reused. After each use it should be filtrated).
This solution is used as a fixer for gels in electrophoresis.

5. M a k in g 5% a c e tic a c id
M easure 950 ml o f distilled water in a cylinder and then add 50 ml o f acetic acid, very
slowly.

6. H D L d e te r m in a tio n in p la s m a

Procedure:

1.

Allow specimens and precipitation reagents to equilibrate to room temperature.

2.

Using a manual pipette, transfer 1.0 ml. aliquot of plasma into appropriately

labelled eppendrof tubes.

3.

Add IOOjiL o f the combined of detrain sulfate-Mg2+ solution to each tube.

Immediately after addition o f this reagent, mix the contents of each tube in sequence for at
least 3 seconds, with a vortex-type mixer.
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Allow the tubes to stand at room tem perature for 10 minutes before sedimenting

the insoluble lipoproteins by centrifugation.

5.

Centrifuge tubes for 30 minutes with a refrigerated centrifuge (4°C, 1500xg) or

with an unrefrigerated benchtop centrifuge at 1000 rpm for 15 minutes.

6.

Remove tubes from the centrifuge and inspect supranatants for turbidity.

Transfer the clear supernatants solution by a Pasture pipette to a second labelled vial for
later compositional analysis.

N o te : Any turbidity or cloudiness in the supranatant indicates incomplete sedimentation

of VLDL, IDL, and LDL and consequent contamination and overestimation o f HDL.
This is usually observed in high triglycerides levels in samples.

7.

Turbid supranatant can be conveniently cleared by one o f the following methods:

(a) W ithout separating the turbid supranatant from the precipitate, add to the separation
tube 1.0 ml. o f 0.15 mol/L NaCl solution and another lOOpL o f combined precipitant
reagent.

Mix thoroughly with a vortex-type mixer, then centrifuge as previously described.

Obtain the clear supranatant for analysis. Supernatant cholesterol must be multiplied x 2
to correct for this dilution.

(b) Alternatively, the turbidity can be removed by ultrafiltration with an 0.22 pm filter.
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7. P r o c e d u r e f o r H D L R cu lio la b elled in th e c h o le s tr y l e s te r m o ie ty
1.

A volume o f 50 ml human plasma (from a healthy volunteer) was adjusted to

density o f 1.13 g/ml with solid KBr and ultracentrifuged for 24 hours at 49,000 rpm in a
TL-50.3 rotor at, at 4°C, by using a L8-70 Centrifuge (Beckman, USA).

2.

The plasma fraction o f d > 1.13 g ! ml was recovered by tube slicing and dialyzed

overnight against TBS (buffer was changed several times during dialyzing period).

3.

A quantity o f 200 jimol of [ l a , 2 a (n)-3H]-cholesterol (specific activity, 46.3 Ci

/mmol) in plastic scintillation vial was evaporated to dryness under a stream o f nitrogen
for approximately 1 hour.

4.

Dried radiolab el led cholesterol was then redissolved in 50 jil o f ethanol.

5.

The plasma fraction of 1.13 g/ml was added to the radiolabelled cholesterol

solution under gentle stirring.

6.

The mixture was incubated for 24 hours at 37°C in a shaking water bath to allow

cholesterol esterification by the LCAT (lecithinxholesterol acyltransferase) reaction.

7.

After incubation period, the solution was measured and adjusted to density 1.13

g/ml with solid KBr and subjected to centrifugation, for 24 hours at 49000 rpm in a 50.3
rotor, at 4°C, by using a L8-70M centrifuge (Beckmann, USA).

The aim o f this last

centrifugation was to remove any radiolabelled lipoproteins o f density < 1.13 g/ml,
possibly produced during the incubation period.
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8.

After slicing, infranatant was collected in cylinder and measured.

9.

The measured plasma fraction was adjusted to density >1.21 g/ml with solid KBr

and centrifugated for 40 hours at 49000 rpm in a TL-50.3 rotor at 4°C.

10.

After slicing, supernatant was recovered as HDL3 radiolabelled.

11.

(Washing Spin): KBr solution density = 1.21 was added to HDL3 radiolabelled

sample and subjected to ultracentrifugation for 16 hours at 100000 rpm in a T LA -100.4
rotor, at 4°C, by using a tabletop TL-100 centrifuge (Beckmann, USA)

12.

After slicing supranatant was dialyzed against TBS for 24 hours (buffer was

changed several times).

13.

Thin

layer

chromatography

(TLC)

was

done

on

radiolabelled

HDL3.

Approximately 95 % of total radioactivity was in cholesteryl ester (CE) as ascertained by
(TLC).

8. TLC determination o f cholesterol ester (CE) in radiolabelled HDL3 and LDL

Prepare following solutions:

1. Extraction solution
160 ml isopropanol
40 ml n-heptane

306

A p p en d ix II

C hem ical Solutions and A ssays

307

4 ml 1 N (0 .5 M )H 2 S O 4

2. Developing solution for TLC plates
45 ml hexane
20 ml diethyl ether
1.5 ml methanol
1 ml acetic acid
The recovery o f cholesterol ester is determined by adding a know amount o f ^ C cholesteryl oleate to the extraction solution. Prepare stock solution by adding 10 ul ^ C cholesteryl oleate to 100 ml extraction solution.

Prepare working solution by diluting

stock solution 1:8 with extraction solution (ie. 0.5 ml stock + 3.5 ml extraction solution).
From this, take 2.5 ml at next step.

procedure:
1.

Add 5 p.1 radiolabelled HDL3 or radiolabelled LDL to 495 \i\ TBS buffer (pH =

7.4).

2.

Add 40 |il unlabelled HDL3 or LDL (carrier lipoprotein)

3.

Add 2.5 ml extraction solution (with 14C-cholesteryl oleate)

4.

Cap and vortex

5.

Stand at room temperature 20 minutes
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6.

Add 1.5 ml n-heptane and 1 ml w ater

7.

Cap and vortex

8.

Stand at room tem perature for 15 minutes. Prepare tank and TLC plate

9.

Transfer 800 p.1 o f heptane (top) phase to a scintillation vial labelled ‘C E’

(cholesteryl ester)

10.

T ransfer 400 |il o f heptane (top) phase to a scintillation vial label TC (total count)

11.

Dry sample under N 2 gas

12.

Add 10 ml scintillation fluid to TC vial

13.

Add 200 jil chloroform to CE vial and dissolve dried lipid

14.

Spot 100 jil o f solution from CE vial onto silica gel TLC plate

15.

Put the silica gel TLC plate in tank and develop until solvent is front about 2 cm

from top o f the silica gel TLC plate (CE runs with solvent front)

16.

Rem ove the silica gel TLC plate from tank and dry in fume cupboard

17.

Develop with iodine (few crystals)

18.

Scrape CE band into scintillation vial. Add 10 ml scintillation fluid

19.

Express CE counts as % o f total 3H counts

20.

Calculate recovery o f 14C-cholesteryl oleate
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CE vial count / TC vial count x 100 = X (% recovery o f CE)

9, CETP activity % in plasma Procedure:
1.

100 jil plasm a was mixed with 50 \û [3H] HDL3 (containing 2.5 nmol cholesterol.

2.2 x 105 counts/m inute per 50 p.1)

2.

Incubate it for 3 hours at 37°C.

3.

Place the tubes immediately on ice.

4.

Precipitated the apo B containing lipoproteins

with

dextran sulfate-M g2+

(W am ick etal, 1982)

The CETP assay procedure is summarized in Table 1

5.

Supranatants (0.8 o f total volume) were collected in plastic scintillation vials. A

volume o f 10 mL o f scintillation fluid (Instagel, Pachard Instrum ent Company, IL, USA)
was added to each vial and the radioactivity was assayed for 10 minute in a ‘HewlettPackard scintillation counter’.

The percentage o f radioactivity transferred to apo B containing lipoproteins was
calculated, as the difference between the total radioactivity o f the assay and the
radioactivity o f the supranatant after precipitation of the VLDL, EDL, and LDL, w ith
adjustment for non-specific transfer.
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Table-1: Summerized CETP assay procedure

Tube

1,2

TBS

100

hdl3

plasma

Total

Incub

volume

Period

50 |il

150 nl

3.h

50 |il

150 Hi

3.h

Total

Recover

volume

volume

TBS

165 Hi

132 Hi

Dextr

165 Hi

132 Hi

165 Hi

132 Hi

165 Hi

132 Hi

165 Hi

132 Hi

15 Hi

nl
3,4

100
111

5,6

sulfate
50 nl

100 Hi

150 Hi

3.h

sulfate

(+cont)
7,8

50 Hi

subject

150 Hi

3.h

sample
9,10

50 Hi

subject
sample

Dextr

Dextr
sulfate

150 nl

3.h

Dextr
sulfate

Incub = Incubation, h = hours, Dextr = Dextran, (+ cont) = positive control, Recover =
Recovery.

Contents

CHOL
M PR 1
MPR 2
MPR 3

1442341
1442350
236 691

C h o le s te ro l

10 x 32 ml
1 0 x 100 ml
4 x 500 ml

2
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MPR 2

MPR 3

10

10

4

, ,

,

RCOOH
, , .
, _
Cholesterol oxIdase
,
Cholesterol + 0 2 --------------------------------> A -cholestenone +
l-|20 2
2 H20 2 + 4-aminophenazone + phenol 4-(p-benzoquinone-monoimino)-phenazone + 4 H20
Clinical in te rpreta tio n according to the recommendations of
the European Atherosclerosis Society’ :
Lipid disorder
< 200 mg/dl
< 200 mg/dl •

Cholesterol

200-300 mg/dl

Cholesterol
Triglycerides

> 300 mg/dl
> 200 mg/dl

Procedure
Wavelength: Hg 546 nm (470-560 nm)
Spectrophotometer: 500 nm
Cuvette: 1 cm light path
Incubation temperature: 20-25°C or 37°C
Measure against reagent blank (RB).
One reagent blank is sufficient for each assay series.
Pipette into test tubes:

sample material
reagent solution

RB

Sample

2.00 ml

0.02 ml
2.00 ml

Mix, and incubate RB and sample for 10 min al 20-25uC
or 5 min at 37°C.
Read absorbance of sample against RB within 1 hour =
A
''sa m p le *

No
Yes,
if HDL cholesterol
< 35 mg/dl
Yes

Dilution threshold
1000 mg/dl (25.9 mmol/l)
At higher cholesterol concentrations, dilute 0.1 ml of sample
material with 0.2 ml of 0.9% NaCI solution and repeat assay
(result x 3).
Calculation
of the concentration (c) of cholesterol in the sample:

Values in mmol/l:
Cholesterol:

35 mg/dl = 0.9 mmol/l
200 mg/dl = 5.2 mmol/l
300 mg/dl = 7.8 mmol/l

Triglycerides:

200 mg/dl = 2.3 mmol/l

Preparation and stability of the reagent solution
MPR 1: Dissolve contents of one bottle 1 by adding 32 ml
redist. water.
MPR 2: Dissolve contents of one bottle 1 by adding 100 ml
redist. water.
MPR 3: Dissolve contents of one bottle 1 by adding 500 ml
redist. water.
The reagent solution is ready to use after 10 minutes.
Stable for four weeks at +2 to 8°C
seven days at +15 to 25°C.

CHOD-PAP method

,_ 1 ,
, .
Cholesterol esterase
, ,
.
Cholesterol esters + H20 --------------------------------» Cholesterol +

Cholesterol
Triglycerides

MPR 1

2

M ethod
Siedel, J., et al. (1983). Clin. Chem. 29:1075.
Kattermann, R., et al. (1984). Clin. Chem. Clin. Biochem. 22:
245.
Trinder, P. (1969). Ann. clin. Biochem. 6:24.
Test principle

Bottle 1
Cholesterol
reagent

Wavelength

mg/dl

mmol/l

Hg 546 nm

c = 853 x Asample

c = 22.1 x Asampte

500 nm

c — 575 x Ason,pie

c = 14.9 x Aso,„ple

C oncentrations of the reagent solution
Tris buffer: 100 mmol/l, pH 7.7; Mg2*: 50 mmol/l; 4-amino
phenazone: 1 mmol/l; sodium cholate: 10 mmol/l; phenol:
6 mmol/l; 3,4-dichlorophenol: 4 mmol/l; fatty alcohol polygly
col ether: 0.3%; cholesterol esterase § 0.4 U/ml; cholesterol
oxidase ^ 0.25 U/ml; peroxidase S 0.2 U/ml
Quality control
Accuracy: Precinorm® U, Precinorm* L, Precipath® U,
Precipath® L
Precision: Precinorm® UPX
Please note
If difficulties encountered in quality control point to inade
quate linear response on the part of the photometer, or if
measurements cannot be taken at Hg 546 nm or 500 nm, a
calibration curve must be constructed using Preciset® Cho
lesterol (Cat.No. 125 512). The cholesterol values are read off
the curve.
Bilirubin concentrations above 4 mg/dl interfere with the test
(results up to 10% too low).
Hemoglobin concentrations up to 200 mg/dl do not affect
the test.
Reference
1 Study Group, European Atherosclerosis Society.
Strategies for the prevention of coronary heart disease:
A policy statement of the European Atherosclerosis Society.
(1987). Eur. Heart J. 8:77.

Sample m aterial
Serum, heparinized plasma or EDTA plasma
Stable for six days at +4 to 25°C
four months at -20°C .
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Free Cholesterol

Use solutions undiluted.

¿J Cholesterol reagent:
Pipette 0.5 ml ol sol. 3 into bottle 2 and add the entire contents ol one
bottle 1. or make up stock solution according to the following table:

Enzymatic colorimetric method
Cat. No 310 328 for 2 x 90 ml

Method
Stahler, F., et al. (1977). Med. Lab. 30: 29.
Trinder, P. (1969). Ann. din. Biochem. 6: 24.

Number
ol samples

solution 1.
ml

solution 2,
ml

solution 3,
ml

ca. 4
ca. 9
ca 19
ca 39

5
10
20
40

5
10
20
40

0.05
0.10
0.20
0.40

Stable for two weeks at -t- 2 to + 8^C
two days at- + 15 to 25°C.

Test principle

Chemical Solutions and Assays

3

Stable up to the expiry dale specilied when stored al i 2 to +^ C .

CHOD-PAP method

. .
. „
cholesterol + 0 ,

and

Pipette into cuvette:

cholesterol oxidase
.
.
,. „
-------------- —-------------->-A -choleslenone + H ,0 ,

POD
2 H ,O j + 4-amlnophenazone + phenol ------- > 4-(p-benzoquinone-monoiminojphenazone + 4 H ,0

Normal values for Iree cholesterol:
22 -3 0 % of total cholesterol
Reference: Wybenga, D. R., and J. A. Inkpen. (1974). Lipids. Page 1421 II
in Henry, R J.. el al., eds. Clinical Chemistry: Principles and
Technics, 2nd ed. Harper & Row, Publishers. Inc., New York.
. San Francisco, and London.

Sample material
Serum, heparinized plasma or EDTA plasma

Mix equal volumes of solutions t and 2 and store away Irom liqhl
Stable for two weeks at + 2 to + 8°C
two days at + 15 to 25"C.
Procedure A

2.00 ml
“
0.02 ml

Mix and incubate SB and sample (or 20 min at 20-25°C or for 10 min
at 37’C Read absorbance ol sample against SB within 2 hrs.. and
AA — AA,ample AArb
subtract AAna Irom AA„mpie.
Calculation
ol the concentration (c) of Iree cholesterol in the sample:
m g/100 ml

mmol/l

Hg 546 nm

c = 855 x AA

c = 22.1 x AA

500 nm

c = 585 x AA

c = 15.1 x AA

Wavelength

If difficulties encountered in quality control point to inadequate linear
response on the part ol the photometer, or If measurements cannot be
taken at Hg 546 nm or 500 nm, a calibration curve must be constructed
using Preciset"-' Cholesterol (Cat.No. 125 512). The cholesterol values
are read off the curve.
A slight yellow coloration of solution 2 does not allec! the lest.

One reagent blank is suflicient for each assay series.
Initial concentrations
of solutions:

Pipette into cuvette:

Buffer (potassium phosphate)
Phenol
methanol

0.4 mo I/I; pH 7.7
20 mmol/l
1.85 mol/l

sample material
solution 4

2

Buffer (potassium phosphate)
4-Aminophenazone
methanol
hydroxypolyethoxydodecane

0.4 mol/l; pH 7.7
2 mmol/l
1.85 mol/l
0.4%

q

Cholesterol oxidase
Peroxidase

s 12 U/ml
â 8 U/ml

Quality control
For control of accuracy: Precilip' E.L., Preclnorm

L

RB

Sample

2.00 ml

0.02 ml
2.00 ml

Mix and incubate RB and sample lor 20 min al 20-25°C or 10 min al
37°C. Read absorbance ol sample against RB within 2 hours (AA).
Procedure B
Sample material: serum or plasma
Wavelength: Hg 546 nm (470-560 nm)
Spectrophotometer: 500 nm
Cuvette: 1 cm light path
Incubation temperature: 20-25°C or 37°C
Measure against sample blank (SB)
Determine AAnB once per series to correct lor the intrinsic colour of the
cholesterol reagent by using redist. water instead of sample in the assay.
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2.00 ml
0.02 ml

Even low concentrations of ascorbic acid and u-methyldopa in the
specimen depress the free cholesterol level.
Solutions 1 and 2 contain methanol, which is poisonous. Do not swallow
or inhale vapors. Avoid contact with skin. If solution comes into contact
with skin or mucous membranes, flush immediately with large quantities
ol water. If solution comes into contact with eyes, immediately flush
liberally with water and consult an ophthalmologist.

Sample material: clear, non-hemolylic serum
Wavelength: Hg 546 nm (470-560 nm)
Spectrophotometer: 500 nm
Glass cuvette: 1 cm light path
Incubation temperature: 20-25°C or 37°C

Contents
•j

Sample

Please note

CJ Reagent for sample blank:
(req'd only for assays on hemolytic or turbid sera)

Measure against reagent blank (RB)
Reagents

solution 4
solution 5
sample

SB

B o e h rin g e r M a n n h e im G m bH

Triglycerides GPO-PAP
High performance
Enzymatic colorimetric test
Perldochrom® Triglycerides GPO-PAP
Cat.No. 701882 for 6 x 13 ml reagent
Cat.No. 701 904 for 15 x 32 ml reagent
Test-Combination Triglycerides GPO-PAP
Cat.No. 701912 for 5 x 100 ml reagent

Chemical Solutions and Assays

Additional reagent lor measurement against standard:
Precimat1* Glycerol, Cat.No. 166 588
Method
Enzymatic hydrolysis of triglycerides with subsequent deter
mination of the liberated glycerol by colorimetry.
References:
Mod. according to Wahleleld, A. W. (1974).
Triglycerides. Delermination aller Enzymatic Hydrolysis. Page 183111. in
H.U. Bergmeyer, ed. Methods ot Enzymatic Analysis. 2nd English ed.
(Transl. Irom 3rd German ed.). Verlag Chemie Weinheim and Academic
Press, Inc., New York and London. 4 vols.
Nägele, U. (Boehringer Mannheim GmbH), personal communication.
Trinder, P. (1969). Ann. Clin. Biochem. 6:24.

Test principle

..

lipasetriglycerides + 3 H , 0 ---------- ►glycerol + 3 RCOOH

glycerol + ATP-----*- glycerol-3-phosphate + ADP
glycerol-3-phosphate + O , —

dihydroxyacetone phosphate + H20 2
peroxidase
H2O j + 4-aminophenazone + 4-chlorophenol —c-----------------►
4-(p-benzoquinone-mono-imino)-phenazone + 2 HaO + HCI

Sample material
Serum, heparinized plasma or EDTA plasma
Reagents
1 Buffer solution
2 Reagent strips or lyophilisate
Reagent concentrations In solution
•1 Trls buffer: 0.15 mol/l, pH 7.6; magnesium sulphate: 17.5
mmol/l; EDTA, disodlum salt: 10 mmol/l; 4-chlorophenol:
3.5 mmol/l; sodium cholate: 0.15%; potassium hexacyanolerrate (II): 6 pmol/l; hydroxypolyethoxy-n-alkanes: 0.12%
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ATP ^ 0.5 mmol/l; 4-aminophenazone: 0.35 mmol/l; lipase ^
3 U/ml; glycerol phosphate oxidase S 2.5 U/ml; glycerol
kinase ^ 0.2 U/ml; peroxidase ^ 0.15 U/ml

Quality control
For control of accuracy: Precinorm® U, Precinorm* L,
Precipath® U. Precipath"1L
For precision control: Precinorm''' UPX

Preparation and stability of reagent solution
Peridochrom"Triglycerides GPO-PAP
Do not touch the reagent patches or surrounding area.

Incubation temperature: 20-25°C or 37°C

Immerse one reagent strip in one bottle of buffer solution and use to
stir the bottle contents for ca. 10 sec. Allow to stand In buffer solution
for 5 min, stir once again for ca. 10 sec, and then discard reagent strip.

c (mg/100 ml] — 200 x

c (mmol/l] — 2.29 x
^standard

A&iandard

Test-Combination Triglycerides GPO-PAP
Connect one bottle 1 to one bottle 2 with one of the adapters provided
in the kit and flush several times to ensure complete dissolution of the
lyophilisate.
Reagent solution from different bottles may be pooled forlarge series
If the triglyceride concentration exceeds 1000 mg/100ml (11.4 mmol/l),
dilute sample 1 + 5 with 0.9% NaCI solution and repeat assay
(result x 6).

Stable for two weeks at + 2 to 8°C
two days at +15 to 25°C.
Sample preparation
The sample can be stored up to three days at +4°C
four months at —20°C.

Clinical interpretation
according to the recommendations of the European Atherosclerosis
Society:

Procedure
Wavelength:
Hg 546nm
Spectrophotometer:
500 nm
Cuvette:
1 cm light path
Incubation temperature: 20-25°C or 37°C

Lipid disorder

Measure against reagent blank. One reagent blank Is sufficient for
each series.
Pipette Into test tubes:
serum or plasma
reagent solution

0.02 ml
2.00 ml

Cholesterol
Triglycerides

< 200 m g/100 ml
< 200 mg/100 ml

No

Cholesterol

2 0 0 -3 0 0 mg/100 ml

Yes,
if HDL cholesterol
< 35 mg/100 ml

> 300 mg/100 ml
> 200 mg/100 ml

Yes

Cholesterol
Triglycerides
Values In mmol/l:

Mix. and incubate at 20-25°C for 10 min.
Read absorbance of sample against reagent blank within 60 min **

Cholesterol:

35 m g/100 ml = 0.9 mmol/l
200 m g/100 ml = 5.2 mmol/l
300 m g/100 ml = 7.8 mmol/l

Triglycerides:

200 m g/100 ml = 2.3 mmol/l

A

^ sample*

If incubating at 37°C (10 min), the absorbance of the standard must be
determined once for each assay series using Precimat* Glycerol
instead of serum or plasma. The absorbance of the sample and the
standard must be read within 30 min.

Reference: Study Group, European Atherosclerosis Society.
Strategies lor the prevention ol coronary heart disease:
A policy statement ol the European Atherosclerosis Society.
(1987).
.
Eur. Heart J. 8 :77.

Calculation via factor
Obtain the concentration (c) of triglycerides in the sample from the
enclosed table of values or calculate as follows:
Incubation temperature: 20-25°C
Wavelength

c (mg/100 ml]

Hg 546 nm

1040 x Aiamp,e

11.9 x Asampla

500 nm

760 x Aiampl,

8 66 x Asample

c (mmol/l]

Calculation via standard
Calculate the concentration (c) of triglycerides as follows:

Boehringer Mannheim GmbH
Diagnostica

March 1991
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UNIM ATE 3 APOA

Art. 07 3688 0

: Apolipoprotein A 1
Intended use

Unimate'3 APOA is an in vitro diagnostic reagent intended for the quantitative
immunological determination of human apolipoprotein A-1 (Apo A-1) in serum.
Method

Immunoturbidimetric.
Principle

Human apolipoprotein A-l forms a precipitate with a specific antiserum which
is determined turbidimetrically (measurement of cloudiness) at 340 nm (fixed
time method).
•
Specimen

Serum.
■
Samples should be fresh, stored for a maximum of 1 week at +2 to +8 °C or
stored frozen once at -20 °C.
Reference values
Apolipoprotein A-1
115-220 mg/dL (1.15-2.2 g/L)
Females
115-190 mg/dL (1.15-1.9 g/L)
Males
Apolipoprotein B
60-150 mg/dL (0.6-1.5 g/L)
Females
70-160 mg/dL (0.7-1.6 g/L)
Males
Ratio Apolipoprotein B/Apolipoprotein A-1
Females
0.35-1.15 ■
Males
0.45-1.25
Forthe IFCC Reference Preparation SP1 (October 1992 WHO-IRP) for apolipo
protein A-1 and the IFCC Reference Preparation SP3-07 for apolipoprotein B
the following additional reference values apply:
Apolipoprotein A-1
Apolipoprotein B
Females
1.20-2.20 g/L
0.55-1.25 g/L
Males
1.10-2.00 g/L
0.55-1.35 g/L
Q u a lity control

Apolipoproteins T Control, art. 07 3721 6 (US # 42391)
Kit contents

R Reagent, 4 x 10.5 mL
Anti-Apo A-1 T antiserum (sheep)
Antiserum specific for human apolipoprotein A-1, in phosphate buffer stabi
lized with 0.09% sodium azide.
Reagents
Working reagent
The reagent Ris ready to use. Warm up the reagent to room temperature prior
to assay.
. . .
The reagent, once opened is stable for 4 weeks at +2 to +8 °C in the original
bottle if it is immediately and tightly closed after use.
Additionally required (not delivered with the kit):
Apolipoproteins T Standard, art. 07 3720 8 (US # 42390)
Apolipoproteins T Control, art. 07 3721 6 (US # 42391)
NaCI solution 154 mmol/L (0.9%)
Procedure

For applications on COBAS® instruments please refer to the corresponding
test instruction manuals.
Notes

Measuring range: 35-550 mg/dL (0.35-5.5 g/L).
The measuring range is determined by the batch specific apolipoprotein A-1 in
the standard serum and the serial dilutions selected.
The reagent R contains < 0.1 % sodium azide as preservative. Avoid swallow
ing and contact with skin or mucous membranes.
References

,

„

_..

1 Becker W„ Rapp, W., Schenk, H.G., Storiko, K.: Z Klin Chem Klin Biochem 6, 113-122 (1968).
L n u
2. Thomas, L.: Labor und Diagnose, 1. Ed., p. 628. Marburg/Lahn. Die Medi
zinische Verlagsgesellschaft, 1978.
.
,
3. Dati, F., Lammers, M., Adam, A., Sondag, D., Stienen, L.: Lab Med 13,
87—90 (1989)
4. Albers, J.J., Marcovina, S.M., Kennedy, H.: Clin Chem 38, 658-662 (1992).
5. Dati, F.: IFCC program for the standardization of assays for apolipoprotein
A-1 and B; in: Progress in Clinical Biochemistry, pp. 419-423. Ed. K. Miyai,
T. Kanno, E. Ishikawa. New York: Elsevier. 1992.
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Apolipoprotein B
T Antiserum
1337289
P-2995/C
e d f ¡ esp
Ed.Nov. 90

A rt 07 29 9 5 7 (4x10.5 ml)
Antiserum (rabbit) for the quantitative immunological
determination of human apolipoprotein B in serum.
For in vitro diagnostic use
Also required: .
T Standard Apolipoproteins (Roche> (art. 07 30688)
NaCI solution 154 m m ol/l (0.9%)
General information

Method

Immunoturbidimetric.

Principle1

Human apolipoprotein B forms with a specific antiserum a
precipitin which is determined turbidimetrically (measurement
of cloudiness) by a fixed time method at 340 nm (or 334 or
365 nm).

Sample2

Fresh serum or stored for a maximum of 1 week at + 2 to + 8 °C.
Very turbid (lipemic) samples should be diluted prior assay. '

Package

T Antiserum Apolipoprotein B
10.5 ml per bottle
Antiserum specific for human apolipoprotein B in phosphate
buffer stabilized with sodium azide.
The bottles, when unopened, are stable at + 2 to + 8°C until the
expiry date stated on the labels.

Reference
values3

Quality control

Apo A-1
Male
Female
Apo B
Male
Female .
Ratio Apo B/Apo A-1
Male
Female

1.15-1.90 g/l
1.15-2.20 g/l

(median 1.45 g/l)
(median 1.60 g/l)

0.70-1.60 g/l
0.60-1.50 g/l

(median 1.15 g/l)
(median 1.05 g/l)

0.45-1.25
0.35-1.15

(median 0.80)
(median 0.65)

T Control Apolipoproteins <Roche> (art. 07 3069 6)
Manual procedure

Preparations

Reagent
The T Antiserum. Apolipoprotein B is ready to use. Prior assay
warm up the reagent to room temperature. The reagent, once
opened is stable 4 weeks at + 2 to + 8 °C. 1weekat +15 to + 25 °C
in the original bottle if it is immediately and tightly closed after
use.
Samples and controls
Dilute the samples and controls with NaCI (0.9%) in ratio 1:21

(1+20).

■■

Main standard
Reconstitute T Standard Apolipoproteins <Roche> with 0.5 ml of
distilled water. Allow to stand at +15 to + 25 °C for 30 minutes.
Then gently swirl for 1 minute. The reconstituted standard is
ready to use and is stable for 1 week at + 2 to +8°C.
Standard serial dilutions
Dilute the reconstituted T Standard Apolipoproteins <Roche>
with NaCI solution in a geometric series, starting with 1:6 in
order to have the following series: 1 :6 .1 :1 2 .1 :2 4 .1 :4 8 .1:96.
For diluting this pipetting schema can be used:
.
Solutions

Dilutions
1:6
1:12

T Standard reconstituted
Dilution 1:6
Dilution 1:12
Dilution 1:24
Dilution 1:48
NaCI 0.9%

100

1:24

1:48

1:96

300
300
300
500

300

300

300

300
300

The dilutions of the standard are stable during 1 week at + 2 to
+ 8°C if stored in closed vials (risk of contamination).
Bibliographie

1. Becker, W.. Rapp. W., Schenk, H. G., Störiko, K.: Z Klin Chem
Kim Biochem 6. 113-122 (1968).
2. Thomas. L : Labor und Diagnose. 1.Ed.. p.628. Marburg/
Lahn: Die Medizinische Verlagsgesellschaft. 1978.
3. Dati, F.. Lammers. M., Adam. A.. Sondag. D., Stienen. L.: Lab
M ed 13. 8 7 -9 0 (1989).
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ABOUT

T H IS

STUDY

This survey is one ol a series designed to describe the current health and
nutrition status of groups ol Australians. It lorms part ol a study on aspects
ol health which has been outlined In a covering letter to you.
In this booklet there are a number ol questions which provide information on
lood habits and usual dietary intake. Such information^ essential il we are
to identify any nutrition problems and understand the relationships between
diet and disease in the general population and in groups of people at special
risk. You may be a member of the general public in good health or you may be
a person with a health problem. Information from both groups of people Is
necessary.
All the Information you give us will be treated in the strictest confidence. No
personal details that can Identity you will be revealed to anyone, and your
name will not be attached to this information: instead, a code number will be
used. If the study In which you are Involved Is one In which we may want to
contact you some time In the future, we need to keep your name, address,
contacts and code number securely on file, but separately from other
information relating to you. All such identifying information which may be
used to contact you in the future will be kept in a secure place by Professor
Calvert.
Please answer all the sections carefully. You may have made arrangements
to return the booklet to a research associate. If you have not made any such
arrangement, please return the booklet to me as soon as possible.
Thank you for your help.
Dennis Calvert
Professor ol Medicine and Public Health
Medical Research Unit
lllawarra Regional Hospital (Wollongong Campus)
Crown St
WOLLONGONG NSW 2500
Telephone (042) 266594

Please ring me on this number if you have any problems. Subsequent
enquiries may be directed to Ms Kim Roser, Secretary to the Human Ethics
Committee of the lllawarra Area Health Service/University of Wollongong.

YOUR HEALTH
On

1-^

0-1 In general, how has your health been in the Iasi year? (Please circle one)

cn

Very Good

Good

Fair

Poor

Very Poor

Q-2 How much ot an ellect do you think the following things have on the health ol people
like yoursell?
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(Circle one lor each)
Ealing the wrong foods

Bad effect

Moderate

No effect

Don’t know

Smoking

Bad effect\

Moderate

No effect

Don't know

Air and chemical pollullon

Bad effect

Moderate

No effect

Don't know

Working In a dirty Job, with dusl
or chemicals

Bad effect

Moderate

No effect

Don't know

Drinking loo much alcohol

Bad effect

Moderate

No effect

Don't know

Hot having a good dcclor

Bad effect

Moderate

No effect

Don’t know

Having parents who have or had
poor heallh

Bad effect

Moderate

No effect

Don't know

Not keeping weigh! under control

Bad effect

Moderate

No effect

Don't know

Excess slress caused by work,
lack ol work or work ail home

Bad effect

Moderate

No effect

Don’t know

Lack ol exercise or physical
activity

Bad effect

Moderate

No effect

Don't know

Problems wilhin the lamily

Bad effect

Moderate

No effect

Don't know

Nol living In a clean, sale house
and neighbourhood

Bad effect

Moderate

No effect

Don't know

Bad luck

Bad effect

Moderate

No effect

Don't know

Worries caused by not having
enough money

Bad effect

Moderate

No effect

Don't know

2

These are questions about your current health and that ol close family or friends, as these factors may
Influence the way you eat.
Q-3 (a) Have you or your spouse (if relevant) ever had any ol Ihe following conditions?
(Circle YES or NO)

YOURSELF

YOUR SPOUSE

(husband/wlfe/partner etc)
Diabetes
High blood pressure
High blood cholesterol
Heart problems (including angina)
Bowel complaints
A malignant growth or cancer
Arthritis
Any other medical condition

YES
YES
YES
YES
YES
YES
YES
YES

NO
NO
NO
NO
NO
NO
NO
NO

YES
YES
YES
YES
YES
YES
YES
YES

NO
NO
NO
NO
NO
NO
NO
NO

(please describe).
Q-3 (b) Has any other close lamily member or friend (parent, child, sister, brother, close
friend) ever suffered from any of the following? (Circle YES or NO for each and tells us
what relation they are to you)

Whal relation?
(sister, brolher.lrlend etc)
Diabetes

YES

NO

High blood pressure

YES

NO

High blood cholesterol

YES

NO

Heart problems (Including angina)
Obesity

YES

NO

Dowel complaints

YES
YES

NO
NO

A malignant growth or cancer

YES

NO

Arthritis

YES

NO

Other condition (please specify)

Q-4 Are you currently on any type ol medication? (Circle one number)
1 No
2 Yes
if Yes, what lype/s ol medication?.
3
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YOUR EATING HABITS

This section Is about the kinds of foods you usually eat. On the next few pages you
will find lists of foods, separated by questions about your dietary habits.
Read through each list of foods and record about how often you usually eat these
foods. We realise that your food Intake may vary from time to time, so Just try to give
us the best ovprall picture of your diet that you can.
We are interested In YOUR diet, not that of someone else In your household.
THIS IS HOW TO ANSWER

Diet and Health Questionnaire Booklet

We are going to ask you "About how often do you usually eat these foods?"
Use the following simple code to write your answer In the space next to each food.
If you NEVER have a food...........................................write N
If you RARELY have a food (less than once a month) ....write R
If you usually eat a food
About once a MONTH................................................. write 1M
About twice a MONTH................................................write 2M
About three times a MONTH........................................ write 3M
About once a WEEK.......
About twice a WEEK......
About three limes a WEEK
and so on......................

write 1W
write 2W
write 3W
(4W, 5W, 6W, etc)

About once a DAY
About twice a DAY
and so o n ........

write 1D
write 2D
(3D, 4D.5D, otc)

SUmderd.aQrYfla
Alongside each food there Is a "standard serve" size. The "standard" serve Is not
necessarily a "normal" serve, It Is simply there to help us measure food Intake. If you
usually eat more or Ies9 than the standard serve size for a particular food, please
Indicate on the COMMENTS line how much more, or less, Is eaten at a time.

Appendix III

For example, if when you eat Icecream you have one "scoop" Instead of our
"standard" serve of two "scoops", Indicate how often Icecream Is eaten, and then write
"one scoop only" on the comments line.

On the opposite page you will see some examples of how to fill out the questionnaire.
Please read these carefully before you start to fill out the answers for your dlot.

4

NEVER

HOW TO ANSW ER
T im e s a
T im e s a
W EEK
RARELY
MONTH

N

R

T im e s a
DAY

jW

iM

and so on

and so on

HERE ARE SOME EXAMPLES
COMMENTS
C u s ta rd

1/2 cup

M

B o ile d egg

1 egg

3M i\rto

C ucum ber

3 slices (each
0.5 cm thick)

Tea

1 Cup

4D

B e e tro o t - c a n n e d

2 slices

,2M.. one slice._______

...
e q q s

CO

...S ...

The person above has, on average
- A standard serve of custard three times a week
- Two boiled eggs three times a month
- Rarely eats cucumber
- Four cups of tea every day
- Half a standard serve (1 slice) of beetroot - canned,
twice a month

We realise that some people have an exact Idea of how often they eat particular
foods, whilst others only have an approximate Idea. Be as accurate as you can
but do not spend too much time choosing your answers.

PLEASE GIVE AN ANSWER FOR EVERY FOOD.

5

HOWTO ANSWER

<N

NEVER

RARELY

N

R

Tim es a
MONTH

Tim es a
W EEK

Tim es a
DAY

ÏW
3

I3 D

and so on

and so on

A B O U T HOW OFTEN DO YOU USUALLY EAT THESE FOODS?
C O M M EN TS

Diet and Health Questionnaire Booklet

CEREALS
Porridge/Oalmeal

1 cup (cooked)

Muesli

1/2 cup

Other breakfast cereal

1 cup

Plain bran (raw)

1 tablespoon

Wheatgerm

1 tablespoon

Bread roll
(NOT hamburger buns)

1 roll

Fried rice

1 cup (cooked)

Boiled rice

1 cup (cooked)

Instant noodles (Maggl etc)

1 cup (cooked)

Other pasta
(spaghetti, macaroni etc)

1 cup (cooked)

Q-1 How many slices ol bread do you usually eal? Remember the bread In toast and sandwiches.
If you do not eat bread, write 'none'.
_________ slices/day OR_________ slices/week .
Q-2 What type of bread do you usually eal? (Circle Ihe number beside one answer)

Appendix III

1
2
3
4

Wholemeal or mixed grain
While
About half Ihe lime wholemeal and hall while
Other breads (eg rye, HI-FIbe)
(please specify type).......................................................................
5 I do nol eal bread

Q-3 Do you eal low-salt types of bread? (Circle one answer)
ALL or MOST OF THE TIME

OCCASIONALLY
6

RARELY/NEVER

Q-4

Which ol the following do you usually spread on bread or crackers ? (Circle one answer)

1
2
3
4
5
6
7
0

Butler
Polyunsaturated margarine
Table or cooking margarine
Reduced-fat margarine (eg Era)
Drlpping/Lard
I don't use anything
I don't eat bread or crackers
Something else: please name.............................................................................

Q-5 For whatever spread you use is it usually the regular variety or reduced-sail?
(Circle one answer)
1 I usually use Ihe regular variety

2 I usually use the reduced-salt variety

Q-6 What types ol breakfast cereals do you most commonly eal?
Please name: ........................................................................................................
Q-7 IIyou eal muesli is if:- (Circle one answer)
1 Homemade muesli

2 Pre-packaged muesli

Q-8 How many cups ol milk do you usually add lo breakfast cereal, porridge or muesli?
(Circle Ihe number closes! lo Ihe amount you have)
1
2
3
4
5

None
About a hall a cup
About one cup
About one and a hall cups
About two cups or more (please slate how much............................................. )

Q-9 What type of milk do you usually add lo cereals, porridge or muesli? (eg whole milk, Skimmer, Rev,
Tone, Trim, powdered skim, Shape, High-Low, goat's milk, condensed/evaporaled milk etc)?
Type ol milk added:...........................................................................................
Q-10 How many teaspoons ol sugar or honey do you usually add lo cereal, porridge or muesli?
(Note: I dessertspoon = 2 teaspoons)
Wrile Ihe number of teaspoons you have here: .................
Q-11 Do you add sail lo your porridge? (Circle one number)
1 Yes
2 No
3 I don't eat porridge
7
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NEVER

H O W T O ANSW ER
T im es a
T im e s a
RARELY
MONTH
W EEK

R

N

;m

3

Tim es a
DAY

JD

i-W
3

3

and so on

and so on

ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?
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CEREAL FOO DS

COM M ENTS

Crumpet or Muffin

1

......................................

Croissant

1

......... ...............................

Fruit Loaf/Curranl bread

1 slice

........... .....................................

Sweet bun/Doughnut

1

......... ...............................

Crispbread/Cracker

2

......... .............................

Salted biscuits

3

......... ...............................

Plain sweet biscuits

2

.....................................

Fancy biscuits (eg choc-coated) 2

......... ............................

Cake

1 small cake or

......... ...............................

1 slice large cake

Milk pudding (eg rice, sago)

i/2cup

Steamed sponge - suet

1/4 small pudding

Q-1 What types of cake do you most commonly eat? (eg fruit cake, cheesecake, sponge cake,
iced sponge, tea-cake etc)

Appendix III

Please ñamé ..............................................................
Q-2 Are the cakes you most comm only e a t: (Circle one answer)
1
2
3
4.
5
6

Pre-made wrapped cakes
Frozen wrapped cakes (eg Sara-Lee)
Bought homestyle cakes (eg from bakery)
Homemade (packet mix)
Homemade (own Ingredients)
I do not eat cake

a

HOWTO ANSWER
NEVER

RARELY

N

R

T im e s a
MONTH

T im e s a
W EEK

T im e s a
DAY

jW

I3 D

and so on

and so on

HOW OFTEN DO YOU USUALLY HAVE THESE DRINKS?

COMMENTS

BEVERAGES
Suslagen (made wllh powder)

1 cup

Suslagen Gold

small carton
(300 ml)

Carton of other flavoured milk
(eg Iced coffee, slrawberry etc)

small carton
(300 ml)

Cocoa

1 cup

Drinking Chocolate/Mllo/
Qulkelc

1 cup

Akla-Vlle

1 cup

Glass of milk (as such)

1 glass

Milk shake/Thlck shake

regular size

Tea

1 cup

Herbal lea

1 cup

Inslanl coffee

1 cup

Ground coffee (eg llller/drlp)

1 cup

Decalfelnaled coflee

1 cup

Coffee subslllule (eg Caro)

1 cup

CM Do you have m ilk:
in your lea?
in your coffee?
in your coffee subslilule?

(Circle one breach)
YES
NO
DON’T DRINK TEA
YES
NO
DON'T DRINK COFFEE
YES
NO
DON’T DRINK COFFEE SUBSTITUTE
9

Q-2

Do you make your cocoa/chocolale/Milo/Akta■Vile w ith : (Circle one number)
1 Mostly milk?
2 Mostly waler?

3 About hall and hall?
4 I do nol drink these drinks.
Q-3 What type of milk do you usually add lo (ea/collee /cocoa/chocolate etc? (Please slate
the type of milk used eg whole milk, Skimmer, Rev, Trim, Tone, powdered skim, Shape,
High-Low, goal's milk, condensed milk, evaporated milk ole).

Diet and Health Questionnaire Booklet

Type of milk added.....................................................................................
Q-4 How many teaspoons of sugar/honey do you usually have In each cup o l:
(Circle one number lor each drink)
Tea?

0

1

2

3

4

5

6

Coffee?

0

1

2

3

4

5

6

Coffee substitute?

o'

1t

2

3

4

5

6

Cocoa?

0

1I

2

3

4

5

6

Milo/Quik/Chocolale?

0

1

2

3

4

5

6

Q-5 When you are choosing Ihe type of milk lhat you use how important are the following factors?
(Circle one number for each)

>
cn

7

cn

6

7

5

6

7

4

5

6

7

4

5

6

7

2

3

4

Taste............................. 1

2

3

4

Healthiness.....................1

2

3

4

Convenience of storage..... 1

2

3

Weight (eg easy to carry).... 1

2

10

VERY
IMPORTANT
6

Price............................. 1

CO
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NOTSO
IMPORTANT

H O W T O ANSW ER
T im es a
T im e s a
NEVER

RARELY

N

R

M O N TH

m

W EEK

jw
and so on

T im e s a
DAY
3
and so on

HOW O F TE N DO YO U U S U A L L Y E A T T H E S E F O O D S ?
C O M M E N TS

D A IR Y PR O D U C TS M d EGGS

Cheese

30 qrams (1 slice)

............

Low-lal Collage Cheese

100qm
(1/2 carlon)

............

Cream

1 lablespoon

............

Yoghurt

200 qm (1 carlon)

............

Icecream (Irom a lub)

2 scoops (SUMMER! ............
(WINTER) ............

Icecream dcsserls
(eg Symphony, Vlenella)

1 sorvlnq (SUMMER! ...........
(WINTER! ...........

Icecream (on a sllck/cone)

1 icocronm(SUMMER!............
(WINTER! ............

Vllarl

1 cone

(SUMMER) ............
(WINTER! ............

Ice Block/lcy Pole

1

(SUMMER! ...........
(WINTER! ............

Cuslard

1/2 cup

...........

Fried egg

1 oqq

...........

Dolled egg

1 L’qq

...........

Omolcllc/Scrnmbled eggs

2 oqqs

...........
11
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Q-1

When you eal cheese, do you have the reduced-salt varieties? (Circle one number)

1
2
3
4

Always or nearly always
Sometimes •
Rarely or never
I do no! ealcheese

Q-2 When you eat cheese, do you have the re d u ce d -fa t varieties? (Circle one number)
1
2
3
4

Always or nearly always
Sometimes
Rarely or never
I do £¿1 eat cheese

Diet and Health'Questionnaire Booklet

Q-3 When you eat yoghurt which type is it? (Circle one number)
1
2
3
4
5
6

Plain (eg not fat-reduced)
Plain, low-fat
Fruit flavoured (not fat-reduced)
Fruit flavoured, low-fat
Frozen yoghurt
I do nol eat yoghurt

Q-4 When you eat ice-cream, diet-ice o r sim ilar is it u s u a lly? (Circle one num ber)
1 Low calorie
2 Regular Ice-cream
3 Other (please slate.................................................................................. )

Q-5 In recent years have you m ade any changes to y o u r intake o f the following foods?
(Circle one for each food)

I am having

I am having

........ ....... ............... MORE

LESS

the SAME

Cheese .............. ............... MORE

LESS

the SAME

Eggs ............... ............... MORE

LESS

the SAME

Coflee............... ................MORE

LESS

the SAME

............... ................ MORE

LESS

the SAME

I am having

Appendix III

Milk

Tea

12

HOWTO ANSWER
NEVER

RARELY

N

R

T im e s a
MONTH
3

T im e s a
DAY

T im e s a
WEEK

Iw

3

and so on

and so on

ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?
MEATS

COMMENTS

Sleak (ealen as such)

1 medium

Pork chop

1chop

Lamb chop

2 chops

Hoast pork/Pork fillet

2 slices

Roast beef/veal

2 slices

Roast Iamb

2 slices

Sausages

2 thick or 3 thin

Franklurlers/Saveloys

2 thick or 3 thin

Bacon

2 rashers

Ham

3 thin or
2 thick slices

Luncheon meat/Frllz/Devon/
Windsor elc

3 slices
(1 cm thick)

Continental sausage
(Salaml/MettwurstiCabanosst)

3 slices

Pale/Llver paste

1 tablespoon

Liver

1/2 liver (150 gm)

Kidney

2 kidneys

Brains

1/2 cup

Pureed meat dishes
(canned/bollled)

1/2 cup

HOWTO ANSWER
NEVER

RARELY

N

R

T im es a
MONTH

T im es a
W EEK

m

Tim es a
DAY

W

iw

3

3

a n d s o on

a n d so on

ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?

COMMENTS

M IX E P P IS H E S

Appendix III
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Hamburger WITH bun

1 medium

...........

Hamburger pally (WITHOUT bun) 1 medium

...........

Pizza (frozen)

1 mini or 1/4
large pizza

Pizza (homemade or take-away)

1/2 small or 1/4
large pizza

...........

Sausage roll

1 large, 2 small

..........

Meat pie

1 pie

..........

Meal pie
(homemade)

1 indiv. pie OR
1 slice large pie

........

Paslle

1

........ •-------------------------

Crumbed veal (schnllzel)

1 large piece

..........

Slew/Casserole/Curry/Goulash
(with meat or chicken)

1 cup

..... .

Slew/Casserole/Curry/Goulash
(wllhoul meat or chicken)

1 cup

..........

Chinese meat & veg dish

1 cup

..........

Savoury ples/paslrles
(eg quiche)

1 indiv.

pie QR
1 slice large pie

..........

Mince meal (ealen as such)

1 cup

.........

Mince meat dishes
(eg shepherds pie)

1 piece (Bx8x4cm).........

Spicy mince added to
pastas (eg spag. sauce)

1/2 cup mince

14

.................

.........

----------------------

NEVER

N

HOWTO ANSWER
Times a
Times a
WEEK
RARELY
MONTH

;m

R

3

Times a
DAY

1W
3

I3 D

and so on

and so on

ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?

CHICKEN. FISH and SEAFOOD.:

COMMENTS

Roasl/Barbecue chicken

2 slices breast or ...
1 drumstick/2 wings

Boiled chicken

as above

Crumbed, fried chicken

4 small pieces

Chlcken/Flsh nuggels

6 nuggets

Fish fried

1 piece

Fish without baiter
(sleamed/grllled/bolled)

1 piece

Canned fish (luna, salmon elc)

1/3 cup

Fish fingers

3-4 fingers

Seafood (prawns, crab,
lobster elc)

1/2 cup

Mornay dishes

1cup

Q-1 IIyou eat the following meals, how are they usually cooked? (Circle one lor each food)
Steak
Chops
Sausages
Bacon
02

FRIED
FRIED
FRIED
FRIED

GRILLED/BAKED
GRILLED/BAKED
GRILLED/BAKED
GRILLED/BAKED

MICROWAVED
MICROWAVED
MICROWAVED
MICROWAVED

When you eat meal with fat on it, do you eat: (Circle one number)
1
2
3
A
5

All of the lai
Most of the fat
About hall ol the fai
Lillie or none ol Ihe fai
1do not eal meal

DON'T EAT
DON'T EAT
DON'T EAT
DON'T EAT

03

Do you take the skin oft chicken? (Circle one number)
1 Always or nearly always
2 Sometimes (about hall the time or less)
3 Rarely (less than a quarter of the time)
4 Never
5 I do not eat chicken

VO

<N

04

If you eat fried fish, In which of the following is it usually coated? (Circle one number)
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1
2
3
4
5
05

Batter
Breadcrumbs
Flour
Other coating; please name.................................................................
Fried without coaling

When you eat fish coated in batter, crumbs etc how often is it: (Circle one (or each)
Coated at home......... ... ALWAYS
Pre-packed, frozen
cooked at home......... ... ALWAYS
Bought ready cooked
from fish shop............ ... ALWAYS

06

SOMETIMES

RARELY

NEVER

SOMETIMES

RARELY

NEVER

SOMETIMES

RARELY

NEVER

How often do you eat complete main meals bough l from the fre e ze r section at the shops?
(eg Lean Cuisine, TV dinners) (Circle one number)

1
2
3
4
5

Daily
About weekly
About once a fortnight
About monthly or less
Never

07 How often do you eat ‘meals in a can *(eg, Irish Stew, ready to heat and eat meats)
(Circle one number)

1
2
3
4
5

Appendix III

08

Daily
About weekly
About once a fortnight
About monthly or less
Never

How often do you eat canned meats such as Camp Pie, corned beef, tinned ham etc
(Circle one number)

1
2
3
4
5

Daily
About weekly
About once a fortnight
About monthly or less
Never

16

NEVER

HOWTO ANSWER
Times a
Times a
RARELY MONTH
WEEK

N

R

¡M

;W

3

«

and so on

Times a
DAY

¡D
3

and so on

ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?

COMMENTS

CANNED and DRIED VEGETABLES
Potato-canned

2*3 small

Potato-packet (powdered)

1/3 cup (cooked)

Potato salad

1/3 cup

Carrots - canned

1/3 cup

Beetroot-canned

2 slices

Green beans-canned

1/3 cup

Haricot, Lima beans - canned

1/3 cup

Baked beans In tomato sauce

1/3 cup

Green peas - canned

1/3 cup

Lentils -drled/canned

1/3 cup

Zucchini salad

1/3 cup

Sweetcorn-canned
(Including creamed corn)

1/3 cup

Mushrooms-canned

6-7 small ones

Mushrooms - canned In sauce

1/3 cup

Olives

3 medium

Gherklns/PIckled onions

3 pieces

Pureed vegetables
(canned/bollled)

1/3 cup
17

NEVER

<N

HOW TO ANSWER
Times a
Times a
WEEK
MONTH
RARELY

N

R

m
3

Times a
DAY

iW

I3 D

and so on

and so on

The following list of foods contains some vegetables that may be eaten much more frequently
at some times of the year than others (eg In the warmer or cooler weather). Please fill in how
often each food os eaten in BOTH the warmer months of the year (SUMMER) and the cooler
months (WINTER).

Diet and Health Questionnaire Booklet

For example- If you usually have:

v.

A standard serve of peas about twice a week during the warmer months of the year
and about every day during the cooler months:
and:
Two medium potatoes (roasted) a week throughout the year:
You would write......
Summer Winter
Green peas

1 cup

Potato*roasted

1 medium

.fr.W..

iLD ...______
..l.V.1
/.. ^ ^

ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?

SEASONAL VEGETABLES

Summer Winter

Potato* fresh Smashed
(with milk)

1/3 cup

........................

Potato-fresh, bolted

1 medium

........................

Potato-roasted

1 medium

........................

French Frles/Hot chips

17-18 chips

........................

Potato Gems/
Pommes Noisettes

about 5

......................

Carrots (fresh/frozen)

1/3 cup

........................

Turnip, Swede(fresh/lrozen) 1/3 cup

........................

Broad beans (IreshJIrozen) i/2cup

.......................

•a

c
<
D
a

a
<

Green beans (fresh/frozen) i/3cup

18

.......................

Summer Winter

SEASONAL VEGETABLES (continued)

Green peas (Iresh/trozen)

1/3 cup

Cabbage

1/3 cup

Brussels sprouts
(Iresh/lrozen)

5-6

Silver beet/Sptnach
(Iresh/lrozen)

1/3 cup

Broccoli (Iresh/lrozen)

1/3 cup

Cauliflower (Iresh/lrozen)

1/2 cup

Pumpkin

1/3 cup

Sweetcorn (Iresh/lrozen)

1 small cob

Zucchini (courgettes)

1 medium sized

Onion-fried

1/4 cup

Onion (raw, baked, boiled)
(Iresh/lrozen)

1 medium

Tomato - fresh

1 medium

Tomato - grllled/lrled

1/2 medium

Lettuce

2 small leaves

Cucumber

3 slices (each
0.5 cm thick)

Coleslaw

1/2 cup

Celery (Iresh/lrozen)

one 15cm stick

Capsicum (Green Pepper)
(Iresh/lrozen)

2 strips (each
0.5 cm thick)

Mushrooms - Iresh

6-7 small ones

Sprouted bean shoots

1/3 cup

Fried mixed vegetables
(eg stir tried)

1/2 cup
19

CM When you use canned vegetables, are they reduced-salt varieties? (Circle one number)
1 Always or nearly always
2 Sometimes
3 Never or rarely
4 Only for some vegetables (please slate which.......................................................
Q-2 Is salt added to the cooking water when boiling the following foods? (Circle one lor each food)
Vegetables

USUALLY

SOMETIMES

Pasta and rice

USUALLY

SOMETIMES

NEVER
'

NEVER

Diet and Health Questionnaire Booklet

Q*3 If sail is added to Ihe cooking water when boiling foods, is the water: (Circle one number)
1
2
3
4
5

Lightly sailed
Medium sailed
Heavily salted
Sailing is highly varied
Salt is flQl added to cooking water

CM H ow often do yo u a d d sail to meals a fte r they are cooked? (Circle one number)
1 Rarely or never
2 Sometimes
3 Always or nearly always
Q-5 When you add salt at Ihe table, how much do you usually add?
(Circle one number)
1
2
3
4
5

A light sprinkle
A medium sprinkle
A heavy sprinkle
Sailing is highly varied
I do not add salt at Ihe table

Appendix III

Q-6 When your vegetables are cooked which o f the following methods is Ihe one m o s t c o m m o n ly
used? (Circle one num ber)
1 Boiled In a little water
2 Boiled in a lot ol water
3 Steamed
4 Cooked in a pressure cooker
5 Microwaved
6 Stir-fried
20

1

VegeLoble oils (olive, sunflower etc)

4

2

Cooking or table morgarlne

5 Polyunsaturated margarine

3

Butter

6

Drlpplng/lard/mealjulcea
Nothing

From ¡he list above wrile which type of tat/oil is most commonfy used:
(a) When roasling/frylng meals/lish........................... .......................................
(b) When roasling/frylng vegetables.................................................................
(c) On vegetables when served (eg butter on peas)...............................................
Q-8 Is butter or margarine added to your potatoes when they are mashed? (Circle one number)
1 Yes, always
2 Yes, occasionally
3 Never

NEVER

N

HOWTO ANSWER
Times a
Times a
WEEK
MONTH
RARELY

R

m
3

■w
and so on

Times a
DAY
3
and so or

HOW OFTEN DO YOU USUALLY EAT THESE FOODS?

COMMENTS

E E LllI
Orange, Mandarin, Grapefruit

1 medium

Apple, Pear - Iresh/baked

1 medium

Banana

1 medium

Fresh fruit salad

1 cup

Dried fruit (apple/aprlcol etc)

4-5 pieces

Raisins, sultanas or currants

1/3 cup

Fruit In syrup or slewed
(Including fruit salads)

1/2 cup

Fruit canned In waler(low-cal)
(Including fruit salads)

1/2 cup

Fruit plo or pastry
or fritters

1 small pie or
1 slice large

Os

CN
m

NEVER

H O W T O ANSW ER
T im es a
T im e s a
RARELY
MONTH
W EEK

N

R

;m

T im es a
DAY

jD

iw
and so on

and so on

The Irull3 listed below are only available tor a short lime during the year. There loro ive only want you to
record how often you have them when they are IN SEASON.

H O W OFTEN DO YOU EA T TH ESE FOODS W HEN TH EY AR E IN SE AS O N ?

SEASONAL FRUITS

COMMENTS

Berries * fresh/lrozen

3/4 cup

Melon (nol watermelon)

1 large slice

Peach-fresh

1 medium

Plum-fresh

3-4 plums

Nectarine - fresh

1 medium

Apricot - fresh

3 apricots

a

Grapes - fresh

about 20

a

Pineapple-Iresh

1 slice

X

Avocado

1/2 an avocado

o
2o
o

PQ
CD

Vn

'3

CD

3

<D

T3
C

3
O

5

P lease lis t Im re, a lo n g w ith y o u r sta n d a rd se rve size, a ny o th e r fru it th a t y o u eat
(eg m anfo; purecd, canned/bollled fruits)

HOW OFTEN DO YOU U S U A L LY EAT TH ESE FOODS?
COMMENTS

HUTS anti SHACKS

*3
c
CD

a(X

<

Potato crisps, Twlstles etc

1 small bag qr
14-15 pieces

Peanuts (Iresh)

9-10 nuts

Nuts - salted & cooked

9-10 nuts

Olher unsalted nuts
(fresh walnuls/almonds etc)

5-6 nuts
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T im e s a
WEEK
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iw
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and so on

and so on

3

3

ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?

SOUPS
Canned soup (ealen as such)

COMMENTS

1 cup (WINTER)..................................................
(SUMMER)..................................................

Packet soup (ealen as such)

1 cup (WINTER)..................................................

(SUMMER)..................................................
Homemade soup (ealen as such) 1 cup (WINTER)..................................................

(SUMMER).................................................
Write an example of the type of soup you most often eat (eg canned tomato;
homemade pea and ham)

Below we have listed a number of products that may be used as Ingredients when you
are cooking (for example you might add these foods to casseroles, stews etc).
Please fill In how often you would use these foods as Ingredients in cooking.

Canned or Packet soup mixes

......... .........................................

Bottled sauces (eg soy sauce, lomalo sauce)

......... ............ ............................

Gravy mlxes/powders

......... .........................................

Slock cubes/powders

......... ........................................

Canned tomatoes

......... ........................................

Tomato pastes/purees

......... ........................................

Olher pureed foods (eg apple, baby foods)

......... .........................................

Evaporated milk

..................................................

Condensed milk
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a n d so on
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DAY
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3

a n d so on

ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?
COMMENTS

Chocolate

1 small bar
(50 grams)

Chocolale covered bar
(eg Mars/Bounly)

1 bar

Individually wrapped
lollies; toffees

4-5 lollies

Packet lollies
(eg Lllesavers/Polos)

1 small packet

Muesli bar/Mealth bar

1bar

Honey, Jam, marmalade

1 tablespoon

Vegemlte, marmite etc

1/2 teaspoon

Thick sauces (tomato/HP etc)

1 tablespoon

Polyunsaturated Mayonnaise/
Salad Cream

1tablespoon

Regular Mayonnaise/
Salad Cream

1tablespoon

Low calorie salad dressings

1 tablespoon

Polyunsaturated salad
dressings

1 tablespoon

Appendix III
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CONFECTIONERY. JAMS and SAUCES
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NEVER

HOWTO ANSWER
Times a
Times a
RARELY
MONTH
WEEK

N

R

IM

Times a
DAY

?W
and so on

D
and so on

ABOUT HOW OFTEN DO YOU USUALLY HAVE THESE FOODS?
COMMENTS
Glass ol cordial

medium glass

Glass of cola (eg Coca-Cola)

medium glass

medium glass
Glass of fizzy drink
Includes mineral waler with Juice
Glass of low-calorle llzzy drink medium glass
Fruii drink (eg Fruit Box)

1 carton (250 ml)

Pure fruit Juice

medium glass

Vegetable Juice

small glass

Water/Sprlng waler

medium glass

Mineral waler

medium glass

Low-alcohol beer

medium glass
230 mis

Beer

medium glass
230 mis

Alcoholic cider

medium glass
230 mis

Wine

1wine glass

Wine Cooler

1wine glass

Sherry/Porl/LIqueur

1 standard serve

Spirits (whisky, brandy elc)

1 nip
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II you have any other loods or drinks that we have not mentioned, at least once a month, please
write them down here and tell us how olten you have them using the same response scale as before
(eg 1D, 3M etc).
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HOW TO ANSW ER
T im e s a
T im e s a
RARELY
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W EEK
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IM
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T im es a
DAY

|W

3

and so on

and so on

FOODS AND DRINKS I CONSUME THAT HAVE NOT BEEN MENTIONED:

Diet and Health Questionnaire Booklet

Name of Food

Your usual serve
size

How often
do you eat It?

VITAMIN AND MINERAL SUPPLEMENTS
If you take any vitamins or minerals, or any other dietary supplement, such as fibre tablets, lecithin, kelp,
yeast, 'slimming' products, etc, please till in the table below. (Check Ihe label on the box or bottle it you
are unsure of some ol Ihe answers).
NAME OF PRODUCT
(e.g. vitamin C pill)

SIZE OF DOSE
(e.g. 250 mg)

Appendix III

BRAND
(e.g. Nyal)
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NUMBER OF DOSES
(e.g. 2 per day)

S H O P P IN G

Q-1 In your household, who does most oflhe shopping? (Circle two It necessary)
1 Self
2 Spouse/Partner
3 Someone else (specify who............ .................................................................... )
Q-2 How much do you feel that your eating habits are influenced by
(Circle one number breach)
MAJOR
------- ► INFLUENCE

NOT
RELEVANT
Lack of money.................. ........ 1
Transport problems............ .........1

2

Availability of foods in shops.. ........ 1
Nutritional value of food...... ........ 1

2

Physical disabilities............ ........ 1

2

Some other factor.............. ........ 1

2

2
2

3
3
3
3
3
3

4
4
4
4
4
4

5
5
5

5
5
5

(please state..................
0 3 Do you ever pay attenlion to the nutrients or ingredients listed on food labels?
"(Circle one number)
1 No
2 Yes
3 Never noticed them
0 4 When you look at the information on food labels, do you ever use it to avoid a particular ingredient
ornutnent, or avoid gelling too much of it? (Circle one number)
1 I don’t look al food label information
2 No
3 Yes - If so, whal do you try to avoid?
(Please be specific)................................................................................
0 5 When you look at the nutrients or ingredients listed on food labels, do you use this information to
compare different brands? (Circle one number)
1
2
3
4

I don't look at food label information
I don't use it to compare brands
I sometimes use it to compare brands
I ollen use It to compare brands
27

Q-6 When you are choosing between brands of sim ilar items (eg two types of high fibre breakfast
cereal or two varieties of low-salt margarine), how Important would these factors be to you?
(Circle one number for each)
NOT SO __________________
IMPORTANT
Price........................................ ... 1
2
3
4
5
T a ste ....................................... ....1
2
3
4
5
Fat, sail or sugar content............... ....1
2
3
4
5
Additives or preservatives............. ....1
2
3
4
5
Convenience o( packaging............. ....1
2
3
4
5
Endorsement by health authorities........1 v
2
3
4
5
Health claims by the manufacturer........1
2
3
4
5
Q-7 (a) What do you think are the advantages, If any, of canned foods?

Q-7 (b) What do you think are the disadvantages, If any, of canned foods ?

Q-8 (a) What do you think are the advantages, If any, of frozen foods ?

Q-8 (b) W/ial do you think are the disadvantages, if any, of frozen foods ?

20

>

VERY
IMPORTANT
6
7
6
7
6
7
6
7
6
7
6
7
6
7

N U TR ITIO N AL RATING
Q-1 How would you rale Ifw nutritional value of the following? (Circle one (or each food)
VERY _______________ w VERY
POOR
7 GOOD

Fresh fish.......................... ..1

2

3

4

5

Fresh carrots.................... ..1

2

3

4

5

Frozen fruits..................... ..1

2

3

4

5

Complete frozen meals...... ..1

2

3

4

5

Canned fish...................... ..1

2

3

4

5

Canned peas.................... ..1

2

3

4

5

Frozen mixed vegetables... ,.1

2

3

4

5

Canned meats................. ....1

2

3

4

5

Frozen pizza..................... ...1

2

3

4

5

Fresh peas....................... ...1

2

3

4

5

Frozen carrots................. ...1

2

3

4

5

Canned fruit..................... ...1

2

3

4

5

Frozen fish....................... ...1

2

3

4

5

Frozen peas.................... ...1

2

3

4

5

Takeaway pizza............... ,...1

2

3

4

5

Fresh red meat................ ....1

2

3

4

5

Frozen meats.................. ....1

2

3

4

5

Complete canned meals ........1

2

3

4

5

Canned carrots................ ....1

2

3

4

5

Fresh fruit....................... ....1

2

3

4

5

Canned mixed vegetables.....1

2

3

4

5
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Q-1 Have you tried to make any of the following changes to yo ur diet In the last few years?
(Circle one answer for each)
Increase fibre Inlake
Reduce fat inlake
Reduce sugar Intake
Increase caldum inlake
Reduce sail inlake
Eat less food In general
Something else

YES
YES
YES
YES
YES
YES
YES

NO
NO
NO
NO
NO
NO
NO

Diet and Health Questionnaire Booklet

(please describe...........................................................................
Q-2 If you have NOT TRIED to make changes stale, In your own words, why not?

0*3 Ifyou have TRIED to make dietary changes, either successfully or unsuccessfully, in the last few
years, whal were the m ajor difficulties you encountered?

CM Ifyou have TRIED to make changes:
In your own words, what specific changes have you tried to make to the foods you eat or your
cooking methods etc?_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ • • •

Appendix III

Why have you made these changes?_
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CM

Whal is your current height?

________ (eel________ inches OR

What is your current weight?

______ stones______ pounds OR_________ kilograms

____________ centimetres

Q-2 About how often do you exercise? (Please circle one number)
1
2
3
4

Less than once a week
Once or twice a week
Three times a week or more
NOT AT ALL-»go to Question 3 below

Q-2(a) About how long do you exercise for each lime? (Circle one number)
1 Less than 20 minutes
2 20-30 minutes
3 More than 30 minutes
Q-2(b) How much of the exercise you do makes you puff and sweat? (Circle one number)
1 None ol it
2 Some of it
3 Most or all ol it

Q-3 (a) Have you ever smoked on a regular basis? (Please circle one number)
1 YES
2 NO
Q-3 (b) Do you currently smoke cigarettes, pipes or cigars? (Please circle, and write in amount)
1 YES, I smoke____________ cigs/day
2 YES, I smoke____________ cigars/day
3 YES, I smoke____________ pipes/day
4 NO, I don’t smoke at all
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BACKGROUND
ÿ

-------------- ------------------:— —

---------------------------------------------- ■
-------------- -----------

I Please answer these questions accurately so that we can examine general relationships between lifestyles
I and diet. Let us reassure you aoain that this inlormation will be kept completely conlldenllat

..................... ........................

....................... ....

Q-1 Your sex: (Circle one)
1 Male
2 Female

Diet anfl Health Questionnaire Booklet

Q-3 What is your usual occupation?
,
Even if you are retired or otherwise not
currently employed, please stale what your
occupation usually would be. (Be specilic)

Are you (circle numbor(s))
1
2
3
4
5
6

JJ

1 Living with spouse or partner and
dependent children
2 Living with spouse or partner
3 Living alone v/illi dependent children
4 Living alone
5 living with my family (eg mother, lather,
brother, sister)
6 Share house or Hat with others
7 Living with my child's family
(eg daughter or son's family)
0 Retirement home
9 Another situation; please describe:

Q-2 Your present age:______ YEARS

04

,

0 8 Which one ol these best describes your
situation? (Circle one number)

Employed lull-lime
Employed part-time
Not employed outside the home
Student
Retired
Unemployed

_________________________
0 8 What is your country ol birth?
_________________________
0 9 If you were born overseas, (or how long
. have you lived in Australia?

0 5 If you live with a spouse or partner, what is
his/her usual occupation? (Be specific)

YEARS
Q-10 What is the current level of income (before
lax) in y o ilr household? (circle number
next to range)

Appendix III

0 6 lls your spouse/partner (circle number(s))
1
2
3
4
5
6

Employed lull-lime
Employed part-time
Not employed outside the home
Student
Retired
Unemployed

1
2
,3
4
5
6
32

nil - $7,000 per year
$7,001-$15,000 per year
$15,001-$25,000 per year
$25,001-$40,000 per year
$40,001 and over per year
l do not wish to answer this question

ft*************************************************************

At this stage, we ask you to please go back through the questionnaire and
check that have answered all questions

YOUR COMMENTS
Thank you very much for your help.

We realise that you had to give up

some of your time to answer our questions. We would like you to know that
wc appreciate this help.
We believe that the results from this survey will be useful in determining
what people eat, and in llie future, possible relationships between diet and
disease.
If you have any further comments to make about the design o f this
questionnaire please feel free to write them down here. We might be able to
incorporate your suggestions in our future work.
Thank you again for your help.

Copyright CSIRO Division of Human Nutrition.
purposes only.

Designed for research

